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Abstract 
 
Follicular Lymphoma (FL) is a common B cell Non-Hodgkin Lymphoma with 
a median survival of 8-10 years. Patients frequently undergo transformation to 
a more aggressive lymphoma and this is associated with drastically reduced 
survival. The hallmark of FL is the t(14;18) translocation yet this alone is 
insufficient for lymphomagenesis. While a number of secondary genetic 
changes have been described, epigenetic studies have lagged behind. 
Epigenetics refers to mechanisms that alter gene expression without a change 
in the primary DNA sequence. DNA methylation was quantitatively profiled at 
1505 CpG loci in 164 untreated FL as well as 10 pairs of pre- and post-
transformation samples and 24 benign haematopoietic controls. 
 
Tumour-specific methylation occurred in >100 genes, preferentially occurring 
within CpG rich areas known as CpG islands and in genes marked by a 
repressive histone modification in embryonic stem (ES) cells, trimethylated 
Lysine 27 of Histone H3 (H3K27Me3). Significant inverse correlation with 
gene expression was identified for a small number of genes. Significant 
changes in methylation were not seen in FL samples upon transformation. 
These findings suggested that widespread DNA methylation occurred as an 
early ‗pre-programmed‘ event in lymphomagenesis rather than being due to 
silencing of individual tumour suppressor genes. 
 
Methylation profiling of a subset of these samples at >27,000 CpG loci 
revealed aberrant methylation in FL in >700 CpG islands. These 
hypermethylated genes were enriched for high-density CpG promoters and for 
a key set of genes with developmental function which were marked by both 
repressive (H3K27Me3) and activating (H3K4Me3) marks in ES cells. 
Examination of H3K27me3 expression by immunohistochemistry in pre- and 
post-transformation biopsy samples showed wide variation in expression. 
Furthermore, mutations were identified in the histone methylase EZH2 that 
catalyses H3K27Me3, in 7 of 20 patients. We can conclude therefore that 
deregulation of DNA and histone methylation are critical inter-related events 
for FL pathogenesis. 
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Chapter 1. Introduction 
1.1 Cancer and the B Cell 
 
The term cancer encompasses a variety of different malignant neoplasms (neo: 
new; plasia: growth) and may be most simply defined as a growth caused by 
uncontrolled cell division. These neoplasms have varying cells of origin with 
epithelial-derived malignant neoplasms referred to as carcinomas while 
connective-tissue derived (mesenchymal) malignant neoplasms are referred to 
as sarcomas. The focus of study within the Centre for Medical Oncology at St. 
Barts Hospital has been on malignant neoplasms derived from blood and 
related tissue such as lymphoid tissue. These neoplasms are broadly classified 
as being leukaemias or lymphomas dependent on their cell of origin and their 
anatomical distribution i.e. whether they are disseminated in circulating blood 
(leukaemia) or are predominantly in solid form confined to lymph nodes 
(lymphomas). 
 
1.1.1 Lymphoma 
 
The classification of lymphomas has been a complex, confusing and seemingly 
ever-changing area. In recent years, collaborative efforts have led to the World 
Health Organisation (WHO) Classification of Tumours of the Haematopoietic 
and Lymphoid Tissues becoming the accepted classification. Lymphomas are 
currently broadly categorised as being of either Non-Hodgkin Lymphoma 
(NHL) or Hodgkin Lymphoma (HL) subtype. NHL accounts for the vast 
majority of all lymphomas with an annual age-standardised incidence rate of 
14.2 per 100,000 population in United Kingdom compared to an incidence rate 
of 2.6 per 100,000 for HL (2007 Cancer Research UK data). NHL cases may 
be divided according to their cell of origin as being either of B cell 
(approximately 85% of NHL), T cell or Natural-Killer (NK) cell origin 
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(Anonymous 1997, Armitage and Weisenburger 1998). As the malignant cell 
in B cell lymphoma subtypes often has morphological and immunophenotypic 
features that correspond with stages of normal B-cell differentiation, 
subclassification of B cell lymphomas takes account of the benign counterpart 
of the malignant cell. Indeed, mature B cell neoplasms are defined as ―clonal 
proliferations of B cells at various stages of differentiation, ranging from naïve 
B cells to mature plasma cells.‖ Follicular Lymphoma (FL), the focus of my 
study, is regarded as a germinal centre lymphoma, the germinal centre being an 
important structure in the normal lymph node, through which the B cell transits 
during normal differentiation. Therefore, an understanding of the normal 
structure and function of the lymph node and normal physiological B cell 
differentiation is required to understand lymphoma classification and biology.  
 
1.1.2 Physiology of B cell differentiation and its link to lymphoma 
classification 
 
As part of the human adaptive immune system, B cells play an important role 
in recognising and binding antigen. To do this, they require a functional surface 
B cell receptor (BCR) composed of immunoglobulin. While the abbreviation B 
originally comes from the Bursa of Fabricius, the site of maturation of such 
cells in birds, B cells in the human begin their development in the bone 
marrow. The development process (outlined in Figure 1-1; (Jaffe, et al 2008, 
Kuppers 2005)) begins with precursor B cell lymphoblasts differentiating into 
mature naïve B cells through a process called immunoglobulin VDJ 
recombination. This involves the random rearrangement of variable (V), 
diversity (D) and joining (J) gene segments of the heavy- and light-chain 
immunoglobulins of which the B cell receptor (BCR) is composed (Figure 
1-2). This rearrangement acts to make the BCR functional as an antigen 
receptor. Such small resting lymphocytes leave the bone marrow and circulate 
in the blood as naïve B cells expressing surface IgM and IgD. Upon 
encountering antigen, these cells become activated, and undergo transformation 
into blast cells. These blast cells migrate into primary follicles where they 
clonally proliferate to form the germinal centre (GC) and push non-
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proliferating naïve B cells to the peripheral mantle zone (Figure 1-3). These 
blasts cells are called centroblasts (blast cells of the GC) and can be recognised 
in histological sections of normal lymph node as a group of large cells with 
vesicular nuclei, one or more prominent nucleoli and a small amount of 
cytoplasm (Figure 1-3). Centroblasts proliferate within what is known as the 
GC ―dark zone‖  (Figure 1-3). These centroblasts switch off expression of the 
anti-apoptotic protein BCL2 and characteristically express BCL6 and CD10. 
 
Within the dark zone the centroblasts are first modified by a process called 
somatic hypermutation that leads to the introduction of mutations of the Ig V 
region, which changes their affinity for stimulating antigen. Many of these 
centroblasts acquire mutations that result in decreased affinity for antigen and 
as their function is diminished they undergo programmed cell death by 
apoptosis. A few cells acquire mutations in the BCR that increase the 
receptor‘s affinity for antigen and these cells are positively selected to undergo 
further differentiation. These cells migrate into the light zone of the GC where 
they are in close contact with CD4-positive T cells and bind to antigen trapped 
on the processes of Follicular Dendritic Cells (FDCs). In addition, a proportion 
of these selected B cells will undergo a process called class-switch 
recombination which leads to some cells switching from IgM production to 
IgG or IgA production. This results in an antibody that retains the same 
antigen-binding domain but with a different effector function. During these 
events the cells have matured from centroblasts to centrocytes, medium-sized 
cells with irregular/cleaved nuclei and inconspicuous nucleoli (Figure 1-3). 
Their interactions with T cells and FDCs save them from apoptosis and they 
reexpress the BCL2 protein. In the final step of differentiation, selected cells 
switch off BCL6 and differentiate into post-GC cells which may be either long-
lived antibody-secreting plasma cells or memory / marginal zone B cells.  
 
The distinctive mutation events and protein expression profiles acquired 
throughout this process form much of the basis of classification of B cell 
lymphomas according to their putative cell of origin within the B cell 
differentiation pathway  (Figure 1-1). The focus of our study is FL, a neoplasm 
of germinal centre B cells that accounts for 20-25% of all NHL.
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Figure 1-1 B cell differentiation and lymphoma classification. 
 
Precursor B cells mature in the bone marrow. Here they undergo Ig gene 
rearrangement through VDJ recombination. They may either undergo apoptosis 
or mature into naïve B cells that may enter the germinal centre (GC) following 
exposure to antigen and transform into centroblasts. These cells then either 
undergo apoptosis or develop into centrocytes. FL is a B cell lymphoma 
composed of centrocytes and centroblasts. Cells that transit through the GC 
may become long-lived plasma cells or memory B cells. Typically, B cell 
neoplasms express the same immunophenotype to that of their corresponding 
normal B cell stage. 
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Figure 1-2  Immunoglobulin genes in normal B cell development. 
 
Igs consist of variable (V) and constant (C) regions. 
 
A: VDJ recombination: 
In this process three gene segments of the heavy chain region of the Ig gene 
(V,D and J) are joined. The first step involves the joining of D and J regions 
followed by joining to the V region. These rearrangements result in the 
expression of a pre-B-cell receptor. As there are a number of different 
functional V, D and J segments, a diverse range of rearrangements may occur 
allowing for the generation of receptors with varying effector functions. 
 
B: Somatic hypermutation 
SHM occurs within the germinal centre and leads to the introduction of 
mutations, deletions and duplications in the previously rearranged V region. 
These alter the affinity of the antibody produced by the B cell for antigen. This 
process has been implicated in causing chromosomal translocations. 
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Figure 1-2 (continued) 
 
C: Class switch recombination 
CSR also occurs within the germinal centre and leads to replacement of the 
original C region with the C region of another Ig gene. In this figure, the C 
region of IgG (C) replaces the C region for IgM (C) at the switch region for 
each of these regions (S and S). The antibody thus created has the same 
variable region and antigen-binding domain but with a different effector 
function. 
 
Text and Figures 1-1 and 1-2 modified from review of B cell lymphomagenesis 
(Kuppers 2005) and from the WHO Classification of Tumours of 
Haematopoietic and Lymphoid Tissues, 2008. 
 
 
 
Figure 1-3 Histological features of normal germinal centres. 
 
The low power image demonstrates a typical follicle in a benign lymph node. 
A rim of small cells (mantle zone; MZ) surrounds the germinal centre, which 
contains a light zone (LZ) and a dark zone (DZ). The higher power images 
show that the DZ is composed predominantly of larger cells with multiple 
peripheral nucleoli (centroblasts) while the LZ is composed predominantly of 
small cleaved cells called centrocytes. 
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1.2 Follicular Lymphoma 
 
The World Health Organisation defines FL as a neoplasm of follicle centre B 
cells that has at least a partially follicular pattern. It has an average annual 
incidence rate of 2.6 per 100,000 people, predominantly affects adults with a 
median age of diagnosis of 59 years and a male: female ratio of 1:1.7 
(Anonymous 1997). FL has a heterogenous clinical course with a relatively 
long median survival of 7.8 years (Swenson, et al 2005). Although patients 
initially exhibit high rates of response to treatment, the illness follows a 
fluctuating course of remission and recurrence with reduced response to 
conventional chemotherapy over time (Johnson, et al 1995). Approximately 1 
in every 3 patients undergo transformation to a high-grade lymphoma (t-FL), 
most often DLBCL, a process outlined in Section 1.3. 
 
What we know today as FL was probably first described in 1925 by Brill and 
colleagues who described ―patients with enlargement of spleen and lymph 
nodes, characterised pathologically by a proliferation of lymphoid follicles‖ 
(Brill 1925). Additional cases were described by Symmers in 1927 (Symmers 
1927) and the disease became known as Brill-Symmers disease. While 
numerous classification systems were used in the following years, the 
discovery of distinct lineages of lymphocytes in the 1960s led to the 
classification of lymphomas into B, T and NK cell lymphomas and thus to 
recognition of this disease as a B cell neoplasm. In the 1970s, it was noted that 
many lymphomas resembled GC cells and lymphomas with a nodular growth 
pattern were linked to the lymphoid follicle (Lennert, et al 1975). With the 
advent of immunohistochemistry and its optimisation for use in formalin-fixed, 
paraffin-embedded tissue (FFPE), classification according to not only lineage 
but also the corresponding differentiation stage at which the lymphoma 
appeared to be ―frozen‖ became possible through the comparison of 
characteristic surface markers. This relationship to the normal GC is reflected 
in the range of synonyms used in previous classification systems for what we 
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know today as FL, such as ―centroblastic / centrocytic follicular‖ and ―small 
cleaved cell‖ lymphoma.  
 
1.2.1 Histopathology 
 
The neoplastic follicle centre B cells of which FL is composed may be either 
centrocytes or centroblasts (Section 1.1.2). Centrocytes typically predominate 
with lesser numbers of centroblasts. FL is divided in the 2001 WHO 
classification into three grades based on the amount of centroblasts present 
(Table 1-1). This grading system was modified during the course of my thesis 
with an updated classification published in 2008. As it had become apparent 
that Grade 1 and 2 FL did not differ with respect to clinical outcome and 
response to therapy, these cases with few centroblasts were grouped together as 
―FL Grade 1-2 (low grade FL)‖. A further change was that the segregation of 
Grade 3 into 3a and 3b was made mandatory having been previously optional. 
This was to allow stratification for future outcome analysis as studies had 
suggested that Grade 3b might resemble DLBCL in behaviour (Bosga-Bouwer, 
et al 2003, Ott, et al 2002). Grading within this thesis refers to the WHO 2001 
classification in place at the commencement of the thesis. 
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Grade 1  0-5 centroblasts / hpf 
Grade 2 6-15 centroblasts / hpf 
Grade 3 >15 centroblasts / hpf 
 
Table 1-1 Histopathological grading of FL  
 
Grading of FL as per WHO Classification of 2001. Grade 3 may be subdivided 
into Grade 3a in which centrocytes are still present and Grade 3b in which 
there are sheets of centroblasts. Grading is performed by taking an average 
count from representative follicles from 10 high power fields (hpf). 
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1.2.2 Immunophenotype 
 
B cell lymphomas tend to have a distinct immunohistochemical protein 
expression profile corresponding to their putative normal counterpart, which 
provides further evidence for the theory of malignant B cells being ―frozen‖ at 
a stage of B cell differentiation. These profiles are outlined in Figure 1-1 in 
relation to that of their normal cell counterpart. 
 
FL cells are typically positive for BCL2 and the GC markers CD10 and BCL6 
and express B-cell associated antigens such as CD19, CD20, CD22 and 
CD79a. They are negative for other markers used in the differential diagnosis 
of lymphomas of small lymphocytes (CD5 and CD23). Meshworks of 
follicular dendritic cells (CD21, CD23 positive) are also present in follicular 
areas. 
 
The anti-apoptotic BCL2 protein is expressed in the majority of cases. This is 
commonly used as one of the criteria favouring FL in the differential diagnosis 
with reactive follicular hyperplasia. It is not useful in the differential diagnosis 
of other low-grade B cell lymphomas, most of which also express BCL2 
protein. While BCL2 is expressed in nearly 100% of grade 1 FL, it is expressed 
in only 74% of grade 3 FL (Lai, et al 1998). 
 
1.2.3 Molecular pathology 
 
Lymphomas develop as a clonal proliferation of lymphocytes that have 
acquired changes that confer a survival advantage over other lymphocytes. The 
frequent overexpression of the anti-apoptotic BCL2 protein is due to the 
t(14;18)(q32;q21) translocation involving rearrangement of the BCL2 and IgH 
genes (Tsujimoto, et al 1985). This cytogenetic abnormality is a hallmark of 
FL with up to 95% of FL cases characterised by this translocation (Horsman, et 
al 1995, Rowley 1988) which contributes to uncontrolled proliferation. 
However, this change alone is not sufficient for lymphomagenesis (McDonnell 
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and Korsmeyer 1991). Indeed, many healthy individuals carry the t(14;18) 
translocation without progressing to FL (Roulland, et al 2006, Schuler, et al 
2009). 
 
A number of studies have attempted to determine the secondary events 
necessary for follicular lymphomagenesis. These may be considered with 
respect to the malignant cell, its microenvironment or predisposing risk factors 
related to the individual. 
 
Genetic studies of the malignant B cell have demonstrated a complex 
heterogenous accumulation of secondary genetic events in the tumour 
including loss of 1p, 6q, 10q and 17 p, gains of chromosomes 1, 6p, 7, 8, 12q 
and X (Hoglund, et al 2004, Offit, et al 1993, Tilly, et al 1994, Viardot, et al 
2002) and areas of acquired uniparental disomy (aUPD) affecting multiple 
chromosomal regions (Fitzgibbon, et al 2007). While such additional changes 
are identified in 90% of FL patients, the majority of these changes occur in 
only a small subset of patients.  
 
Recent studies from our own group have further demonstrated this 
heterogeneity of secondary chromosomal changes. In studies of 185 FL 
patients, Single Nucleotide Polymorphism (SNP) profiling identified genomic 
abnormalities in 65% of patients, yet no individual chromosomal abnormality 
occurred in more than 14% of patients (O'Shea, et al 2009). Studies on the 
same patient group showed TP53 mutation to be associated with worse 
prognosis but this mutation was only present in 6% of patients at diagnosis 
(O'Shea, et al 2008).  
 
Along with acquired somatic genetic changes in the B cell, germline genetic 
changes predisposing to malignancy may be present in an individual. While 
familial FL is rare (Last, et al 2000, Marco, et al 1999), genetic predisposition 
has recently been investigated by genome wide association study (GWAS) in 
FL (Skibola, et al 2009). This study identified a novel susceptibility locus on 
chromosome 6p21.3 while the finding of a 4-fold increased FL risk in first 
degree relatives of FL patients (Goldin, et al 2009) supports a role for germline 
Chapter 1           
 
 31 
susceptibility factors in this disease.   
 
Much recent interest has focussed on the role of the inflammatory cells 
surrounding the tumour – the tumour microenvironment. In a study 
published in 2004 in the New England Journal of Medicine, Dave and 
colleagues examined gene expression profiles of a series of 191 FL patients 
and defined two gene expression signatures associated with prognosis (Dave, et 
al 2004). While one signature reflecting expression of T cell and macrophage 
genes was associated with long survival, the other signature included genes 
expressed by macrophages and/or dendritic cells and was associated with short 
survival. These findings suggested a critical role for the tumour 
microenvironment in FL biology in influencing gene expression and prognosis. 
This led to a number of subsequent immunohistochemical studies examining 
the link between FL prognosis and numbers and location of particular types of 
inflammatory cells, which have shown partly conflicting results (Alvaro, et al 
2006a, Alvaro, et al 2006b, Carreras, et al 2006, Farinha, et al 2010, Farinha, 
et al 2005, Glas, et al 2007, Lee, et al 2006a). 
 
Epidemiological studies provide clues as to individual risk factors for 
developing this disease. The incidence of FL is higher in the United States than 
in Asia and the developing world (Anderson, et al 1998), suggesting a possible 
role for environmental factors although infectious agents have not been 
implicated as they clearly are in other B cell lymphomas. Although the 
stimulus for t(14;18) itself remains unexplained, increased t(14;18) positive 
cell frequency in farm workers exposed to pesticide (Agopian, et al 2009) 
supports a role for environmental factors in development of this disease. 
 
1.2.4 Prognosis in FL 
 
A persistent difficulty in FL has been in identifying prognostic factors. 
Attempts have been made to predict prognosis based on both clinical and 
pathological criteria and these have been the subject of a recent review 
(Relander, et al 2010). Clinical criteria include the Follicular Lymphoma 
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Prognostic Index (FLIPI), which examines five clinical parameters (age, stage, 
anaemia, number of nodal sites involved and serum Lactate Dehydrogenase) 
(Solal-Celigny, et al 2004). This has been used to stratify patients into three 
groups with 10 year overall survival (OS) rates of 71%, 51% and 36%.  While 
this has been refined recently as the FLIPI-2 index (Federico, et al 2009), 
variations in outcome within the risk groups remain.  Attention has also 
focussed on assessing whether the pathologic factors outlined above (such as 
histologic grade, cytogenetic and molecular changes, host constitutional 
genetic changes and the microenvironment) impact on prognosis. To date, 
however, no consistent biomarker has been identified to predict prognosis. In 
particular, there is still a need to understand the processes that drive a key 
event in determining prognosis: the transformation from FL into aggressive 
lymphoma.  
  
1.3 Transformation of FL 
 
In 1938, Symmers described a case of  ―Giant follicular lymphadenopathy with 
or without splenomegaly: its transformation into polymorphous cell sarcoma of 
the lymph follicles‖ (Symmers 1938). This progression into a large cell 
neoplasm corresponds to what we know today as transformation of FL, a 
process where the histopathological appearance of the lymphoma changes from 
that of FL to a more aggressive lymphoma (t-FL), usually diffuse large B-cell 
lymphoma (DLBCL).  
 
1.3.1 Incidence and significance of transformation of FL 
 
Transformation occurs in as many as half of patients and is often associated 
with particularly poor outcomes (Bastion, et al 1997, Cullen, et al 1979, 
Gallagher, et al 1986, Garvin, et al 1983, Horning and Rosenberg 1984, 
Hubbard, et al 1982, Montoto, et al 2007). In one of the most recent and largest 
studies examining transformation, Montoto and colleagues analysed a series of 
325 patients diagnosed at Barts between 1972 and 1999 with a median follow-
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up of 15 years (Montoto, et al 2007). The risk of histologic transformation 
(HT) was 28% by 10 years and 37% by 15 years with a median survival post 
HT of just 1.2 years. 
 
1.3.2 Mechanisms of transformation 
 
Given the association of transformation with drastically reduced survival, 
several studies have attempted to elucidate the mechanisms involved in 
transformation. These have examined genetic differences between the two 
disease states in an attempt to gain biological insight into the mechanisms of 
transformation and to improve patient management. Studies have been based 
on examining differences between sequential pre- and post-transformation 
biopsies. These identified a range of cytogenetic abnormalities (Boonstra, et al 
2003, Goff, et al 2000, Hough, et al 2001, Martinez-Climent, et al 2003), 
mutations of tumour suppressor genes such as TP53 (Davies, et al 2005, Lo 
Coco, et al 1993, Sander, et al 1993), c-MYC rearrangements (Yano, et al 
1992) and mutation (Lossos, et al 2002) and inactivation of CDKN2A and 
CDKN2B (Elenitoba-Johnson, et al 1998). While such recurring genetic 
abnormalities have been described, these affect only a small subset of patients 
suggesting that as yet undiscovered events may play a key role in 
transformation. Recent studies have suggested that transformed FL may result 
not only by a stepwise accumulation of abnormalities in the original FL clone 
but also by divergent evolution from a common progenitor cell (Carlotti, et al 
2009). 
 
What is clear is that while many studies have been performed, they have yet to 
identify key secondary genetic changes common to the majority of FL cases or 
involved in the transformation process. This led us to ask whether epigenetic 
changes may play such a role in FL and its transformation. The study of 
epigenetic changes in FL has trailed behind these extensive genetic studies and 
it is only in recent years as technology has advanced, that we have gained 
insights into the epigenetics of FL. 
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1.4 Epigenetics 
 
Conrad Waddington first introduced the term ‗epigenetics‘ in 1939 as ‗the 
interaction of genes with their environment, which bring the phenotype into 
being‘(Waddington 1939). The current commonly accepted definition of 
epigenetics refers to heritable patterns of altered gene expression that are 
mediated by mechanisms which do not alter the primary DNA sequence 
(Holliday 1987). Such epigenetic mechanisms may lead to both gene 
repression and activation. Recently epigenetic abnormalities have been 
identified as frequently occurring in human cancers. The best studied 
epigenetic mechanism involves addition of a methyl group (methylation) to 
cytosine bases within the DNA (Figure 1-4) while histone proteins, the 
principal protein component of chromatin that package DNA, also undergo a 
range of modifications on their amino acid terminal tails (Figure 1-5). These 
modifications include acetylation of lysine amino acids, phosphorylation of 
serines and methylation of either arginine or lysine (Figure 1-6). Together, 
these changes in DNA and histones play a significant role in regulation of gene 
expression. I will first outline how these mechanisms act in concert to affect 
gene expression before concentrating on those key epigenetic mechanisms that 
are the focus of my study. 
 
1.4.1 Epigenetic mechanisms in control of gene expression 
 
 
Changes in gene expression occur in the context of alterations in chromatin and 
transcription factor activity. Alterations to the structures of DNA, nucleosomes 
and their histones act together to affect chromatin configuration. These 
alterations typically occur at the promoter regions of genes, where transcription 
into mRNA begins. 
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Figure 1-4 DNA Methylation  
DNA methylation involves the addition of a methyl (CH3-) group to the 
Carbon-5 position of a cytosine base in a reaction catalysed by DNA 
Methyltransferase (DNMT) enzymes using S-Adenosyl-Methionine as a donor. 
Drugs such as 5-Azacytidine can block this reaction. (Herman and Baylin 
2003). 
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Figure 1-5 Major epigenetic mechanisms 
The two major epigenetic processes involve DNA methylation and 
modifications of the histone proteins that package DNA. (Anonymous 2008) 
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Figure 1-6 Histone modifications 
 
A number of post-translational modifications occur to the amino acids on the 
terminal tails of histones. Modifications include methylation, acetylation, 
phosphorylation and ubiquitinylation. These modifications have a characteristic 
distribution at individual amino acid bases. (Spivakov and Fisher 2007) 
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DNA methylation involves the addition of a methyl group (CH3) to the carbon-
5 position of the pyrimidine ring of cytosine (C) in a reaction catalysed by 
DNA methyltransferases (DNMTs) (Figure 1-4). Typically, this occurs where 
the cytosine is adjacent to a guanine residue in the DNA sequence (CpG 
dinucleotide). These CpG sites are often clustered together in CpG rich areas 
known as CpG islands (CGIs), which are frequently found in association with 
gene promoter regions, where transcription begins. Gains of DNA methylation 
at these sites are conventionally associated with gene silencing. 
 
While DNA methylation is associated with gene repression, the effect of 
histone modifications depends on both the specific amino acid being modified 
and the exact type of modification i.e. methylation, acetylation, 
phosphorylation. Specific patterns of modifications associated with activation 
or repression of gene expression have been termed a ―histone code‖ (Jenuwein 
and Allis 2001, Strahl and Allis 2000) (Figure 1-7). Specific histone 
modification patterns occur in combination with DNA methylation changes to 
affect gene transcription. 
  
While the following is perhaps a simplistic model it is worth outlining the 
typical patterns seen at gene promoters in both the active and repressive states 
(Figure 1-7). In the setting of an active gene with an unmethylated promoter 
region, nucleosomes are widely spaced allowing access to proteins that activate 
transcription – an ―open chromatin‖ configuration. In this situation the amino 
acid tails of the histones are kept in an acetylated state and the histone 
methylation marks are of the ―activating‖ type such as trimethylated Lysine 4 
of Histone H3 (H3K4Me3). 
 
However, when these promoters are methylated, the nucleosomes are tightly 
compacted and regularly spaced, thus excluding proteins involved in activating 
gene transcription – ―closed chromatin‖ (Herman and Baylin 2003). This 
reduction in transcription is also affected by the actions of histone deacetylases 
(HDACs) which deacetylate the histone tails (Bird and Wolffe 1999, Jenuwein 
and Allis 2001, Kuzmichev and Reinberg 2001, Strahl and Allis 2000).  
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Figure 1-7 Epigenetics and gene expression 
 
Distinct epigenetic modifications and chromatin arrangement are associated 
with active and repressed genes. Actively transcribed genes are typically 
associated with unmethylated CpG loci within CpG islands and a combination 
of histone modifications including H3K4Me3 while inactive, repressed genes 
are associated with methylated CpG islands and histone modifications such as 
H3K27Me3. (Schones and Zhao 2008) 
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Furthermore, HDACs interact with both DNMTs and a group of chromatin 
proteins known as methyl-cytosine binding proteins (MBDs). While 
unmethylated promoters generally lack MBD proteins, MBDs occupy most 
hypermethylated promoters (Lopez-Serra, et al 2006). These regions will also 
tend to be marked by the ―repressive‖ histone methylation marks such as 
trimethylated Lysine 27 of Histone H3 (H3K27Me3). 
 
In summary, an environment conducive to transcriptional repression is 
achieved by the combination of DNMTs, histone deacetylases, histone 
methylases and MBDs. This formation of closed chromatin is associated with 
CGI hypermethylation and a combination of ―repressive‖ histone 
modifications: deacetylation of histone H3 and H4, loss of H3K4 
trimethylation and gain of H3K9 di/trimethylation and H3K27 trimethylation 
(Esteller 2008).  
 
It is worth noting that many of these histone modifications may not be true 
epigenetic changes, as they have not yet satisfied the heritability criteria i.e. 
that the mark is stably transmitted with cell division. Of these various 
modifications, trimethylation of Lysine 27 of Histone H3 (H3K27Me3) is 
relatively stable and is considered to be the most likely to fulfil the heritability 
criteria in that it may carry epigenetic information through cell divisions 
(Hansen, et al 2008). This repressive mark is catalysed by the Polycomb 
Repressor Complex 2 (PRC2)(Cao, et al 2002), a multiprotein complex 
composed of multiple polycomb group (PcG) proteins including the histone 
methyltransferase EZH2 (Enhancer of zeste homolog 2). We will see later that 
intriguing links have emerged between this mark and another key repressive 
mechanism, DNA methylation, in FL. 
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1.5 DNA Methylation 
 
The best-studied epigenetic mechanism and the primary focus of my study is 
methylation of the cytosine base, which along with adenine, guanine and 
thymine forms the DNA sequence. As mentioned, DNA methylation in 
eukaryotes involves addition of a methyl group (CH3) to the carbon-5 position 
of the pyrimidine ring of cytosine (C). Almost all (99.98%) of cytosine 
methylation in differentiated cells occurs at CpG dinucleotides (Lister, et al 
2009). 
 
The DNMTs that catalyse this reaction are a group of highly related enzymes 
that use S-adenosylmethionine as the donor molecule for the methyl group 
(Figure 1-4). Maintenance of DNA methylation in somatic cells is associated 
with DNMT1 while de novo methylation during embryonic development is 
typically attributed to DNT3A and DNMT3B (Bestor 2000, Hermann, et al 
2004, Okano, et al 1998) although there is overlap in function of these 
enzymes (Bestor 2000, Graff, et al 1997, Hermann, et al 2004, Liang, et al 
2002, Vertino, et al 1996). While cytosine methylation was first described over 
50 years ago (Hotchkiss 1948), it was over 20 years later before it was 
proposed to act as a stably inherited modification affecting gene regulation and 
cellular differentiation (Holliday and Pugh 1975, Riggs 1975)  
 
1.5.1 DNA Methylation in normal physiology 
 
In normal tissue the majority of CpGs are methylated. As methylated cytosine 
undergoes spontaneous deamination to uracil, the genome has become 
evolutionarily depleted of these CpG dinucleotides to offset their mutagenic 
potential. However, certain regions of the genome contain areas rich in 
preserved CpGs referred to as CpG islands (CGIs). These are defined either 
according to the 1987 ‗relaxed‘ criteria proposed by Gardiner-Garden and 
Frommer as regions of at least 200 base pair (bp) length with a C+G content of 
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50% and an observed CpG/expected CpG in excess of 0.6 (Gardiner-Garden 
and Frommer 1987) or according to the more stringent criteria of Takai and 
Jones (500-bp; C+G content ≥55%; observed CpG / expected CpG ratio of 
>0.65) (Takai and Jones 2002). Using the latter definition, there are 
approximately 28,000 CGIs located within non-repetitive areas in the human 
haploid genome (McCabe, et al 2009). These CpG islands span the 5´end 
region of genes with 37% localising to promoter regions. Approximately 70% 
of known genes contain a CpG island within a 3kb region (2kb upstream - 1kb 
downstream) of their transcriptional start site (TSS).  
 
The conventional view is that in the normal physiological state the CpGs 
within these islands are unmethylated while the more sparsely distributed CpGs 
in the remainder of the genome are methylated (Figure 1-8). However, 
changes in methylation occur in a number of physiological situations. For 
instance, methylation is associated with transcriptional silencing of genes on 
the inactive female X chromosome (Reik and Lewis 2005) and with silencing 
of imprinted genes (Feinberg, et al 2002). Gradual increases in methylation 
within non-imprinted autosomal CGIs in normal somatic tissue have been 
reported in aging (Christensen, et al 2009, Issa, et al 1994, Issa, et al 1996). 
Recent studies have also shown that a minority of CGIs are normally 
methylated across a range of non-diseased somatic tissues (Eckhardt, et al 
2006, Illingworth and Bird 2009, Shen, et al 2007, Weber, et al 2005, Weber, 
et al 2007).  
 
1.5.2 Introduction to DNA methylation in cancer  
 
In cancer, the situation outlined above in relation to normal tissue is reversed, 
with the CpGs within the CpG island becoming methylated and the genome 
becoming globally hypomethylated (Herman and Baylin 2003) (Figure 1-8). 
Indeed, loss of DNA methylation at CpGs was the first epigenetic abnormality 
described in cancer (Feinberg and Vogelstein 1983). Typically, this 
hypomethylation occurs within repetitive elements, coding regions and introns 
rather than within promoters / CGIs (Feinberg, et al 1988) and has been linked 
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with chromosomal instability (Qu, et al 1999) as it favours mitotic 
recombination with consequent deletions and chromosomal rearrangements.  
 
Aberrant hypermethylation occurring in a CpG island associated with a gene 
promoter region was linked with reduction in gene expression in the early 
1990s and has conventionally been viewed since as correlating with gene 
silencing i.e. loss of mRNA expression (Bird 2002, Herman 1999, Herman and 
Baylin 2003, Jones and Baylin 2002, Jones and Laird 1999). The first reports 
identifying hypermethylation within CGIs associated with tumour suppressor 
genes (TSGs) were in the Rb gene in retinoblastoma (Greger, et al 1994, Sakai, 
et al 1991) and soon after at other TSGs such as VHL1 (Herman, et al 1994), 
CDKN2A (Gonzalez-Zulueta, et al 1995, Merlo, et al 1995), MLH1 
(Cunningham, et al 1998, Herman, et al 1998, Kane, et al 1997, Veigl, et al 
1998) and BRCA1 (Esteller, et al 2000). This led to methylation in cancer being 
viewed as being a potential mechanism for one of the two ‗hits‘ required for 
gene silencing as per Knudson‘s hypothesis (Herman and Baylin 2003, 
Knudson 1971) (Figure 1-9). Such findings led to aberrant methylation in 
cancer being conventionally equated with TSG silencing.  
 
The advances in our understanding of DNA methylation have been due in a 
large part to the huge advances in methylation analysis technology over the last 
decade. As such technology has advanced, insight has been gained into the 
frequency and extent of hypermethylation in cancer. I will first outline the 
development of this technology before outlining our knowledge of DNA 
methylation in cancer and particularly in FL as it was at the start of my studies. 
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Figure 1-8 CpG Methylation patterns in normal and malignant tissue. 
 
Illustration of differing distribution of DNA methylation in normal and 
cancerous tissue at CpG islands and outside of CpG islands. Within non-
cancerous cells CpG loci within CpG islands are typically unmethylated while 
the more sparsely distributed CpG loci in the remainder of the genome are 
methylated. In cancer, this pattern is typically reversed with aberrant 
hypermethylation occurring at CpG islands while a global hypomethylation 
occurs at sites outside of CpG islands. White circle = unmethylated CpG loci; 
black circles = methylated CpG loci. (Herman and Baylin 2003) 
Chapter 1           
 
 45 
 
 
 
Figure 1-9 Mechanisms of TSG silencing 
 
Methylation has conventionally been viewed as a method of silencing TSGs in 
combination with genetic events according to Knudson‘s two-hit hypothesis. 
The figure illustrates mechanisms by which DNA methylation, coding region 
mutations and chromosomal deletions may combine to cause TSG silencing 
either as part of an inherited cancer with a germline first-hit event or as a 
sporadic cancer involving two sporadic hits. (Herman and Baylin 2003) 
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1.6 Techniques for study of DNA methylation 
 
The standard molecular biology techniques used for examination of genetic 
information have traditionally not been applicable to study of DNA 
methylation. Methylation analysis requires an initial step to select for 
methylated DNA and this DNA can then be combined with standard techniques 
such as Polymerase Chain Reaction (PCR), array hybridisation and sequencing. 
Earlier studies of methylation typically focused on small numbers of candidate 
genes on a gene-by-gene basis. Recent advances in methylation technology 
have shifted the focus towards more genome-wide studies in an attempt to 
evaluate multiple genes simultaneously in a large number of samples.  
 
While numerous methods have been developed to examine DNA methylation, 
most of these are based on an initial DNA selection step using one of three 
basic methods: 
 Examination of bisulphite converted DNA 
 Cutting of DNA by methylation-sensitive restriction enzymes 
 Immunoprecipitation using antibodies against methylation-related 
proteins 
While there are myriad techniques to study methylation, I will outline the 
principles behind the three main methods and discuss a selection of techniques 
representing each method.  
 
1.6.1 Bisulphite conversion 
 
One of the key events in the progression of methylation studies was the 
application of bisulphite conversion to methylation analysis in the early 1990s 
(Clark, et al 1994, Frommer, et al 1992). This chemical reaction is a three-step 
process that converts unmethylated cytosine bases to uracil while methylated 
cytosines remain unchanged (Figure 1-10 & Figure 1-11).  
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Figure 1-10 Chemistry of bisulphite conversion.  
 
In this method, DNA is first denatured with sodium hydroxide prior to 
bisulphite-modification. Unmethylated cytosines undergo deamination by 
sodium bisulphite by the following three steps: 
 
-  Sulphonation of cytosine to form cytosine sulphate 
-  Hydrolytic deamination to give a uracil-bisulphite derivative 
-  Removal of the sulphonate group by a subsequent alkali treatment to 
form uracil 
 
The initial two steps are performed at acidic pH while the final step is alkali 
treatment. (Clark, et al 1994) 
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Figure 1-11 Effect of bisulphite conversion on DNA sequence 
 
While unmethylated cytosines (highlighted in blue or green) are converted to 
uracil, methylated cytosines (highlighted in red) remain unchanged following 
bisulphite conversion. The sequence difference thus created between 
methylated and unmethylated alleles facilitates design of subsequent PCR-
based assays that can discriminate between methylated and unmethylated 
DNA.  
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The discovery of the effects of bisulphite conversion led to a revolution in 
DNA methylation analysis in the subsequent years. An epigenetic modification 
of DNA could now be analysed as a genetic difference, in effect a SNP, 
allowing numerous standard molecular biology techniques to be coupled with 
the initial bisulphite conversion step. 
 
Among the first of these techniques was Methylation-specific PCR (MSP) 
(Herman, et al 1996) in which two primer sets are designed to bisulphite-
converted DNA. One primer set is complementary to methylated DNA (M-
MSP reaction) while the other primer set is specifically complementary to 
unmethylated DNA (U-MSP reaction). Bisulphite-converted DNA is amplified 
in two separate reactions and the products analysed in parallel by agarose gel 
electrophoresis. This is an extremely sensitive method of detecting methylation 
allowing detection of as little as 1 in 1000 methylated alleles in an otherwise 
unmethylated sample. This sensitivity is arguably both a strength and a 
weakness. MSP is useful as a screening tool as a negative M-MSP reaction 
suggests absence of methylation. However, the method is at best semi-
quantitative with a positive M-MSP reaction generally being unable to 
distinguish between samples with high and low levels of methylation. This has 
been one of the most widely used techniques for methylation analysis of single 
genes given its flexibility to interrogate almost any CpG site, its relative ease 
and its cost efficiency. Subsequent years have seen modifications of basic MSP 
such as the MethyLight technique (Eads, et al 2000) that provides quantitative 
values through a methylation-specific modification of the real-time PCR based 
mechanism. 
 
Bisulphite converted DNA has also been coupled with sequencing techniques. 
In the early 1990s, this involved Sanger sequencing of cloned PCR products 
from individual loci (Frommer, et al 1992) or direct sequence analysis (Clark, 
et al 1994). Recent years have seen this method applied on a large scale to 
analyse the methylation patterns of human Chromosomes 6, 20 and 22 as well 
as the coupling of bisulphite-converted DNA with sequencing-by-synthesis 
methods. These methods involve sequential addition of nucleotides and their 
incorporation into a primer-directed polymerase extension. As each nucleotide 
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is incorporated they release pyrophosphate which is enzymatically converted to 
give a measurable light signal. This allows quantitative measurement of 
methylation status at each locus by examining the ratio of T and C signals. 
Such methods are not only applicable to single gene analysis as with 
Pyrosequencing (described in detail in Chapter 2.12), they also form the basis 
for some of the rapidly developing next-generation sequencing technologies. 
While these technologies have great potential, they are not currently suitable 
for genome-wide examination of large numbers of clinical samples. 
 
On the other hand, hybridisation of bisulphite-converted DNA to arrays holds 
potential to examine large numbers of samples. However, such applications 
have traditionally been difficult as bisulphite-converted unmethylated DNA 
contains 3 bases (A, G and T) rather than 4 as the unmethylated cytosine is 
converted to thymine (Figure 1-10 & Figure 1-11). This reduced complexity 
of bisulphite-converted DNA results in reduced hybridisation specificity. The 
first descriptions of array-based methylation profiling of bisulphite-modified 
DNA were published in 2002 (Adorjan, et al 2002, Gitan, et al 2002). 
Bisulphite-converted DNA was first amplified by PCR at specific regions and 
hybridised to oligonucleotide probes designed specific to either methylated or 
unmethylated state at each CpG locus being studied.  
 
The commercial array platforms we use in our studies are based around the 
BeadArray technology developed by Illumina Inc. (San Diego, California, 
U.S.A). First described in 2006 (Bibikova, et al 2006b), the Illumina 
GoldenGate method again involved modifying an established genetic test to 
obtain epigenetic information. In this case, the Illumina Single Nucleotide 
Polymorphism (SNP) array was modified as the bisulphite conversion 
effectively creates a C/T SNP between methylated and unmethylated DNA. 
This platform allowed the examination of quantitative methylation values at 
1505 CpG loci in up to 96 patients simultaneously on a single array. Illumina 
followed the commercial release of the GoldenGate platform in 2007 with the 
release early in 2008 of the Infinium Human Methylation 27 array which 
expanded the number of CpGs examined to over 27,000 (Bibikova, et al 2009), 
a huge leap forward in scope of analysis. While the chemical processes behind 
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both arrays differ, both rely on amplifying methylated and unmethylated DNA 
followed by hybridisation to corresponding probes arranged on microscopic 
beads. Quantitative methylation values are obtained by comparison of the 
relative quantities of hybridised methylated and unmethylated products. The 
technology of each method is detailed in Chapter 2. 
 
1.6.2 Use of Restriction enzymes 
 
Restriction enzymes are enzymes that cut DNA at specific sequences known as 
restriction sites. DNA may be cut into methylated and unmethylated genomic 
DNA by methylation-sensitive restriction enzymes that can distinguish 
between methylated and unmethylated recognition sites. This is used as an 
initial selection step that is then coupled with standard genetic techniques. 
These initially included techniques such as Southern Blotting (Singer-Sam, et 
al 1990) which required large amounts of starting DNA and while PCR 
amplification (Restriction enzyme-related PCR) assisted with this issue, the 
technique still suffers from the fact that it can only detect methylation changes 
at sites where the enzyme had recognition sites.  Restriction enzyme method 
has also been used in tandem with bisulphite conversion methods for locus–
specific studies in a technique called Combined Bisulphite Restriction 
Analysis (COBRA) (Xiong and Laird 1997). This had the advantage over the 
previously described restriction-enzyme based techniques in that it is 
applicable to DNA isolated from FFPE sections unlike the Southern Blot 
technique.  
 
Restriction enzyme based analysis was one of the first methods used to 
examine methylation on a more global scale when Costello and colleagues 
used Restriction Landmark Genomic Scanning (RLGS) in an important 
study of methylation in multiple human tumours (Costello, et al 2000). 
Another technique using restriction enzymes that has been adapted for multiple 
gene analysis is Differential Methylation Hybridisation. This technique uses 
methylation-sensitive restriction enzymes to cut genomic DNA into fragments 
containing CpG islands. These fragments are then amplified by PCR and 
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hybridised onto probes on a nylon membrane or glass slide microarray (Huang, 
et al 1999). 
 
1.6.3 Immunoprecipitation 
 
An alternative study method is to treat genomic DNA with an antibody specific 
for a component of methylated DNA allowing the methylated fragments to be 
immunoprecipitated. The best-known application of this is Methylated DNA 
Immunoprecipitation (MeDIP). Following sonication of genomic DNA, anti-
5´-methylcytosine antibody is used to precipitate methylated DNA. This can 
then be compared with input DNA by differentially labelling both samples and 
hybridising to a CpG array (Weber, et al 2005). This has since been coupled 
with array Comparative Genomic Hybridisation (Wilson, et al 2006) and more 
recently with high-throughput sequencing techniques so that fragments 
captured by 5-methylcytosine can be sequenced and mapped to a reference 
genome sequence to more specifically identify sites of methylation (MeDIP-
seq). 
 
An advantage of this approach is that unlike many other methods, such as the 
Illumina bead arrays, the CpG sites for study are not pre-selected which leads 
to a less biased approach to identifying methylation sites. One of the 
disadvantages of this technique has been the inability to distinguish between 
sites with low or high percentage of positive CpGs as the efficiency of 
immunoprecipitation is dependent on density of methylated CpG sites. This has 
necessitated the development of complex bioanalytical tools to analyse data 
such as BaTMAn (Bayesian Tool for Methylation Analysis), which aim to 
estimate absolute methylation levels from MeDIP enrichment ratios (Down, et 
al 2008).  
 
Notably, a technique known as Chromatin Immunoprecipitation (ChIP) 
employs similar principles to document histone modifications. DNA is first 
treated with an antibody to the specific histone modification (e.g. H3K27Me3) 
and this selected DNA is immunoprecipitated. Identification of those genes 
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bound by the histone modification can then be carried out either by subsequent 
PCR for individual genes or by combining selected DNA with arrays (ChIP-
on-Chip) or sequencing platforms (ChIP-seq). 
 
1.6.4 Comparison of techniques 
 
While there has been a proliferation of methods to analyse methylation, there 
has been a distinct lack of critical systematic comparisons of these methods, in 
part because of the difficulty in comparing the results obtained by such diverse 
and complex techniques. No one array is perfect and each has various 
advantages and disadvantages related to factors such as sample DNA 
requirement, scale of coverage, inbuilt biases, sensitivity, specificity, sample 
throughput, ease of analysis, reproducibility and cost efficiency. Figure 1-12 
shows how a number of selected techniques compare in terms of two key 
considerations: sample throughput and extent of genome coverage.  
 
The advances in methylation profiling technology over the past decade have 
facilitated the explosion of interest in epigenetic research. I will outline how 
our knowledge of DNA methylation in cancer has evolved over the past few 
years, in particular in relation to FL.  
Chapter 1           
 
 54 
 
 
 
 
 
 
Figure 1-12 Comparison of methylation profiling technology. 
 
Comparison of a number of commonly used methylation technologies in terms 
of sample throughput and number of CpGs studied.  
 
HELP = HpaII tiny fragment Enrichment by Ligation-mediated PCR; WGSBS = 
whole genome shotgun bisulphite sequencing. 
  
(Adapted from (Irizarry, et al 2008, Laird 2010)). 
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1.7 DNA methylation in cancer – what we knew then… 
 
As the field of methylation research continues to advance rapidly in terms of 
both technology and concepts, I will attempt to outline our understanding of 
methylation in cancer, as it was at the start of my studies in early 2007. The 
intervening years have seen further advances and these are predominantly 
discussed in individual chapters as they relate to the development and progress 
of my studies. 
 
As the initial reports of aberrant tumour methylation in the late 1990s and early 
21
st
 century were confined to well-established tumour suppressor genes and 
were linked with reduction in gene expression, these findings led to 
methylation being considered as a potential second ‗hit‘ in silencing TSGs, 
alongside intragenic mutation and loss of chromosomal material, as per 
Knudson‘s hypothesis (Figure 1-9). In support of this, inactivation of these 
methylated genes by other mechanisms such as mutation had already been 
described, particularly in familial cancer scenarios. Methylation of TSGs was 
generally observed only on the wild-type allele where the other allele was 
mutated while biallelic methylation was often observed where neither allele 
was mutated (Esteller, et al 2001b, Myohanen, et al 1998). Such findings 
supported selective pressure as the primary reason for aberrant methylation in 
cancer with methylation as a localised event leading to TSG silencing and 
selective growth advantage for tumour clones. 
 
By the turn of the century, it was becoming clear that there was widespread 
loss of protection of multiple CGIs against DNA methylation (Jones and Laird 
1999). Around this time, Costello and colleagues produced one of the first 
multiple gene analyses of cancer (Costello, et al 2000). They examined 1,184 
CpG islands in 98 primary human tumours by RLGS. Noting that prior studies 
had focused on a mere 15 of the tens of thousands of CGIs, they estimated that 
an average of 608 CpG islands (range of 0 to 4,500) were aberrantly 
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methylated in the cancers studied. Methylation of some CGIs was 
demonstrated to be common to multiple tumour types while other CGIs were 
shown to be methylated in a tumour-type specific manner. This tumour-type 
specificity was also demonstrated by Esteller in 2001 (Esteller, et al 2001a) 
and Paz in a study of human cancer cell lines in 2003 (Paz, et al 2003). By 
2007, Esteller suggested the occurrence of 100-400 hypermethylated CpG 
islands in the promoter regions of a given tumour and that each tumour type 
has its own distinctive ―methylome‖ (Esteller 2007). 
 
This high frequency of methylation in certain tumours suggested that not all 
aberrantly methylated genes could be TSGs. Baylin & Herman, in a 2001 
editorial, posed the question ‖Promoter hypermethylation – can this change 
alone designate tumour suppressor gene status?‖ (Baylin and Herman 2001). 
Further support for this was the finding that many of the genes becoming 
aberrantly methylated were not necessarily involved in tumour growth or 
genesis. These arguments suggested that aberrant methylation may not be a 
random event and may be influenced by factors such as differential 
susceptibilities of individual CGIs. Despite the distinctive methylation profile 
of individual tumour types, a subset of CGIs is frequently methylated in many 
tumour types (Costello, et al 2000, Ehrich, et al 2008). The question therefore 
arose as to why certain CGIs become methylated in a given cancer while other 
CGIs do not. Do some CGIs have an inherent susceptibility to undergo aberrant 
methylation and what are the factors influencing this susceptibility? 
 
 
1.7.1 Factors determining CGI methylation 
 
 
The last 10 years have seen much progress towards establishing the factors that 
lead to certain CGIs being susceptible to aberrant methylation. At the start of 
this century, a number of studies addressed the issue of what mechanisms 
established methylation patterns (Di Croce, et al 2002, Fuks, et al 2001, 
Robertson, et al 2000). They identified links between DNA methylation and 
transcription factors. DNMT1 was found to exert its influence on specific 
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target genes through cooperation with Rb to repress transcription at promoters 
that contain binding sites for the Rb product E2F1 (Robertson, et al 2000). 
Fuks and colleagues showed that DNMT3a is recruited to promoters by RP58, 
which acts as a sequence-specific transcriptional repressor (Fuks, et al 2001). 
The finding that the PML-RAR fusion protein found in acute promyelocytic 
leukaemia (APL) led to DNMT recruitment and consequent gene 
hypermethylation established a link between a specific genetic event and 
epigenetic events (Di Croce, et al 2002). These observations that DNMTs 
interact with transcription factors supported a model that particular regions 
may be targeted for methylation through interaction with sequence-specific 
DNA-binding proteins. Thus, there may be an inherent susceptibility to 
aberrant methylation in certain CGIs due to their DNA sequence. 
 
A number of investigators attempted to define which DNA sequences are most 
prone to aberrant methylation. Feltus examined genes susceptible to CGI 
methylation by generating 3 single cell clones which expressed 50-fold 
increased levels of DNMT1 enzyme from independent human fibroblast clones 
(Feltus, et al 2003). Examination of the methylation profile of 1,749 unselected 
CGIs of these clones demonstrated that a subset of 66 CGIs (3.8%) were 
―methylation-prone‖, in that they were consistently hypermethylated. While 
methylation-prone (MP) and methylation-resistant (MR) CGIs did not differ 
significantly in terms of their length, C+G content, CpG density, chromosomal 
location or whether they were associated with promoters, they differed in terms 
of the DNA sequence of the CGI. The authors devised a classifier based on 
seven DNA sequence patterns that were reported as being capable of 
discriminating MP from MR CGIs with 82% accuracy. Similarly, Keshet and 
colleagues identified several short sequence motifs that were significantly 
enriched in methylated promoters as compared with total CGI promoters in 
colon cancer and prostate cancer cell lines (Keshet, et al 2006). These data 
suggested that certain CGIs with particular DNA sequences were inherently 
susceptible to methylation in cancer, possibly through targeting by sequence 
specific transcription factors that in turn recruit DNMTs. Further insight into 
which CGIs become aberrantly methylated in cancer was gained through 
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studies linking DNA and histone methylation published during the course of 
my studies, which I will outline here. 
 
1.7.2 Link between histone methylation and DNA methylation 
 
As previously discussed, DNA methylation does not act in isolation to alter 
gene expression and a range of histone modifications are associated with both 
gene activation and repression. While DNA methylation is typically associated 
with transcriptional repression, the effect of modification of histone proteins by 
methylation is dependent on the individual histone and protein being modified 
and the extent of methylation.  
 
We will focus here on a specific repressive epigenetic modification that has 
been linked with DNA methylation, the addition of three methyl groups to 
Lysine 27 of Histone H3 (H3K27me3). As mentioned, the Polycomb Repressor 
Complex 2, whose key component is the histone methyltransferase EZH2, 
catalyses this repressive mark. The polycomb family of proteins were first 
described in Drosophila where they are involved in the epigenetic repression of 
the homeotic (Hox) genes, which are key developmental genes. They function 
in humans to epigenetically repress differentiation-related genes in embryonic 
stem (ES) cells, thus maintaining pluripotency (Lee, et al 2006b). This 
repression may then be lost during differentiation as genes become active. 
Intriguing links have emerged between the EZH2 / H3K27Me3 pathway and 
DNA methylation in cancer in the past decade and particularly throughout the 
course of my research. These studies provide further insight into which genes 
are susceptible to aberrant methylation. The HOX family genes had been noted 
to be frequent targets of hypermethylation-associated downregulation in human 
cancer cells with HOX gene clusters described as a ―hotspot of de novo 
methylation in lung cancers‖ (Shiraishi, et al 2002) while Strathdee and 
colleagues demonstrated frequent hypermethylation of HOXA and HOXB 
cluster genes in a large series of lymphoid and myeloid leukemias (Strathdee, 
et al 2007). These studies had suggested that genes targeted by PRC2 such as 
the HOX family genes were susceptible to methylation. This was confirmed 
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with the comparison of hypermethylated gene lists with genome-wide studies 
that identified PRC2 target genes. 
 
While DNA methylation target genes had been identified in a range of benign 
and malignant tissues, identification of PRC2/H3K27Me3 target genes on a 
genome-wide scale was first reported in 2006. Due to the key role of 
PRC2/H3K27Me3 in controlling cell differentiation, H3K27Me3 target genes 
have been best profiled in embryonic stem cells (ESCs). Those genes targeted 
for repression by PRC2 in ESCs have been mapped on a genome wide scale 
(Lee, et al 2006b) by ChIP-on-Chip studies for H3K27Me3, which established 
H3K27Me3 occupancy at over 16,000 gene promoters. They also used similar 
methods to examine for occupancy by two other components of the PRC2 
complex - EED (embryonic ectoderm development) and SUZ12 (suppressor of 
zeste 12). They identified that H3K27Me3 marks approximately 7% of these 
gene promoters in ESCs.  
 
A number of groups utilised this genome-wide profiling data of PRC2 
occupancy in ESCs and examined for links between DNA methylation in 
cancer and PRC2 target genes in ESCs. In three independent studies published 
simultaneously in Nature Genetics in 2007 it was shown that genes that are 
targets of PRC2 in ESCs were statistically significantly overrepresented among 
hypermethylated genes in colorectal, breast, ovarian and lung cancer (Ohm, et 
al 2007, Schlesinger, et al 2007, Widschwendter, et al 2007). The findings of 
these studies are outlined in Table 1-2. 
 
The consistent finding from these 3 groups of overrepresentation of PRC2 
targets among hypermethylated genes in carcinomas led to speculation from 
the authors regarding the significance of these findings. Widschwendtner 
proposed that methylation at these sites acts to ―lock in stem cell phenotypes‖ 
and lead to abnormal clonal expression (Schuebel, et al 2006, Widschwendter, 
et al 2007). Ohm suggested that their findings ―suggest that a stem cell-like 
promoter ‗ground state‘ involving …trimethylated H3K27, may be indicative 
of the contribution of stem cell and/or progenitor cells to the derivation of adult 
cancers‖ (Ohm, et al 2007). Schlesinger and colleagues saw their findings that 
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gene promoters methylated in prostate and colon cancer were highly enriched 
for specific sequence motifs as further evidence for their group‘s theory that 
methylation occurred as part of a pre-programmed ―instructive‖ mechanism 
(Keshet, et al 2006).  
 
The links with PRC2 target status, in combination with the other findings of 
sequence specificity, suggest that the majority of aberrant methylation in 
tumours occurs due to such an instructive mechanism. Notably, not all PRC2 
targets become hypermethylated in cancer and not all hypermethylated genes 
are PRC2 targets. This suggests that hypermethylation also occurs by PRC2-
independent methods. Indeed, an exact mechanistic link between PRC2 and 
hypermethylation is not established despite a 2006 study linking EZH2 to 
direct control of DNA methylation via interaction with DNA 
methyltransferases (Vire, et al 2006). It is worth noting however, that clear 
silencing of known TSGs has been demonstrated (Esteller, et al 2001b) 
suggesting that some aberrant methylation is indeed a result of silencing of 
individual TSGs to gain selective growth advantage, often viewed as the 
primary mechanism and goal of DNA methylation (Jones and Baylin 2002).  
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Reference Samples studied Results 
(Ohm, et al 
2007) 
Range of human 
cancers (from 
literature review) 
68% of 29 known hypermethylated 
genes are PRC2 targets in ES or EF 
cells. 
Cell line HCT116 56.5% of 23 hypermethylated 
genes are PRC2 targets in ES or EF 
cells. 
(Schlesinger, et 
al 2007) 
Colon cancer cell line 
Caco-2  
50/109 (45.8%) hypermethylated 
genes are PRC2 targets in ES cells. 
Prostate cancer cell 
line PC3 
47/91 (51.6%) hypermethylated 
genes are PRC2 targets in ES cells. 
Primary colon 
tumours 
55/171 (32%) hypermethylated 
genes are PRC2 targets in ES cells. 
(Widschwendter, 
et al 2007) 
Primary colorectal 
tumours 
 
44% of 77 hypermethylated genes 
had at least one PRC2 mark in ES 
cells; 32% had all three PRC2 
marks. 
Ovarian cancer 
 
5 of 9 (56%) hypermethylated 
genes had at least two PRC2 marks 
in ES cells. 
Breast cancer 10 of 18 (56%) hypermethylated 
genes had at least two PRC2 marks 
in ES cells. 
Lung cancer cell line 96 of 273 (35%) had at least one 
PRC2 mark in ES cells. 
 
Table 1-2 Links between PRC2 and hypermethylation in cancer 
Summary of the 2007 studies, which showed that those genes marked at their 
promoters by PRC2 components in ESCs, are overrepresented among 
aberrantly hypermethylated genes in carcinoma. The enrichments described in 
all 3 studies were highly statistically significant when compared to the 
reference Polycomb Group (PcG) mapping studies. 
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1.8 Previous studies of DNA methylation in FL 
 
The growth of our knowledge regarding DNA methylation in FL reflects the 
situation in cancer in general. Initial studies of methylation in FL focused on 
methylation status of single genes, reflecting the technology available at the 
time and the prevalent thinking regarding methylation as a local event leading 
to TSG silencing and consequent selective growth advantage. Indeed, such 
studies were the focus of a recent review (Hayslip and Montero 2006) and 
despite the advances in technology and thinking, many studies continue to 
focus on individual genes. These studies typically used non-quantitative 
methods to look at a small number of selected candidate genes in a small 
number of patients (range 2 – 33). Few studies have been large enough to 
attempt correlation with clinical outcome although one group has claimed that 
DAPK1 methylation identified patients with inferior progression free survival 
(Voso, et al 2006). Table 1-3 provides a summary of gene-specific studies to 
date in FL.  
 
More recent studies from the group of Charles Caldwell in the University of 
Missouri have used emerging technology to gain a more global view of 
methylation in FL as part of studies examining a number of different NHL 
subtypes. Initial studies by this group examined 156 CpG loci from CGIs of 38 
genes, selected because of their relationship to the cell cycle. MSP was 
followed by hybridisation to a methylation-specific oligonucleotide microarray. 
Relative methylation values were obtained in 76 NHL samples including 26 FL 
cases (Guo, et al 2005, Shi, et al 2003, Yang, et al 2003). These were the first 
studies comparing NHL subtypes and significant preferential methylation was 
identified in FL relative to Mantle Cell Lymphoma (MCL) and Chronic 
Lymphocytic Leukaemia / Small Lymphocytic Leukaemia (B-CLL/SLL) for 
20 and 17 loci respectively. This suggestion of increased relative methylation 
in FL compared to other small B cell lymphomas was supported by similar 
findings in a 2006 study from the same group (Rahmatpanah, et al 2006) which 
used DMH  to examine 256 CpG loci in de novo patient samples from 43 NHL 
patients (15 FL, 16 B-CLL/SLL, 12 MCL).  
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The authors noted that the reasons for this preferential methylation were 
unclear but suggested that the increased methylation may be related to ongoing 
somatic hypermutation occurring in the germinal centre. These studies had 
provided the impetus for further studies of methylation in lymphoma and 
suggested a particular susceptibility for aberrant methylation in FL. However, 
to date these studies had still focused on relatively low numbers of genes in 
small patient series. Similarly, despite the abundance of studies of individual 
genetic changes in transformation of FL, the only study of DNA methylation in 
transformation analysed just 3 genes in 9 patients by the non-quantitative 
method of MSP (Rossi, et al 2004). Perhaps most importantly, no study had 
been able to correlate methylation values with gene expression or clinical 
outcome on a relatively global scale. Neither had any study attempted to 
determine what factors made certain CGIs susceptible to methylation in FL. 
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Table 1-3: Previous studies of individual gene methylation in FL. 
 
 
 
Gene Number of 
methylated 
samples (%) 
Method of 
analysis 
Reference 
ABF-1 9/15 (60) BS/PS (Ushmorov, et al 2008) 
AR 25/26 (96) MSP (Yang, et al 2003) 
BMP-6 0/19 (0) COBRA/BS (Daibata, et al 2007) 
CASP8 0/9 (0) MSP (Rossi, et al 2004) 
DAPK1 25/29 (86) MSP (Rossi, et al 2004) 
DBC1 24/24 (100) MSP / BS (Gronbaek, et al 2008) 
GADD45- 1/6 (17) MSP (Ying, et al 2005) 
GSTP1 10/18 (56) MSP (Rossi, et al 2004) 
ID4 10/10 (100) COBRA (Hagiwara, et al 2007) 
IL-12Rß-2 2/2 (100) MSP (Airoldi, et al 2004) 
MGMT 5/20 (25) MSP (Rossi, et al 2004) 
p14 0/14 (0) RE, MSP (Baur, et al 1999) 
p15 22/57 (39) RE, MSP (Chim, et al 2007, Martinez-
Delgado, et al 1998) 
p16 22/46 (48) RE, MSP (Chim, et al 2007, 
Villuendas, et al 1998) 
p57 8/18 (44) MSP (Li, et al 2002) 
p73 1/10 (10) MSP (Rossi, et al 2004) 
Rb 13/30 (43) MSP (Chim, et al 2007) 
SHP1 32/33 (97) MSP (Chim, et al 2004, Koyama, 
et al 2003) 
Snk/plk2 2/4 (50) MSP (Syed, et al 2006) 
SOCS1 0/9 (0) MSP (Chim, et al 2004) 
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1.9 Aims / Intent of thesis 
 
As part of the Leukemia & Lymphoma Molecular Profiling Project (LLMPP) 
collaboration, our group has been involved in a number of the previously 
mentioned studies analysing the genetic aspects of FL and its transformation to 
high grade lymphoma (Dave, et al 2004, O'Shea, et al 2009, O'Shea, et al 
2008). These have included studies of the effects of genetic changes and the 
tumour microenvironment on gene expression. At the start of my studies, 
epigenetic analysis in FL had been predominantly restricted to studies of small 
numbers of individual genes in small sample series with no significant study of 
its role in transformation. Nonetheless, the few larger studies had suggested 
that aberrant DNA methylation was more frequent in germinal centre 
lymphomas such as FL than other B cell lymphomas.  
 
Our starting hypothesis was that this frequent aberrant methylation in FL might 
have an additional role in altering gene expression and thus potentially clinical 
behaviour. Our aim was firstly to gain a detailed picture of the methylation 
status of a large series of diagnostic FL cases, paired pre- and post-
transformation FL cases along with appropriate controls with the following 
specific goals: 
 
 To determine the frequency of aberrant methylation in FL  
 To determine which genes undergo aberrant methylation in FL and the 
factors accounting for these genes‘ susceptibility to aberrant 
methylation 
 To assess whether hypermethylation of genes correlated with changes 
in gene expression 
 To assess the role of methylation in the transformation of FL to a more 
aggressive lymphoma 
 To determine the effect of methylation in FL on clinical outcome 
 
A further impetus for studying DNA methylation in FL is that epigenetic 
changes are potentially reversible, in contrast to genetic changes. Both 
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demethylating drugs and HDAC inhibitors can lead to re-expression of genes 
silenced by DNA methylation and histone deacetylation. Demethylating agents 
such as azacytidine have been approved for use in the treatment of 
Myelodysplastic Syndrome (Mack 2006, Muller, et al 2006, Oki, et al 2007). 
The significance of DNA methylation in FL is an important question as clinical 
trials of demethylating therapy in FL are currently in progress. We anticipated 
that in such a rapidly developing field, our aims would evolve to take account 
of both the findings of our initial studies and emerging literature over the 
course of the thesis. Indeed, where possible, literature emerging throughout the 
course of these studies is discussed alongside the results of the relevant 
experiments.  
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Chapter 2. Materials & Methods 
2.1 Patients and samples 
 
DNA samples were obtained from patients with untreated FL as well as 
sequential samples from patients with transformed FL from the tissue bank at 
Centre for Medical Oncology, Institute of Cancer, St. Bartholomew‘s (Barts) 
Hospital. DNA samples from untreated FL patients and benign haematopoietic 
tissues were obtained through the LLMPP group. Tissue microarrays 
previously constructed within the Centre for Medical Oncology were 
examined. Dr. Nathalie Johnson of the British Columbia Cancer Agency, 
Vancouver, Canada, provided clinical data on the LLMPP cases.  
 
2.2  Ethical Considerations 
 
The use of clinical material for analysis was governed by the requirements of 
the local Research Ethics Committee (LREC) (East London and the City 
LREC) under the relevant approved ethics submissions (05/Q0601/88 and 
05/Q0605/140). All samples were identified by code only with patient details 
held securely in a password protected computer file. 
 
2.3  Cell lines  
 
Cell lines were obtained from Cell Services at Cancer Research UK (CRUK). 
In total, 2 benign B lymphoblastoid cell lines and 4 B cell lymphoma cell lines 
were examined. Each of the benign B lymphoblastoid cell lines (HRC57 and 
Nc-Nc) had been established through EBV transformation from peripheral 
blood lymphocytes of healthy individuals. The four malignant germinal centre 
lymphoma cell lines examined are detailed in Table 2.1. 
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Cell Line 
Name 
Origin Immunology t(14;18) 
DoHH2 From pleural effusion of a 
60 year old male with 
transformed FL. 
CD10 +ve 
CD20+ve 
Positive  
Karpas-422 From pleural effusion of a 
73 year old woman with 
diffuse large B cell 
lymphoma. 
CD10 +ve 
CD20+ve 
Positive 
RL From ascitic fluid of 52 
year old male with B-
NHL (diffuse, 
undifferentiated, small 
non-cleaved/large cell) 
CD10 +ve 
CD20+ve 
Positive  
WSU-NHL From pleural effusion of 
46 year old woman with 
histiocytic lymphoma. 
CD10 +ve 
CD20+ve 
Positive 
 
Table 2-1 Details of malignant lymphoid cell lines analysed. 
 
All 4 cell lines show features of germinal centre B cell lymphomas with CD10 
expression and the presence of the t(14;18) translocation. 
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Cell lines were grown in suspension in sterile flasks in RPMI 1640 media 
supplemented with 10% (v/v) filtered, heat-inactivated foetal calf serum (FCS) 
and 1% (v/v) penicillin / streptomycin antibiotics. They were maintained in an 
incubator with a humidified atmosphere at 37ºC containing 5% CO2. Cells 
were passaged approximately 3 times per week as required to maintain optimal 
cell concentration. Cell viability measurements were obtained using the Vi-Cell 
XR Cell Viability Analyser (Beckman Coulter, Fullerton, CA, USA), which 
provides an automated analysis of cells using the trypan blue dye exclusion 
method, with video imaging used to distinguish viable cells which do not stain 
with trypan blue from the dye-stained non-viable cells. Where required for 
nucleic acid extraction, cells were centrifuged at 1300 rpm for 5 minutes and 
frozen until extraction. 
 
2.4  DNA extraction 
 
DNA extraction was performed on centrifuged cell line material (pellets) using 
the DNeasy Blood & Tissue kit (Catalogue number 69506, Qiagen, Hilden, 
Germany). Frozen cell pellets were thawed and resuspended in 200µl 
Phosphate Buffered Saline (PBS) in a microcentrifuge tube (Eppendorf, 
Hamburg, Germany). Lysis was performed by adding 20µl Proteinase K 
followed by the addition of 200µl Buffer AL. Contents were mixed by 
vortexing before incubation at 56ºC. After 10 minutes, the tube was returned to 
room temperature and 200µl 100% ethanol was added to the sample and the 
tube contents were mixed by vortexing. The mixture was transferred into a 
DNeasy Mini spin column containing a silica-based membrane and placed in a 
2ml collection tube and centrifuged at 6000xg (8000rpm). The DNeasy Mini 
spin column was placed in a new 2ml collection tube, 500µl Buffer AW1 was 
added and the column and tube were centrifuged for 1 minute at 6000xg 
(8000rpm). The DNeasy Mini spin column was again placed in a new 2ml 
collection tube, 500µl Buffer AW2 was added and centrifuged for 3 minutes at 
20000xg (14000rpm) to dry the DNeasy silica membrane. The spin column 
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was then placed into a 1.5ml polypropylene tube (Eppendorf, Hamburg, 
Germany) and a typical volume of 100µl elution buffer (Buffer AE) was 
pipetted directly onto the DNeasy membrane. The column and tube were 
incubated at room temperature for 1 minute before being centrifuged for 1 
minute at 6000xg (8000rpm) to elute the DNA.  
 
2.5  RNA extraction 
 
RNA extraction was performed from cell pellets using the RNeasy Mini kit 
(Catalogue number 74106, Qiagen, Hilden, Germany). As cell lines may be 
rich in ribonucleases (RNases), 10µl -mercaptoethanol was added to each ml 
of lysis buffer (Buffer RLT) to denature the nucleases and 600l of this lysis 
buffer was added to a thawed cell pellet and mixed by pipetting. The lysate was 
homogenized by pipetting it into a QIAshredder spin column placed in a 2 ml 
collection tube and centrifuging for 2 minutes at full speed. This shears high 
molecular weight cellular components to create a homogenous lysate, reducing 
viscosity and increasing efficiency of binding of RNA to the RNeasy spin 
column silica membrane in subsequent steps. An equal volume of 70% ethanol 
was added to the homogenized lysate and mixed well by pipetting. Up to 700µl 
of the sample was added to an RNeasy spin column placed in a 2ml collection 
tube and centrifuged for 15seconds at 8000xg (10000rpm). For samples 
where the sample volume exceeded 700µl, successive aliquots were 
centrifuged in the same RNeasy spin column. Following addition of 700µl 
Buffer RW1 to the RNeasy spin column, the column was centrifuged for 15 
seconds at 8000xg (10000rpm). This was followed by the addition of 500µl 
Buffer RPE (containing ethanol) to the RNeasy spin column, which was 
centrifuged for 15 seconds at 8000xg (10000rpm). This step was repeated, 
this time centrifuging for 2 minutes. The RNeasy spin column was then placed 
in a new 2ml collection tube and centrifuged at full speed for 1 minute in order 
to eliminate any carryover of buffer before transferring the column into a 1.5ml 
polypropylene tube. To elute the RNA, 40µl RNase free water was added 
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directly to the spin column membrane and centrifuged for 1 minute at 8000xg 
(10000rpm). 
 
2.6  Estimation of nucleic acid concentration and 
quality 
 
Nucleic acid solutions diluted in H2O, TE buffer or Qiagen Elution Buffer were 
examined using the NanoDrop ND-1000 Spectrophotometer (NanoDrop 
Technologies, Wilmington, DE, USA). Optical density (OD) of a 1.5l sample 
was measured at a wavelength of 260nm (the wavelength at which DNA and 
RNA absorb) relative to a blank standard (H2O, TE buffer or Qiagen Elution 
Buffer as appropriate). As proteins and phenol and other contaminants absorb 
at or near 280nm, the ratio of absorbance at 260nm/280nm was used to assess 
sample purity. Ratios of 1.8 or higher were accepted as indicative of 
contaminant-free DNA while ratios of 2.0 or higher were accepted as indicative 
of contaminant-free RNA.  
 
2.7  Bisulphite conversion of DNA 
 
The principles of bisulphite conversion of genomic DNA are outlined in 
Chapter 1 and the steps involved are summarised in Figure 1-10 & Figure 
1-11. Bisulphite modification was performed according to the following 
protocols using the EZ DNA Methylation kit (Zymo Research, California, 
U.S.A.) for Pyrosequencing (Individual sample format; Catalogue Number 
D5001/D5002) and Illumina GoldenGate array (96-well format; Catalogue 
Number D5004). Bisulphite modification for Methylation-specific PCR and 
Illumina Infinium array was performed using the EZ DNA Methylation Gold 
Kit (Zymo Research, D5005/D5006). Detailed protocols are available at 
http://www.zymoresearch.com/content/protocols-zymo-research. The EZ DNA 
Methylation Kit procedure is detailed here with the modifications for other kits 
noted. 
 
Chapter 2      
 
 72 
DNA samples contained 100-120ng DNA per l. Five µl of M-Dilution Buffer 
was added to a 5µl DNA sample in a 1.5ml polypropylene tube and the total 
volume was adjusted to 50µl with water and mixed by pipetting. The sample 
was incubated at 37°C for 15 minutes to denature the DNA. During this 
incubation the conversion reagent supplied in powder form was prepared by 
adding 750l H2O and 210l M-Dilution Buffer and dissolving reagent by 
frequent vortexing and shaking for 10 minutes. Following sample incubation, 
100µl of the prepared conversion reagent was added to each sample and mixed 
before incubation at 50°C in the dark for 12-16 hours. Following this overnight 
incubation, the sample was placed on ice for 10 minutes before being added to 
a Zymo-Spin IC Column (within a collection tube) to which 400µl of binding 
buffer had been added. The cap of the column was closed and mixed by 
inverting several times. The column / collection tube were centrifuged at 
≥10,000xg for 30 seconds and the flow-through was discarded from the 
collection tube. The column was washed by adding 100µl of ethanol-
containing wash buffer (24ml 100% ethanol / 6 ml concentrate) to the column 
and centrifuging at ≥10,000xg for 30 seconds. Desulphonation was performed 
by adding 200µl of M-Desulphonation Buffer to the column and allowing it 
stand at room temperature for 15-20 minutes. After this incubation, the column 
/ tube were centrifuged at ≥10,000xg for 30 seconds. Two further washing 
steps were then carried out by adding 200µl wash buffer and centrifuging at 
≥10,000xg for 30 seconds. The column was then placed into a labelled 1.5ml 
microcentrifuge tube and H2O was added directly to the column matrix before 
centrifuging column/tube at ≥10,000xg for 30 seconds to elute the DNA into 
the tube. Volume of H2O varied according to required concentration for 
subsequent experiments. 
 
The 96-well format involved a similar process with appropriate modifications 
in volumes and centrifugation speeds and durations as per protocol. Reactions 
were performed using a 96 well filter plate and collection plates in place of 
individual spin columns and collection tubes. The main difference in protocol 
for the EZ DNA Methylation Gold kit involves the conversion step. Instead of 
an overnight incubation at 50°C, samples were placed in a thermal cycler at 
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98°C for 10 minutes, 64°C for 2.5 hours with storage at 4°C for up to 20 hours. 
Input DNA volumes and elution volume differed according to the requirements 
of the subsequent experiments. For instance, a starting volume of 5µl of DNA 
(at 100-120ng/ µl) was used for MSP and eluted in 100µl ddH2O while DNA 
volume was 15µl for Infinium array with elution in 12µl of the company-
supplied elution buffer. 
 
2.8 Polymerase Chain reaction (PCR) 
 
PCR was performed as an initial step in direct sequencing and pyrosequencing 
reactions. PCR reactions were performed in thin walled 0.5ml PCR tubes 
(Applied Biosystems, Foster City, California, U.S.A.) on temperature-
controlled wells of a PTC-225 DNA Engine Tetrad automated thermal cycler 
(MJ Research, Waltham, Massachusetts, USA). Primer sequences, reaction 
mixtures and thermal cycling conditions for each gene studied are listed in 
Appendix C & E.  
 
2.9  Methylation-specific PCR (MSP) 
 
The development of bisulphite conversion led to the ability to differentiate 
between methylated and unmethylated sequences by taking advantage of the 
sequence differences between each state. The principles are outlined in 
Chapter 1.6.1. Each sample underwent two separate reactions with primers 
specific for unmethylated and methylated sequences. Primer sequences, 
reaction mixtures and thermal cycling conditions for each gene studied are 
listed in Appendix B.  
 
2.10 Agarose Gel Electrophoresis 
 
PCR products were separated according to size by electrophoresis of an 
agarose-based gel to which the PCR products had been loaded. Agarose (Life 
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Technologies, Paisley, Scotland) was diluted to 2% in Tris-Borate-EDTA 
(TBE) buffer, melted and cooled. Ethidium bromide was added to the cooled 
gel. The gel was poured into trays with appropriately sized combs used to form 
the loading wells. Samples were loaded into the wells with loading buffer. An 
appropriate DNA ladder (100bp or 1kb) containing DNA fragments of known 
size was also run in parallel. Gels were electrophoresed at 100V using 
electrophoresis tank apparatus (Flowgen Bioscience, Nottingham, U.K.). The 
position of the DNA products on the gel (and thus their size) were then 
visualised by transillumination with ultraviolet light and photographed as a 
record. For MSP, samples were electrophoresed with ―methylated‖ and 
―unmethylated‖ reactions adjacent to each other facilitating identification of 
methylation status in each sample. 
 
2.11 Illumina GoldenGate Methylation Cancer Panel 1 
 
The Illumina GoldenGate platform has been shown to be a reproducible and 
accurate method of methylation quantification (Bibikova, et al 2006b, Irizarry, 
et al 2008, Ladd-Acosta, et al 2007). Indeed, bisulphite genotyping methods 
such as this platform and Pyrosequencing have been regarded by many as the 
―gold standard‖ to measure DNA methylation (Brunner, et al 2009, Clark, et al 
2006, Paz, et al 2003). 
 
The procedure we followed is outlined here with a more detailed protocol 
adapted from the full operating protocol (http://www.illumina.com/support/ 
documentation.ilmn) available in Appendix A. An overview of the procedure 
is illustrated in Figure 2-1. 
 
DNA underwent bisulphite conversion (Section 2.7) and subsequent 
biotinylation with precipitation of biotinylated DNA samples to remove free 
biotin. The precipitated DNA pellets were dissolved and resuspended in 
solution prior to the addition of both Allele-specific and Locus-specific 
oligonucleotides (ASOs & LSOs), which hybridised to the DNA (Figure 2-1). 
The mixture was then bound to paramagnetic particles coated with streptavidin, 
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which has a high affinity for biotin. A master mix was added with polymerase 
enzyme to extend from the allele-specific oligonucleotide and ligate to the 
locus-specific oligonucleotide so that a single strand of amplifiable DNA is 
created. The beads were washed following this step to separate amplifiable 
template from genomic DNA and the template was transferred to a 96-well 
PCR plate containing mix for PCR reaction. The ligated template sequences 
next underwent PCR with fluorescently labelled common primers at 37°C for 
10 minutes, 95°C for 3 minutes followed by 34 cycles of 95°C for 35 seconds, 
56°C for 35 seconds and 72°C for 2 minutes. A final extension step at 72°C for 
10 minutes was performed before cooling to 4°C. The biotinylated, fluorescent 
double stranded amplicons produced by PCR were then bound to paramagnetic 
beads. The amplicons were denatured and biotinylated strands were filtered out 
so that only fluor-labelled strands remained. This bound PCR product was 
washed, eluted and transferred to a new plate. These samples were then 
hybridised to a Sentrix Array Matrix (SAM), which contains 96 corresponding 
fibre-optic bundles composed of beads containing sequences complementary to 
the tested oligonucleotides.  
 
The SAM was then washed before being imaged using Illumina iScan 
software. Methylation values were expressed as a beta (ß) value (between 0 
and 1) for each CpG site representing a continuous measurement from 0 
(completely unmethylated) to 1 (completely methylated). This value is 
calculated by subtracting background hybridisation levels obtained from 
negative control probes on the array and calculating the ratio of the fluorescent 
signal from the methylated allele (M) to the sum of the fluorescent signals from 
both unmethylated (U) and methylated alleles (M / U & M).  
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Figure 2-1 Illumina GoldenGate Methylation  
 
Overview of the process involved in the Illumina GoldenGate Methylation 
Cancer Panel 1 assay. Details of the procedure are provided in Section 2.11. 
Illustration is from Illumina product documentation. 
 
 
 
 
Chapter 2      
 
 77 
2.12 Pyrosequencing 
 
Pyrosequencing involves the following procedural steps, which are outlined 
individually below: 
- Bisulphite conversion of genomic DNA. 
- Assay design involving design of amplification and sequencing primers 
for individual regions. 
- PCR amplification of target region. 
- Sequencing-by-synthesis of amplified bisulphite-converted DNA 
(illustrated in Figure 2-2). 
- Analysis of results. 
 
Bisulphite conversion of genomic DNA 
Samples underwent bisulphite conversion as per Section 2.7. 
 
Assay design 
Primers for PCR amplification of bisulphite-converted DNA and subsequent 
sequencing were designed using the PSQ AssayDesign Software (Biotage 
Assay Design Software Version 1.0.6). Assays were designed to interrogate a 
sequence including individual CpG sites examined by select probes on the 
Illumina GoldenGate Array (Probe locations and details in Appendix C). The 
sequencing primer was complementary to the biotinylated strand from the 
amplification reaction since this strand is immobilised on the streptavidin beads 
and acts as the template for the sequencing reaction. The selected primer 
sequences are listed in Appendix C for the 4 genes studied (CDH1, DAPK1, 
FAT, SLIT2).  
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Figure 2-2 Pyrosequencing  
 
Overview of Pyrosequencing procedure. DNA is bisulphite-converted, PCR 
amplified and denatured (not shown). The pyrosequencing reaction involves 
hybridisation of a sequencing primer complementary to this single stranded 
DNA. Nucleotides are dispensed sequentially (dark blue circles) and following  
incorporation an enzymatic cascade converts the released pyrophosphate (PPi) 
molecules into a quantitative light signal thus creating a sequence trace. The 
incorporation of the complementary nucleotide by DNA polymerase at the 3‘-
end of the sequencing primer leads to PPi release, which reacts with APS to 
give ATP. The energy provided by the ATP enables the formation of an 
unstable luciferase-luciferin-AMP complex. In the presence of oxygen this 
complex results in the release of light in an amount proportional to the amount 
of available ATP and thus PPi. Unincorporated nucleotides are degraded by 
apyrase. 
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PCR amplification of target region 
PCR was performed using bisulphite-treated DNA as template. One of the 
primers is biotinylated at its 5‘ end as this allows subsequent immobilisation of 
biotinylated PCR products on streptavidin-coated beads. Twenty-five samples 
were selected for analysis having previously been tested using the GoldenGate 
array and were examined for each of the 4 assays designed. Primer sequences, 
reaction mixtures and thermal cycling conditions for each gene studied are 
listed in Appendix C.  A no template control (NTC) (water instead of template 
DNA) was also included to exclude the possibility of contamination. Samples 
then underwent agarose gel electrophoresis. Only those samples that produced 
a strong specific band with a negative water control sample were used for 
subsequent pyrosequencing reactions. 
 
Sequencing-by-synthesis (Pyrosequencing) of amplified bisulphite-converted 
DNA. 
 
Pyrosequencing was performed using the amplified bisulphite-converted DNA 
as template using specific reagents and hardware (Biotage, Uppsala, Sweden). 
The first step involves immobilisation of the PCR product on streptavidin-
coated sepharose beads. For each sample, 20µl of PCR product is added to an 
individual well of a 96-well reaction plate to which 3µl Streptavidin Sepharose 
beads and 37µl Binding Buffer have been added. The plate was sealed and 
vortexed at 1300rpm at room temperature for at least 10 minutes. After 
binding, the plate seal was carefully removed and the plate transferred to the 
vacuum preparation tool station to prepare sample for sequencing reaction. The 
96-prong tool is first prepared by aspirating water for approximately 10 
seconds with the vacuum on at both the pump and station. To ensure all 
reagents have left the tube, the vacuum tool is held in the air and shaken lightly 
after each step. The tool is placed in the plate and the sample is aspirated so 
that the liquid is removed by vacuuming and the beads containing the bound 
PCR product are immobilised on the tool tips. The tool is immersed in 70% 
Ethanol for 5 seconds and then transferred to 0.2M NaOH for 5 seconds to 
denature the product before washing in Wash Buffer for 10 seconds. 
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The vacuum was turned off at the station to ensure no liquid would be aspirated 
during the subsequent step. During this step, the tool is placed in a separate 96 
well plate in which each well contains 5µl of 3µM sequencing primer (Sigma-
Aldrich Ltd., Gillingham, United Kingdom) and 40µl Annealing buffer. The 
tool is briefly agitated to allow transfer of the beads to the plate containing the 
sequencing primer. This plate was incubated at 80°C for 2 minutes on a PTC-
225 DNA Engine Tetrad automated thermocycler.  Following this step, the 
plate was allowed to cool to room temperature to enable annealing. 
 
Meanwhile, substrate, enzyme and nucleotides were added into the correct 
compartments of a special dispensation cartridge. Nucleotides used are -S-
dATP, dCTP, dGTP and dCTP. The modified nucleotide -S-dATP is used 
instead of dATP as the latter acts as a direct substrate of the luciferase enzyme. 
The biochemical reactions involve a four-enzyme mix containing the Klenow 
fragment of DNA polymerase I (from Escherichia coli), an ATP sulfurylase 
(Saccharomyces cerevisiae), a luciferase (Photinus pyralis) and an apyrase 
(Solanum tuberosum). Adenosine phosphosulphate (APS)  and luciferin is 
added as a substrate. Both substrate and enzyme mixes were prepared by 
dissolving powder in 620µl Milli-Q water in each container. Volumes of 
substrate mix, enzyme mix and individual nucleotides to be added to the 
reagent cartridge varied according to samples and genes being studied and 
were calculated by the pyrosequencing software following input of sequence 
and sample details.  
 
The cartridge and pyrosequencing plate containing PCR product and annealed 
sequencing primer were loaded onto the Pyrosequencing PSQ MA machine. 
Substrate, enzyme and nucleotides were dispensed sequentially at controlled 
volumes and temperatures from the cartridge to the 96-well pyrosequencing 
plate. As the nucleotides are incorporated, pyrophosphate (PPi) molecules are 
released and an enzymatic cascade leads to a quantitative light signal thus 
creating a sequence trace. Specifically, the incorporation of the complementary 
nucleotide by the Klenow fragment of DNA polymerase I at the 3‘-end of the 
sequencing primer leads to PPi release, which converts APS into ATP. The 
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energy provided by the ATP enables the formation of an unstable luciferase-
luciferin-AMP complex. In the presence of oxygen this complex results in the 
release of light in an amount proportional to the amount of available ATP and 
thus PPi. Unincorporated nucleotides are degraded by apyrase. 
 
Analysis 
Analysis was performed using Biotage software using the Allele Quantitation 
algorithm. Successful incorporation of a nucleotide results in light emission 
and a proportional sequence peak. At each CpG studied, the percentage of 
Cytosine (C) and Thymine (T) present at each site is documented. Sequences 
are presented as pyrograms (Figure 3-3).  
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2.13 Illumina Infinium HumanMethylation27 
 
The procedure is outlined here (illustrated in Figure 2-3) with a more detailed 
protocol adapted from the full protocol (http://www.illumina.com/ 
support/documentation.ilmn) in Appendix D.  
 
Following bisulphite conversion of 750ng genomic DNA and elution in 12µl 
water (using EZ-DNA Methylation Gold kit; Section 2.7), the DNA samples 
were denatured and neutralised in preparation for whole genome amplification. 
The denatured DNA was amplified via random hexamer priming using a DNA 
polymerase enzyme at 37°C for 20-24 hours. The amplified product was 
fragmented using end-point fragmentation, precipitated with isopropanol and 
collected by centrifugation at 4°C. Precipitated DNA was resuspended in 
buffer and hybridised to an Illumina BeadChip at 48°C for 16-24 hours. During 
this hybridisation, the amplified and fragmented DNA samples anneal to locus-
specific 50 nucleotide oligonucleotide probes (50mers) linked to beads. Each 
CpG site examined has a pair of corresponding 50mers which differ only in 
their final base at the free end with one 50mer corresponding to the methylated 
state and one to the unmethylated state. The BeadChip is washed to remove 
unhybridised and non-specifically hybridised DNA. The captured DNA is then 
used as a template for single-base extension using hapten-labelled ddNTPs. 
Only those probes that have complementary bases at their free (3‘) end will be 
extended. Following this step, the bead types are fluorescently stained and 
scanned. The intensities of methylated and unmethylated bead types are 
measured and a ratio of methylated bead type intensity / combined bead type 
intensity is calculated to give beta values. Beta values are expressed in a 
similar manner to the GoldenGate system with a range from 0 (completely 
unmethylated) to 1 (completely methylated). 
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Figure 2-3 Illumina Infinium Methylation assay 
 
Overview of principle involved in the Illumina Infinium Methylation assay. 
Details of the procedure are provided in Section 2.13. Illustration is from 
Illumina product documentation. 
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2.14 DNA Sequencing 
 
Direct sequencing was performed using modified standard sequencing with 
labelled dye terminators. An initial PCR reaction was performed on genomic 
DNA samples using 1µl of genomic DNA (at 100ng/µl) to 24µl of the reaction 
mix. Primer details, reaction mix and cycling conditions are listed in Appendix 
E. Five µl of the PCR product underwent fragment separation using standard 
agarose gel electrophoresis to ensure presence of an appropriately sized 
product. PCR products were purified by addition of 4µl of an ExoSAP (USB, 
Cleveland, Ohio, U.S.A.) stock solution to 5µl of the PCR products. The 
ExoSAP stock solution consisted of 1µl exonuclease (to remove leftover 
primers) and 20µl Shrimp Alkaline Phosphatase (to remove dNTPs) with 179µl 
of water. This mix underwent thermal cycling at 37°C for 15 minutes, 80°C for 
15 minutes before storage at 4°C prior to the sequencing reaction.  
 
Sequencing reaction mix was prepared by the addition of 0.5µl Big Dye 
Terminator mix, 3.75µl 5x Buffer (Applied Biosystems) and 1µl of sequencing 
primer (3.2µM) to 2µl of the purified DNA in water in a 20µl reaction mix. 
The sequencing reaction involved an initial denaturation step at 96°C for 1 
minute, followed by 26 cycles of denaturation at 96°C for 1 minute, annealing 
at 50°C for 15 seconds and extension at 60°C for 4 minutes before storage at 
12°C. 
 
Removal of unincorporated dyes and other contaminants was performed using 
ZR DNA Sequencing Clean-up Kit (Zymo Research, Orange, CA, U.S.A.). 
The entire 20µl from the sequencing reaction was transferred to a Zymo-Spin 
column in a 2ml collection tube, 240µl of Sequencing Binding Buffer was 
added and the mixture centrifuged at 13,000 rpm for 30 seconds. Following 
this, 300µl Sequencing Binding Buffer was added to the column and 
centrifugation was repeated. The column was then transferred to a labelled 
1.5ml microcentrifuge tube, 20µl water was added to the column and the 
column and tube were centrifuged for 15 seconds to elute the purified DNA. 
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The purified samples were dried using a vacuum centrifuge (DNA Speed Vac, 
DNA120; Savant). Samples were then transferred to CRUK sequencing 
services for size separation and measurement by capillary electrophoresis on 
the Prism 3730 system (Applied Biosystems). 
 
2.15 Immunohistochemistry 
 
Immunohistochemistry is a method designed to localise and visualise proteins 
in tissue sections. Its general features and principles are outlined in Figure 2-4. 
5µm sections were cut from formalin-fixed, paraffin-embedded (FFPE) tissue 
microarrays (TMAs). These were mounted on glass microscope slides 
(Thermoscientific Superfrost Plus; Menzel, Braunschweig, Germany) and 
baked overnight at 60ºC. After cooling to room temperature, slides were 
deparaffinised in xylene, immersed in endogenous peroxidase blocking 
solution and rehydrated in graded ethanols. As formalin fixation leads to 
formation of protein cross-links, it may be difficult to access antigen sites in 
FFPE tissue. To overcome this problem, a variety of techniques have been used 
to break these cross-links and thus aid in antigen retrieval. The most commonly 
used technique is the application of heat to FFPE tissue in an aqueous solution 
(Heat Induced Epitope Retrieval (HIER)). Antigen retrieval was achieved by 
immersion in a pressure cooker containing 3 litres pre-boiled buffer (Antigen 
Unmasking Solution; Catalogue number H-3300; Vector Laboratories, 
Burlingame, CA, U.S.A) for 10 minutes. 
 
The slides were then washed with Tris Buffered Saline (TBS) and incubated 
with the appropriate primary antibody. Volumes were as required to cover the 
outlined tissue section on the glass slide. Antibodies were diluted in Bovine 
Serum Albumin (BSA). Antibody dilutions and incubation conditions 
(temperature and duration) are listed in Table 5-1. Secondary antibody and 
reagents for the subsequent step were part of the Vectastain Universal Elite 
ABC kit (Catalogue number PK-6100; Vector Laboratories, Burlingame, CA, 
U.S.A). Secondary antibody (Diluted 1:200 in BSA) was added to the slides 
and incubated for 30 minutes. Vectastain ABC solution (20l Solution A and 
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20l Solution B per 1ml PBS) was added to the slides and incubated for 20 
minutes. A single tablet of 3,3-Diaminobenzidine-tetrachloridedihydrate 
(DAB; Kem-En-Tec Diagnostics, Taastrup, Denmark) was added to 10ml of 
water with 100µl of 3% hydrogen peroxide H2O2. This was then added to the 
slides as a chromogen and incubated for 10 minutes. Following these steps, the 
slides were placed directly into water and subsequently stained with 
haematoxylin (2 minutes), acid alcohol (3 dips) and Scott‘s tap water substitute 
(5-30 seconds). Slides were rinsed in water between each of these steps. The 
slides were dehydrated by sequential immersion in graded alcohols, cleared in 
xylene and coverslipped with xylene-based DPX mounting solution. 
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Figure 2-4 Immunohistochemistry 
Outline and principles of identification of proteins in formalin-fixed paraffin-
embedded (FFPE) tissue by immunohistochemistry. The method involves 
application of a primary antibody, which has been raised against the antigen 
(Ag) of interest. A biotin-labelled secondary antibody is then added which is 
raised against the IgG of the primary antibody species and binds the primary 
antibody. This is then coupled with a reagent containing a complex of 
streptavidin and the horseradish peroxidase (HRP) enzyme. The streptavidin 
has a high affinity for biotin and thus binds to the secondary antibody. This is 
then reacted with a chromogen such as 3,3-Diaminobenzidine (DAB) with 
added hydrogen peroxide, which acts as a substrate for the complex containing 
the peroxidase enzyme. The reaction produced wherever the horseradish 
peroxidase is present produces a colour, which can be used to visually identify 
the location of proteins under the microscope. 
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2.16 Buffers and solutions 
 
TBE electrophoresis buffer 
10x stock solution: 
108g Tris base 
55g boric acid 
40ml 0.5M EDTA, pH 8.0 
Working solution: 0.089 M Tris base, 0.089M EDTA 
 
TE buffer 
10mM Tris-HCl 
imM EDTA pH 8.0 
 
Agarose gel electrophoresis loading buffer 
25mM EDTA 
50% glycerol 
0.25% bromophenol blue 
2.17 Glossary of statistical procedures  
 
Analysis of contingency tables: Contingency tables demonstrate the 
frequencies of events within groups. The significance of differences in 
frequencies between these groups can be analysed by Chi squared test (2) or 
Fisher‘s exact test. The Chi squared test (2) is a test of association between 
two categorical variables used to analyse contingency tables to establish a 
difference between actual and expected frequencies. The expected frequency is 
that there is no difference between the sets of results (the null hypothesis). The 
greater the 2, the larger the actual difference between the sets. This may then 
be converted to a P value. The Fisher’s exact test is an alternative method to 
the chi-squared test for analysing contingency tables. This is particularly used 
for smaller sample sets. In contrast to the chi-squared test, which gives an 
approximate P value, the Fisher‘s exact test provides an exact value. 
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ANOVA (Analysis of Variance): A group of statistical techniques used to 
compare the means of two or more samples to see whether they come from the 
same population. 
 
Correlation: Used to assess the extent of a linear relationship between two 
variables. Correlation is measured on a scale from -1 (perfect negative/inverse 
correlation), through 0 (no relationship between the two variables), to +1 
(perfect positive/direct correlation). This strength of correlation is known as the 
correlation coefficient (r). The Pearson correlation coefficient is used if the 
samples are from a normally distributed population. Otherwise, the Spearman 
correlation coefficient is used. Scatter plots demonstrate correlation 
graphically. The correlation coefficient r may be adjusted into a z score where 
z= ln [(r+1)/(r-1)]/2. In our study, Fisher z score transformation was used to 
assess for the significance of anti-correlation between methylation and gene 
expression (test performed by Dr. George Wright, National Institute of Health, 
Bethesda, U.S.A). 
 
False Discovery Rate (FDR): A method used when multiple statistical 
comparisons are made in order to control the number of incorrectly rejected 
null hypotheses i.e. false positive significant results. For example, an FDR of 
0.2 indicates that 20% of results shown to be statistically significant may be 
false positives. This is of particular importance when assessing results from 
thousands of genes such as in the methylation arrays used in this study. 
 
Kaplan-Meier survival plot:  
A method of graphically displaying the survival of a sample cohort. A log rank 
test is used to compare the survival between two groups, the P value of which 
indicates the significance of the difference. 
 
t test: A test used to compare the means of two groups where the examined 
data has a normal distribution.  
 Chapter 3. DNA methylation profiling in FL 
3.1  Introduction 
 
The natural history and the clinical course of Follicular lymphoma (FL) is 
characteristic of so-called ‗indolent‘ or ‗low-grade‘ lymphomas, with a 
relatively prolonged survival and a pattern of repeat responses to treatment 
followed by subsequent recurrences, with shortening of the duration of the 
responses over time (Johnson, et al 1995). The disease has marked 
heterogeneity in outcome, with frequent transformation to aggressive 
lymphoma carrying a dismal prognosis (Montoto, et al 2007). Such clinical 
diversity is reflected in the variety of secondary genetic abnormalities 
described in these tumours, differences in the tumour microenvironment and 
variations in the pattern of the clonal evolution of the disease (Carlotti, et al 
2009, Dave, et al 2004, O'Shea, et al 2009, O'Shea, et al 2008). In comparison 
with such extensive genomic analyses of these tumours, the investigation of 
methylation in FL has lagged behind.  
 
The study of methylation in FL has been predominantly restricted to the 
analysis of small patient cohorts focused on individual candidate tumour 
suppressor genes, using locus-specific non-quantitative methods. With the 
introduction of newer technologies, the focus has been moving away from 
studies of single genes to a global analysis of the lymphoma ―methylome‖. I set 
out therefore to examine quantitative methylation profiles in a large series of 
untreated FL and paired pre- and post-transformation samples with the aim of 
determining the frequency and heterogeneity of tumour-specific methylation in 
FL, its relationship with gene expression and to test whether these profiles can 
account for the clinical variability observed both at diagnosis and disease 
progression. 
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In choosing the method of analysis we considered the issues raised in Chapter 
1 including genomic coverage, quantitative ability, sample throughput, amount 
of starting DNA, cost efficiency and requirement for statistical analysis.  
Considering these factors, we chose to use the Illumina GoldenGate 
Methylation Cancer Panel 1 (hereafter referred to as GoldenGate). This array 
allows high-throughput, reproducible and accurate analysis of samples using 
96-sample arrays and provided quantitative methylation values at 1505 CpG 
loci from 807 genes for each sample without a requirement for specialist 
biostatistical input or complex post-experiment computational algorithms. This 
platform, first described in 2006 in two papers authored by Illumina Inc. 
(Bibikova, et al 2006a, Bibikova, et al 2006b), included Illumina Bead Studio 
software which provided a user friendly and reliable method of calculation of 
significant differential methylation between groups of samples. A number of 
publications since have used this platform to investigate methylation profiles in 
a range of human tissues (Christensen, et al 2009, Ladd-Acosta, et al 2007). 
 
In such a rapidly developing field, both in technological and conceptual terms, 
it was inevitable that emerging literature would shape analysis of this data. In 
particular, our findings were examined in relation to the recognised links 
between gene regulation by histone modification in embryonic stem cells and 
DNA methylation in cancer. The findings reported in this chapter were 
published as an original research article in Leukemia in 2009 (O'Riain, et al 
2009) - article provided in Appendix F with supplementary data free to access 
at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762475/?tool=pubmed. 
 
3.2  Materials & Methods 
 
3.2.1 Illumina GoldenGate Methylation Cancer Panel 1  
 
Following bisulphite conversion (as per Chapter 2.7), 5µl of bisulphite-
modified DNA (corresponding to 250ng of starting gDNA) was analysed using 
the Illumina GoldenGate Methylation Cancer Panel as per procedure outlined 
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in Chapter 2.11 (Detailed protocol in Appendix A). Samples were analysed 
on 96 sample arrays (x3). 
3.2.1.1 Samples 
 
DNA from whole lymph node biopsies from the series of 191 patients with FL 
at diagnosis with accompanying clinical, gene expression (Dave, et al 2004) 
and genomic SNP array data (O'Shea, et al 2009) was obtained through the 
LLMPP following submission of a project outline and discussion with LLMPP 
committee. Of the original series of 191 patients, 165 samples were available 
for analysis. DNA from 40 samples of paired pre- and post-transformation 
lymph node biopsies from 20 patients previously examined for TP53 mutation 
(Davies, et al 2005) was also available from St. Barts Centre for Medical 
Oncology tissue storage facility.  
 
Two FL samples that had been separated into CD19+ve B cells and CD3+ve T 
cells as well as their whole sample unfractionated equivalents were also 
examined. Purity of the CD3 and CD19 positive fractions was assessed by flow 
cytometry and was found to be >90% in all cases. (Cell separation was 
previously performed by Dr. Rifca Le Dieu using CD3 and CD19 microbeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany)).  
 
In addition, 27 non-tumour DNA samples were examined. These included 24 
benign haematopoietic samples and 3 commercially available ―control‖ 
samples. The benign haematopoietic samples consisted of 19 lymph nodes 
from a variety of anatomical locations with multiple non-malignant histological 
diagnoses, 4 tonsil samples and a single sample of pooled peripheral blood 
mononuclear cells. In addition, enzymatically methylated human male genomic 
DNA (CpGenome™ Universal Methylated DNA) and 2 samples of human 
male genomic DNA and genomic DNA extracted from a human fetal cell line 
(CpGenome™ Universal Unmethylated DNA A & B) were examined. DNA 
samples examined are summarised in Table 3-1. 
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Table 3-1 Samples examined with Illumina GoldenGate array 
List of samples examined using Illumina GoldenGate Methylation Cancer 
Panel 1. * Some benign lymph nodes included multiple diagnostic categories. 
Sample n= Mean Age,  
years (Range) 
Lymphoma DNA 184  
Previously untreated FL  164 52 (23-90) 
Paired FL and transformed FL:    
Pre-transformation FL 10  
Transformed FL 10  
Benign Lymph Node DNA* 19 27 (4-55) 
Hyperplastic 14  
Granulomatous  3  
PTGC 3  
Dermatopathic lymphadenitis 2  
Granulation Tissue 1  
Tonsils / Adenoids 4 13 (7-27) 
Hyperplastic 4  
Pooled Peripheral Blood MNCs  1  
CpGenome Universal Unmethylated 
DNA  
  
Vial A – Human genomic DNA 1  
Vial B – Human fetal cell line DNA 1  
CpGenome Universal Methylated DNA  1  
FL Cell Suspension DNA   
Whole tumour 2  
Purified CD19+ve B cells 2  
Purified CD3+ve T cells 2  
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3.2.1.2 Sample methylation analysis 
 
Array data was analysed using the Methylation Module in Illumina BeadStudio 
software. Methylation profiles were obtained for all individual DNA samples. 
The readout from this array provided quantitative methylation values for each 
sample tested at 1505 CpG loci representing 807 genes in total (230 genes 
containing one CpG site per gene, 463 genes containing two CpG sites and 114 
genes with three or more CpG sites). Methylation values are expressed as a 
beta (ß) value for each CpG site representing a continuous measurement from 0 
(completely unmethylated) to 1 (completely methylated). Where replicates 
were performed, the ß value of that sample for each locus was derived from the 
mean of the ß value across all replicates. To identify samples and CpG loci 
with similar methylation values, unsupervised agglomerative hierarchical 
cluster analysis of CpG ß values and samples was performed using the 
Manhattan clustering method within BeadStudio software.  
 
3.2.1.3 Differential methylation analysis 
 
Differential methylation analysis allows comparison of one group of samples 
(condition group) to a reference group. For the purposes of assessing 
differential methylation between tumour and benign tissue, all untreated FL 
samples from the LLMPP series were grouped into group ―u-FL‖ while pre- 
and post-transformation samples were grouped into ―pre-t-FL‖ and ―t-FL‖ 
groups respectively.  
 
Differential methylation was assessed by comparing the mean methylation 
level (ß value) of these groups to the mean ß value of the reference group 
consisting of 19 non-tumour lymph nodes (Table 3-1) for each CpG locus 
using BeadStudio software. Significance of differential methylation between 
condition and reference groups was calculated by using a two-sided t test 
model. This model calculated a DiffScore which is directly related to a p value 
indicating significance level (DiffScore = 10*log
10
(p-value)). For example, a 
DiffScore of 30 or -30 equates to a p value of 0.001 while a DiffScore of 40 or 
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-40 equates to a p value of 0.0001. To allow for the number of CpG loci being 
tested, a False Discovery Rate (FDR) correction factor of 0.01 was included.  
 
Selection of the most significantly differentially methylated loci was based on 
(1) a p value of < .00001 (DiffScore = >50 or <-50) and (2) a ß value 
difference (Delta Beta (∆ß)) of at least 0.34 between the reference and tumour 
groups. These criteria were selected as they represent the most stringent criteria 
applied in previous studies that used the Illumina GoldenGate Methylation 
array (Bibikova, et al 2006a, Bibikova, et al 2006b, Ladd-Acosta, et al 2007). 
The inclusion of an absolute difference in beta value of 0.34 between the two 
groups filters out those loci that may show spurious statistically significant 
differential methylation. As the GoldenGate assay has previously been 
demonstrated to be accurate to ß value differences of 0.17, the selection of 0.34 
as the ∆ß threshold ensures that methylation changes are valid.  
 
3.2.2 Gene expression profiling 
 
Comparison was performed between methylation values and gene expression 
profiles previously obtained on all FL samples studied using the Affymetrix 
U133A and U133B arrays (Dave, et al 2004). In comparing methylation with 
gene expression, only those Affymetrix probesets with a mean log2 expression 
greater than 7.0 were considered well measured. If multiple probesets were 
available for the same gene, the one with the highest average log-expression 
was used. A one sided Fisher Z-score transformation was used to test for anti-
correlation between methylation score and gene expression. Dr. George Wright 
at the National Institute of Health, Bethesda, U.S.A. where the gene expression 
data is held, performed these correlation studies. 
 
3.2.3 SNP Profiling 
 
This patient series had previously been examined for genomic abnormalities by 
SNP analysis using the Affymetrix 10K 2.0 GeneChip (O'Shea, et al 2009). For 
the purposes of our analysis we categorised results into samples having either 
‗normal‘ or ‗abnormal‘ genomic profiles. It is of relevance to our study that 
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detection of abnormalities by SNP profiling is dependent on the level of 
malignant cells (Zhao, et al 2004), with a tumour content of at least 70% 
having been reported as necessary to reliably detect abnormalities. 
 
3.2.4 Links with PRC2 targets in embryonic stem cells 
 
Genes examined in our study were identified as epigenetic repressive targets of 
PRC2 in embryonic stem cells (ESCs) based on previously published data 
(Lee, et al 2006b). The authors tested occupancy of
 
three Polycomb group 
(PcG) marks (H3K27Me3, EED and SUZ12) at 16710 promoters in ES cells. 
This was performed by initial chromatin immunoprecipitation (ChIP) with the 
relevant antibody followed by hybridising immunoprecipitated DNA to a DNA 
microarray. Enrichment values of each protein were converted into binary 
values of either 0 (unoccupied) or 1 (occupied) for each gene studied. These 
data were provided as a supplementary table by the authors with significantly 
bound genes indicated by 1 and absence of binding indicated by 0 for each PcG 
mark. Information on these three PcG marks was available for 674 of the genes 
examined on the GoldenGate array. Occupancy data for these 674 genes were 
exported from the table of Lee and colleagues for analysis alongside our 
methylation data. 
 
3.2.5 Methylation-specific PCR 
 
MSP was performed with primers targeted at CpG sites within the IGFBP7 and 
MGMT genes on 27 u-FL samples, one tonsil sample and one methylated 
control sample. Reactions were performed as per Chapter 2.9 with primer 
sequences and MSP conditions listed in Appendix B. 
 
3.2.6 Pyrosequencing 
 
Pyrosequencing assays were designed to 4 genes (CDH1, DAPK, FAT, SLIT2). 
Each assay interrogated a specific CpG locus present on the GoldenGate array 
as well as 2-4 adjacent CpGs. The CDH1 assay included two CpG loci studied 
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by the GoldenGate array. Twenty-five samples were selected to include a range 
of methylation values so as to assess correlation at both low and high 
methylation values. Pyrosequencing was performed as per Chapter 2.12 on the 
samples listed in Table 3-2. Primer sequences, PCR cycling conditions and 
sequence to analyse are listed in Appendix C. Each gene was studied in two 
separate experiments with a number of duplicate samples studied on both runs 
to ensure reproducibility. 
 
3.3  Illumina Goldengate Array – quality control, 
reproducibility and validation 
 
For each of the 1505 CpG sites studied using the Illumina GoldenGate 
Methylation Cancer Panel 1 array, quantitative methylation values were 
obtained expressed as a beta (ß) value for each CpG site representing a 
continuous measurement from 0 (completely unmethylated) to 1 (completely 
methylated). Before analysis of the data, I will outline the steps taken to ensure 
the quality, reproducibility and validity of the findings. 
 
3.3.1 Examination of control probes 
 
As well as the 1505 cancer-related CpG locus-specific probe sets, the 
GoldenGate system contains a number of oligonucleotide control probes 
designed for quality control purposes to assess the efficiency of each step of 
the conversion and hybridisation protocol. Control tests assessed a number of 
steps of the protocol including the efficiency of the bisulphite conversion, 
hybridisation and extension steps as well as ensuring no contamination of input 
oligonucleotide pools and establishing the assay background signal. All 
samples were examined to assess whether they had passed these control tests. 
Seven samples, a single u-FL sample, 2 pre-t-FL and 4 t-FL samples were 
excluded on the basis of unsatisfactory control probe profiles. 
Chapter 3      
 
 98 
 
 
 
 
Sample Type Sample ID 
 Follicular Lymphoma 878 
 888 
 1073 
 1076 
 1077 
 1081 
 1087 
 1098 
 1107 
 1419 
 1610 
 1622 
 1626 
 1638 
 1644 
 1661 
 1732 
 1880 
 1885 
 1896 
Methylated Control Meth  
Benign Lymph Nodes BLN6 
 BLN10 
 BLN16 
 BLN17 
 
Table 3-2 List of samples analysed by Pyrosequencing. 
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3.3.2 Measurement of reproducibility 
 
In order to assess whether methylation measurements were reproducible, 
replicates of 12 individual samples were tested. Between 2 and 4 replicates 
were performed for these 12 samples. Reproducibility was assessed in relation 
to replicates in different wells of the same array (intra-array reproducibility) as 
well as between replicate samples on different individual arrays (inter-array 
reproducibility). In total, 34 replicate pairs were available for comparison (29 
Inter-array, 5 Intra-array) from 12 individual samples. Correlation between 
individual pairs was assessed both by Pearson and Spearman correlation 
analysis using GraphPad Prism software (GraphPad Software Inc., California, 
U.S.A.). Details of replicate pairs and correlation results are provided in Table 
3-3. 
 
There was excellent inter- and intra-array correlation between replicate DNA 
samples obtained from FL and benign tissue, and the human genomic DNA 
sample (mean r
2
 =0.974; range 0.909 – 0.995). Correlation between replicate 
human fetal cell line DNA and the enzymatically methylated control DNA 
samples were more variable  (mean r
2
 =0.728; range 0.59 – 0.8). Sample scatter 
plots are illustrated in Figure 3-1. 
 
3.3.3 Exclusion of CpG loci 
 
CpG loci showing a mean ß value of <0.5 in enzymatically methylated control 
DNA samples (n=157 CpG loci) were excluded from further analysis. Our 
selection and exclusion criteria is based on the initial study describing the array 
(Bibikova, et al 2006b) which noted that ―~93% of the CpG sites were 
methylated to >50% of completion in the in vitro methylated reference DNA‖ 
and suggested that ―the reduced complexity of bisulphite-converted DNA may 
explain those sites that were undermethylated in the in vitro methylated 
reference DNA‖. We excluded these loci in case that the low values in the 
enzymatically methylated DNA control were indeed a result of mispriming due 
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to reduced complexity of the bisulphite-converted target DNA sequence. This 
is arguably overly cautious and it is worth noting that inclusion of these loci 
did not alter our analysis significantly. A list of excluded loci is provided in 
Appendix A. 
 
As methylation is involved in inactivation of the additional X chromosome in 
females, the methylation pattern of CpG loci on the X chromosome was 
distinctive. Indeed, cluster analysis of the 84 CpG loci on the X chromosome 
allowed division of samples according to gender (Figure 3-2). These 84 CpG 
loci were excluded from further analysis. Analysis was thus restricted to the 
remaining 1264 loci (739 genes), 865 of which were located within CGIs while 
the remaining 399 loci were located outside CGIs. Average ß values for each 
group (Benign Lymph Node, FL, u-FL, t-FL) and purified B and T cell samples 
at each of these 1264 CpG loci are available as free-to-access supplementary 
data (O'Riain, et al 2009) (Supplementary Table S4) at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762475/?tool=pubmed. 
 
3.3.4 Validation of array findings by Pyrosequencing  
 
Quantitative methylation values obtained by Pyrosequencing confirmed the 
validity of the array findings. Sample Pyrosequencing traces representing each 
gene and varying methylation values are presented in Figure 3-3. All values 
for the 4 genes tested in 25 samples are listed in Appendix C and illustrated in 
Figure 3-4. Values obtained from replicate samples tallied well (Appendix C 
and Figure 3-4) and were averaged for the purposes of correlation with array 
results. Comparison of the methylation values at the 5 CpG sites studied by 
both the GoldenGate array and pyrosequencing assays in 25 samples confirmed 
the accuracy of the array, particularly for identifying differential methylation 
(mean r
2 
= 0.852; range 0.787 - 0.886; Appendix C, Figure 3-5).  
 
Notably, values at adjacent CpG sites were generally similar with this low 
variation reflected in low mean standard deviation of methylation values across 
adjacent CpG sites (Full details in Appendix C). Indeed, of the 100 gene 
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methylation values analysed (4 genes in 25 samples), 81% had a standard 
deviation of less than 0.1 across all CpG sites studied (absolute difference in 
methylation of 10%). This suggests that results obtained from single CpG loci 
can be extrapolated to adjacent CpG sites, at least over the short distances 
examined here. 
 
3.3.5 Comparison with MSP results 
 
Our initial pilot studies of candidate genes by MSP in FL samples and 
lymphoma cell lines confirmed the high frequency of aberrant methylation in 
FL. As a result, we decided to expand our study to a more global approach 
using the Illumina array. Two of the genes studied by MSP (MGMT and 
IGFBP7) were included on the array and were used as further validation of the 
GoldenGate findings (Figure 3-6). MSP results demonstrated a mean beta 
value of 0.05 for those samples with a negative methylation-specific PCR 
reaction with a mean beta value of 0.35 for those samples with a positive 
methylation-specific PCR reaction (Figure 3-6). 
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Sample 
ID 
Array 
No. 
Array 
No. Type 
Pearson 
r r2 Spearman 
879 1 2 Interarray 0.988 0.977 0.978 
879 1 3 Interarray 0.982 0.964 0.975 
879 2 3 Interarray 0.972 0.944 0.955 
1097 1 3 Interarray 0.961 0.924 0.947 
1099 1 2 Interarray 0.989 0.979 0.985 
1440 1 2 Interarray 0.986 0.972 0.981 
1582 1 2 Interarray 0.997 0.993 0.993 
1628 1 3 Interarray 0.980 0.961 0.953 
MNCa 1 1 Intraarray 0.995 0.991 0.986 
MNCa 1 2 Interarray 0.993 0.985 0.973 
MNCa 1 3 Interarray 0.992 0.985 0.977 
MNCb 1 2 Interarray 0.989 0.979 0.967 
MNCb 1 3 Interarray 0.989 0.977 0.971 
MNC 2 3 Interarray 0.993 0.985 0.970 
T7 1 2 Interarray 0.998 0.995 0.993 
T7 1 3 Interarray 0.992 0.983 0.981 
T7 2 3 Interarray 0.993 0.985 0.979 
T8 1 2 Interarray 0.954 0.910 0.907 
Ma 1 1 Intraarray 0.771 0.594 0.739 
Ma 1 2 Interarray 0.895 0.802 0.859 
Ma 1 2 Interarray 0.761 0.579 0.706 
Ma 1 3 Interarray 0.808 0.653 0.768 
Mb 1 2 Interarray 0.884 0.781 0.873 
Mb 1 2 Interarray 0.838 0.703 0.785 
Mb 1 3 Interarray 0.925 0.856 0.909 
Ma 2 2 Intraarray 0.847 0.718 0.805 
Ma 2 3 Interarray 0.891 0.794 0.876 
Mb 2 3 Interarray 0.825 0.681 0.781 
U2 1 2 Interarray 0.863 0.745 0.815 
U2 1 2 Interarray 0.887 0.787 0.849 
U2a 2 2 Intraarray 0.877 0.769 0.826 
U1 1 2 Interarray 0.992 0.984 0.985 
U1 1 2 Interarray 0.993 0.986 0.985 
U1a 2 2 Intraarray 0.998 0.995 0.992 
 
Table 3-3 Correlation of replicate sample values 
Correlation coefficient values (Pearson & Spearman) for all inter- and intra-
array replicate samples. 
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Figure 3-1 Correlation between replicate samples.  
 
Sample scatter plots demonstrating correlation between replicate samples. Each 
point represents an individual methylation value at a CpG locus. Plot (a) and 
(b) show correlation between intra-array replicates of Universal Unmethylated 
DNA control samples (a) and Universal Methylated DNA samples (b). Plot (c) 
shows an example of correlation between a FL sample examined on two arrays 
(inter-array correlation). 
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Figure 3-2 Methylation on the X Chromosome 
 
Unsupervised hierarchical clustering of methylation values at 84 X 
Chromosome CpG loci in FL and benign samples. Each row represents a CpG 
locus while each column represents a sample. The horizontal colour bar at the 
top of the heat map indicates sample gender (pink = female; blue = male; white 
= unknown). Colour represents methylation level ß from 0 – 1 as per colour bar 
(Red = high methylation level; Green= Low methylation level). The 
dendrogram at the top of the heat map illustrates the relationship between the 
methylation values of the samples and divides the samples into two main 
groups according to gender. 
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Figure 3-3 Sample Pyrosequencing traces.  
 
Pyrosequencing was performed examining regions of CpG islands from 4 
genes in 25 samples. Each position on the x axis represents dispensation from 
the Pyrosequencing cartridge of enzyme (E), substrate mix (S) or nucleotides 
(A, C, G, T) with corresponding light intensity represented by the peak whose 
intensity units are on the y axis. Each shaded yellow area represents a Cytosine 
within a CpG site - the values highlighted in blue indicate the relative 
proportion of Cytosine and Thymine present at each position (and thus the 
methylation percentage). (A) Methylated Control – SLIT2, (B) Benign Lymph 
node BLN17 – CDH1, (C) u-FL Sample 888 – CDH1.  
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Figure 3-4 Pyrosequencing methylation values 
 
Methylation values obtained at multiple CpG loci within 4 genes by 
Pyrosequencing of 25 samples. Genes tested were CDH1, DAPK1, FAT and 
SLIT2. Each value is a percentage cytosine at an individual CpG site converted 
to a decimal value. CpG sites are labelled in respect to the Transcription Start 
Site e.g. TSS-52 indicates a CpG site 52 base pairs upstream (5‘) of the TSS. 
Methylation values were in general similar across adjacent bases. Replicate 
samples are indicated by the suffix -1 and -2.  
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Figure 3-5 Correlation of Pyrosequencing and GoldenGate results  
 
Scatter plots demonstrating correlation between methylation values from 4 
individual CpG sites obtained using both GoldenGate and Pyrosequencing 
methods. Methylation values obtained using both methods are expressed as a 
decimal value with GoldenGate values on the x axis and Pyrosequencing 
values on the y axis. The individual CpG Probe ID is listed on the x axis with 
the gene name followed by P indicating probe is within promoter region and a 
number indicating number of bases 5‘ of Transcription Start Site. Correlation is 
expressed as Pearson Correlation Coefficient (r
2
), shown in the inset box. 
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Figure 3-6 Comparison of M-MSP and GoldenGate results 
 
Comparison of Methylation-specific MSP (M-MSP) results with quantitative 
methylation values obtained using GoldenGate Methylation Cancer Panel 1 
array for two genes (IGFBP7, MGMT). (a) Rows represent samples (listed in 
centre; T9 = Tonsil; M = enzymatically methylated DNA; remainder samples = 
FL). Columns represent individual genes / probes tested. Results for M-MSP 
are illustrated in left-side panel (Green = no band by M-MSP; yellow = weak 
band; orange = strong band). Methylation values for two probes of CpG loci 
associated with IGFBP7 (IGFBP7_P297_F and IGFBP7_P371_F) and two 
probes of CpG loci associated with MGMT (MGMT_P272_R and 
MGMT_P281_R) are shown in the right-side panel. The beta value scale 
indicates methylation values with green representing low methylation values 
and red representing high methylation values. 
 
(b) Histogram comparing distribution of beta values and mean beta values for 
those samples with no band by M-MSP and those with a strong M-MSP band.  
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3.4 Methylation profiles of benign haematopoietic 
samples / selection of control group 
 
The issue of which control samples to use in epigenetic studies has been a 
thorny one (Martin-Subero, et al 2006). As methylation may be influenced by 
factors such as the environment and aging, finding adequate controls is 
challenging. In the case of lymphoid malignancies, an ideal control tissue is 
particularly hard to find. Typically, multiple lymph nodes will be affected by 
lymphoma, thus healthy lymph node controls from the same individual are 
rarely available. Benign lymph nodes from non-affected patients may also be a 
source for control tissue although these often occur in a younger age population 
and by their nature are only available after being surgically removed as a result 
of some pathological process causing clinical detection, such as infection. 
 
In considering these issues, we attempted to obtain a large series of 
haematopoietic control samples. This included pooled peripheral blood 
mononuclear cells, tonsils and benign lymph nodes from a range of ages and 
conditions (Table 3-1). Along with the enzymatically methylated control 
DNA, we also analysed two commercially available non-haematopoietic 
samples. Unsupervised cluster analysis restricted to these 27 control samples 
only (Figure 3-7) showed that haematopoietic control samples demonstrated 
remarkably consistent methylation profiles across a wide range of ages and 
pathological diagnoses. The benign haematopoietic samples showed little 
variation in methylation profiles across all samples (mean standard deviation of 
ß value = 0.04). This indicates that, regardless of age or pathological process, 
benign lymph nodes typically differ by less than 5% in their methylation values 
at a given CpG locus. 
 
It is possible that use of recently developed higher density arrays may reveal 
differences according to age or pathological diagnosis in haematopoietic 
control samples. Nonetheless, our results suggest that a limited number of 
Chapter 3      
 
 110 
haematopoietic controls are sufficient to allow identification of lymphoma-
specific methylation changes regardless of their underlying age or pathological 
process. While little difference was seen between tonsil and lymph node 
methylation profiles, I chose to select the 19 lymph node benign control 
samples as the reference control group in case factors such as epithelium in 
tonsil or the different method of surgical removal led to any differences in 
epigenetic profiles. 
 
3.5 Analysis of methylation profiles of untreated FL 
samples 
 
Following quality control and selection of samples and CpG loci (Section 3.3), 
DNA methylation levels at 1264 CpG loci of 164 diagnostic FL (u-FL) 
samples, 19 benign lymph nodes, 4 tonsils, pooled peripheral blood 
mononuclear cells and 3 universal controls (Table 3-1) were analysed. For 
each sample, a ß value between 0 (unmethylated) and 1 (fully methylated) was 
assigned to each CpG locus. Unsupervised hierarchical cluster analysis of the 
untreated FL samples and non-tumour samples is shown in Figure 3-8.  
 
3.5.1 Methylation as a discriminator between benign and malignant 
tissue 
 
 
This cluster analysis separated samples into two distinct groups (Figure 3-8), 
one consisting of 163 tumour samples and another group that included all 
benign haematopoietic samples. A single tumour sample and the two Universal 
Unmethylated DNA control samples also clustered with the benign samples. 
The methylated DNA control clustered separately from all other samples.  
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Figure 3-7 DNA Methylation in benign tissue 
 
Unsupervised hierarchical cluster analysis of methylation values (ß) of 1264 
CpG loci in 27 benign samples. Columns represent samples; rows represent 
CpG loci. Colour represents methylation level (ß) from 0 – 1 as per colour bar 
(Red = high methylation level; Green= Low methylation level). Analysis 
restricted to autosomal loci and loci with ß value of ≥0.5 for enzymatically 
methylated control DNA. Vertical colour bar indicates location of CpG within 
(green) or outside (orange) of CpG island. Horizontal colour bar indicates 
nature of benign sample as per figure legend. The enzymatically methylated 
DNA clusters separately from all other samples. The ‗unmethylated‘ 
commercial controls (U1 & U2) cluster separately from the haematopoietic 
samples. The haematopoietic samples form the next major cluster with similar 
profiles across these samples as indicated by the dendrogram. MNC = 
mononuclear cells 
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Figure 3-8 DNA Methylation in FL and benign controls 
 
Hierarchical clustering of methylation values (ß) from 1264 CpG loci from 
diagnostic Follicular Lymphoma samples (u-FL) and control non-tumour 
samples. Top horizontal colour bar indicates tumour samples (Blue; n=164), 
benign haematopoietic samples (Yellow; n=24), human genomic DNA and 
human fetal cell line DNA (Orange; n=2), enzymatically methylated human 
DNA (Brown; n=1). The enzymatically methylated DNA clusters separately 
from all other samples. The remaining samples separate into two distinct 
groups; a group consisting of 163 tumour samples (n=163) and a group 
including all benign / control tissue and a single tumour sample. Red and green 
boxes demonstrate CpG loci that show generally high and low methylation 
values respectively across both benign and malignant samples. The upper 
yellow and orange boxes highlight CpG loci that show loss and gain of 
methylation respectively in FL relative to the benign lymph nodes. 
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The majority of CpG loci showed similar methylation values across all 
samples. Indeed, most were either highly methylated or unmethylated across all 
samples (Red and green boxed areas respectively in Figure 3-8). 
Discrimination between FL and benign samples appeared to be based on 
smaller regions showing relative hypermethylation or hypomethylation 
between groups (Orange and yellow boxed areas respectively in Figure 3-8). 
The analysis of those loci showing significant differential methylation in FL 
relative to benign controls is described in detail in Section 3.5.4. 
 
3.5.2 Correlation of extremes of change in methylation with clinical and 
demographic data 
 
 
While methylation profiles were generally homogenous across all samples, 
those areas showing FL-specific hyper- and hypo-methylation showed widely 
varying heterogenous methylation profiles across FL samples. Two distinct 
areas of FL samples within the heat map showed extremes of change of 
methylation relative to control samples (boxed areas, Figure 3-9). These 
corresponded to distinct sub-clusters of the dendrogram (highlighted with 
coloured bars in Figure 3-9). Analysis confirmed significant difference in 
methylation value relative to controls (∆ß) in these groups. One group of 
samples showed relatively little change compared to the control group, referred 
to as the low ∆ß group (n=34, green branches of dendrogram, Figure 3-9) with 
a mean ∆ß relative to the control group of 0.1. A separate discrete sub-cluster 
showed clear changes in methylation status between the tumour samples and 
the benign group. This group, referred to as the high ∆ß group (n=29, red 
branches of dendrogram) demonstrated a mean ∆ß relative to the control group 
of 0.23.  
 
Chapter 3      
 
 114 
 
 
 
 
 
 
Figure 3-9 Extremes of aberrant methylation changes in FL 
 
This heat map is identical to that shown in Figure 3-8 with samples showing 
extremes of methylation changes highlighted. Two sub-clusters representing 
the extremes of methylation change (∆ß) relative to control group are 
highlighted on the dendrogram – a low ∆ß group (green coloured dendrogram 
bars, green box) and a high ∆ß group (red coloured dendrogram bars, red box). 
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As these groups represented the extremes of methylation changes among the 
samples it was of interest to see which factors were associated with these 
differences. For instance, was there a difference in pathological grade, patient 
age or clinical outcome? The extremes of change groups were compared to 
each other as well as to the entire FL sample set using 2x2 contingency tables 
(Fisher‘s exact test) to assess whether these distinct methylation profiles were 
associated with any demographic or clinical parameter. The results are 
described below. 
 
3.5.2.1 Patient age 
 
 
Increasing age has been associated with changes in methylation (Fraga, et al 
2005). While there was an apparent trend towards age over 60 in the high 
change group, this did not reach statistical significance (Table 3-4; Figure 
3-10). 
 
3.5.2.2 Tumour grade and stage 
 
As FL grading is based on proportions of two different germinal centre B cells, 
centrocytes and centroblasts, it is possible that methylation differences between 
these two cell types could lead to grade-dependent changes in methylation 
values. Progressive gains of methylation may also occur with tumour 
progression. While no difference in grade distribution was seen between low 
and high change groups, Grade III cases were weakly overrepresented in the 
low change group when compared with all samples (p=0.048; Table 3-5; 
Figure 3-10). No significant difference was identified between high and low 
change groups in relation to the proportion of cases with localised Stage I/II 
disease or widespread Stage III/IV disease at diagnosis (Table 3-6). 
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 Age <60 Age ≥60 
Low ∆ß group 21 13 
High ∆ß group 13 15 
P value = 0.31  
 
 Age <60 Age ≥60 
Low ∆ß group 21 13 
All samples 109 55 
P value = 0.69  
 
 Age <60 Age ≥60 
High ∆ß group 13 15 
All samples 109 55 
P value = 0.06 
 
 
Table 3-4 Distribution of age categories 
Contingency tables (2x2) showing the significance (as determined by two-
sided Fisher‘s exact test) of distribution of age categories across all samples 
and in low and high change groups. 
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Figure 3-10 Patient age and FL grade distribution 
 
Dendrogram illustrating distribution of age and grade categories across all 
samples. Dendrogram is as per Figure 3-8 with age and grade for each sample 
indicated by horizontal colour bars. The two sub-clusters representing the 
extremes of methylation change (∆ß) relative to control group are highlighted 
on the dendrogram – the low ∆ß group (green coloured dendrogram bars) and 
the high ∆ß group (red coloured dendrogram bars). 
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 FL Grade I / II FL Grade III 
Low ∆ß group 18 13 
High ∆ß group 23 6 
P value = 0.1  
 
 FL Grade I / II FL Grade III 
Low ∆ß group 18 13 
All samples 120 38 
P value = 0.05 
 
 FL Grade I / II FL Grade III 
High ∆ß group 23 6 
All samples 120 38 
P value = 0.81  
 
Table 3-5 FL grade  
Contingency tables (2x2) showing the significance (as determined by two-
sided Fisher‘s exact test) of distribution of grade categories across all samples 
and in low and high change groups. 
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 Stage 1/2 Stage 3/4 
Low ∆ß group 13 20 
High ∆ß group 6 22 
P value = 0.17  
 
 Stage 1/2 Stage 3/4 
Low ∆ß group 13 20 
All samples 47 115 
P value = 0.3  
 
 Stage 1/2 Stage 3/4 
High ∆ß group 6 22 
All samples 47 115 
P value = 0.5  
 
Table 3-6 Clinical stage 
Contingency tables (2x2) showing the significance (as determined by two-
sided Fisher‘s exact test) of distribution of stage categories across all samples 
and in low and high change groups. 
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3.5.2.3 Presence of genomic abnormalities 
 
Genetic changes such as the PML/RAR translocation in APL have been 
associated with methylation (Di Croce, et al 2002). We examined the extremes 
of methylation groups in relation to previously obtained genetic data from this 
cohort. No correlation was identified between the presence or absence of the 
hallmark t(14;18) translocation in FL and changes in methylation (Table 3-7). 
Numbers of TP53 mutated cases (O'Shea, et al 2008) were not sufficient to 
assess for any significant association, with both high and low change groups 
containing a number of cases with mutated TP53. However, there was a strong 
association between a higher ∆ß and an abnormal SNP profile with patients 
with an abnormal SNP profile highly significantly overrepresented in the high 
change group (P=0.0004; Table 3-8; Figure 3-11).  
 
3.5.2.4 Transformation 
 
In theory, extensive methylation changes could provide the environment for 
further changes leading to transformation to DLBCL. However, no association 
between methylation changes and the presence or absence of a subsequent 
transformation event was identified (Table 3-9). 
 
3.5.2.5 Survival 
 
Changes in methylation have been associated with clinical outcome in a 
number of studies, typically focusing on single genes. In our study, it was 
apparent that multiple genes showed tumour-specific differential methylation. 
We assessed whether there were distinct outcomes according to global 
methylation profiles by comparing the high and low change groups to the entire 
sample set. No significant difference in either progression-free or overall 
survival was identified between these groups (Figure 3-12 and Figure 3-13). 
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 t(14;18) Positive t(14;18) Negative 
Low ∆ß group 22 6 
High ∆ß group 25 3 
P value = 0.47  
 
 t(14;18) Positive t(14;18) Negative 
Low ∆ß group 22 6 
All samples 128 16 
P value = 0.21  
 
 t(14;18) Positive t(14;18) Negative 
High ∆ß group 25 3 
All samples 128 16 
P value = 1  
 
Table 3-7 t(14;18) status 
Contingency tables (2x2) showing the significance (as determined by two-
sided Fisher‘s exact test) of distribution of t(14;18) status across all samples 
and in low and high change groups. 
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 SNP abnormality present SNP abnormality absent 
Low ∆ß group 10 24 
High ∆ß group 22 7 
P value = 0.0004  
 
 SNP abnormality present SNP abnormality absent 
Low ∆ß group 10 24 
All samples 89 72 
P value = 0.0078  
 
 SNP abnormality present SNP abnormality absent 
High ∆ß group 22 7 
All samples 89 72 
P value = 0.04  
 
 
Table 3-8 SNP abnormalities 
Contingency tables (2x2) showing the significance (as determined by two-
sided Fisher‘s exact test) of distribution of cases showing SNP abnormalities 
across all samples and in low and high change groups. 
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Figure 3-11 Distribution of FL cases with abnormal SNP profiles 
 
Heat map and dendrogram illustrating distribution of cases with and without 
genomic SNP abnormalities across all samples. Heat map is as per Figure 3-8. 
The horizontal colour bar indicates cases showing SNP abnormalities (red) and 
cases without a SNP abnormality (lilac). The two sub-clusters representing the 
extremes of methylation change (∆ß) relative to control group are highlighted 
on the dendrogram – the low ∆ß group (green coloured dendrogram bars) and 
the high ∆ß group (red coloured dendrogram bars). 
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 Transformed Not transformed 
Low ∆ß group 4 25 
High ∆ß group 6 19 
P value = 0.49  
 
 Transformed Not transformed 
Low ∆ß group 4 25 
All samples 38 101 
P value = 0.16  
 
 Transformed Not transformed 
High ∆ß group  6 19 
All samples 38 101 
P value = 0.81  
 
 
Table 3-9 Transformation 
Contingency tables (2x2) showing the significance (as determined by two-
sided Fisher‘s exact test) of distribution of cases that subsequently transformed 
to high grade lymphoma across all samples and in low and high change groups. 
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Figure 3-12 DNA Methylation and overall survival in FL 
Kaplan-Meier curves showing comparison of Overall Survival (OS) between 
entire sample group, low ∆ß group and high ∆ß group (P>0.05). 
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Figure 3-13 DNA methylation and progression-free survival in FL 
Kaplan-Meier curves showing comparison of Progression Free Survival (PFS) 
between entire sample group, low ∆ß group and high ∆ß group (P>0.05). 
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3.5.2.6 Summary of individual u-FL sample methylation profile analysis 
 
 
Global methylation profiles had no identifiable impact on clinical outcome. A 
variety of patient and tumour characteristics had little apparent effect on 
methylation values including age and tumour stage. While there was a 
relatively weak association between high grade FL and lower methylation 
change, by far the most significant factor associated with changes in 
methylation was the presence of genetic abnormalities as detected by SNP 
array profiling. 
 
While at first sight this may suggest that extensive epigenetic changes occur in 
cases with extensive genetic abnormalities, I also pursued alternative 
explanations. The SNP array used has been shown to require an estimated 
tumour burden of approximately 70% tumour cells in order to be able to detect 
abnormalities (Zhao, et al 2004). Thus, it may be that the SNP profiling 
underestimates the true prevalence of genomic abnormalities as false negatives 
occur due to poor sensitivity. Thus the overrepresentation of cases with SNP 
abnormalities within the group with high levels of tumour-specific methylation 
and the concurrent overrepresentation of cases without SNP abnormalities 
within the group with low levels of tumour-specific methylation may merely 
reflect high and low levels of tumour content within these respective groups. 
 
3.5.3 Analysis of purified B and T cell populations  
 
To examine this possibility further, I performed methylation analysis on the 
purified B and T cell populations and whole lymph node DNA obtained from 2 
patients with FL in order to establish the relative contribution of each fraction 
to whole tumour methylation values. Both fractions showed distinct 
methylation patterns with the purified B cells showing a higher change in 
average methylation values relative to benign samples than the purified T cells. 
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The two purified B cell samples showed a mean delta beta (∆ß) across all CpG 
loci of 0.29 and 0.27 while the corresponding T cell samples showed a lower 
mean ∆ß of 0.11 and 0.14. The whole tumour samples showed a mean ∆ß 
intermediate between the B and T cell values (0.24 and 0.23) reflecting 
samples with a mixed population of B cells and non-B cells, consisting mostly 
of B cells.  
 
Correlation of sample values for all 1264 CpG loci analysed showed that the 
two B cell samples were more similar to each other than to their corresponding 
T cell populations (Figure 3-14). Reflecting the fact that the whole samples 
contained predominantly B cells, very good correlation was identified between 
B cell populations and their whole sample equivalents (r
2 
= 0.94). 
 
When these samples were included in a cluster analysis with the previously 
analysed samples, the principal clustering pattern remained, with the purified B 
cell samples and whole tumour samples showing extensive changes relative to 
benign lymph node while the T cell samples showed little change relative to 
the benign lymph nodes (Figure 3-15). The fact that the CD3+ group did not 
cluster within the non-tumour cases may be attributed to incomplete purity of 
the two T cell samples (92% and 94.75%) or to a degree of co-methylation of 
tumour microenvironment cells and tumour cells at specific CpG loci. 
 
These findings demonstrated that the changes in methylation are derived 
predominantly from the tumour B cell population and that non-tumour cells 
within the tumour sample affect the methylation value. While this may seem 
intuitive, few studies have looked at the effect that non-tumour cells such as 
stromal cells and inflammatory cells have on quantitative methylation values. 
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Figure 3-14 Purified B and T cell populations in 2 cases of FL 
 
Scatter plots demonstrating correlation between methylation values of purified 
B and T cell populations and whole sample from two patients with FL. Each 
dot represents a beta value at an individual CpG locus of 1264 loci studied. 
Corresponding Pearson correlation coefficient R
2 
values are shown in the table. 
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Figure 3-15 DNA Methylation in purified FL samples 
 
Unsupervised hierarchical clustering of the samples included in Figure 3-8 
with the addition of whole tumour and B and T cell fractions from 2 FL 
patients to the analysis. Both B cell and whole tumour samples (purple lines in 
colour bar) cluster together within samples showing high tumour-specific 
methylation while the 2 T cell samples (green arrows) cluster away from these 
within a group showing lower levels of tumour-specific methylation. 
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3.5.4 Differential methylation 
 
In assessing hypermethylated genes, some authors have used relatively 
arbitrary criteria to distinguish CpG loci as being unmethylated / 
hypermethylated (such as methylation percentage <25% classed as 
unmethylated with values >75% classed as methylated) (Martin-Subero, et al 
2009b). However, such criteria do not assess whether the noted methylation is 
aberrant (i.e. cancer specific) and may include genes that show similar 
methylation patterns in corresponding benign tissue. I was most interested in 
identifying those loci for which significant differential methylation between 
malignant and benign sample sets was present i.e. tumour-specific methylation 
changes. To identify the CpGs demonstrating the most significant tumour-
specific changes in methylation relative to controls, a mean ß value for each 
CpG was determined for the 164 untreated FL samples (u-FL group) and 
compared to the corresponding mean ß value in our reference non-tumour 
lymph node group (BLN).  
 
Using the criteria of p<0.00001 and ∆ß of ≥0.34, 199 loci (corresponding to 
133 genes) were identified with significant increase in methylation in the u-FL 
group (listed in Appendix A). Using the same criteria, only 6 CpG loci showed 
significant loss of methylation in FL relative to controls. Using a less stringent 
∆ß of ≥0.17, 70 CpG loci demonstrated hypomethylation in FL (Appendix A). 
 
3.5.5 Factors determining differential methylation 
 
While the majority of loci examined showed similar methylation levels in both 
benign and malignant samples, the discriminative ability of the array was 
predominantly based on relative hypermethylation at selected loci in tumour 
samples relative to controls (Figure 3-8). There are several reasons why these 
particular loci underwent tumour-specific hypermethylation. 
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3.5.5.1 Changes in methylation are dependent on whether CpG sited 
within or outside of CpG islands  
 
Hypermethylated loci were significantly more likely to be located within a CGI 
with only one of the 199 CpG loci located outside of a CGI (P<0.0001, 
Fisher‘s exact test). CpG loci outside of CGIs were significantly 
overrepresented in the hypomethylated group (61 of 70 (87%); p<0.0001, 
Fisher‘s exact test). This finding supports the basic methylation theory (Figure 
1-8) that CpGs located within CGIs in non-tumour tissue are unmethylated 
while CpGs outside CGIs are methylated with the inverse pattern occurring in 
tumour tissue (Herman and Baylin 2003). 
 
3.5.5.2 The hypermethylated gene set is enriched for targets of the 
Polycomb Repressor Complex 2 (PRC2) in ES cells 
 
The question arises as to why the majority of CpG loci within CGIs remain 
unmethylated in both benign and malignant samples while a distinct subset 
become hypermethylated. The recent findings that those genes targeted for 
repression by PRC2 in ES cells were overrepresented among hypermethylated 
genes in epithelial malignancies (Ohm, et al 2007, Schlesinger, et al 2007, 
Widschwendter, et al 2007) led to the investigation of whether this held true 
for lymphoid malignancies. 
 
The basis for this investigation was the genome-wide (16710 genes) mapping 
studies of Lee and colleagues who examined these genes for occupancy in 
embryonic stem cells by H3K27Me3 (catalysed by EZH2) and the PRC2 
components EED and SUZ12. A comparison of frequency of the repressive 
PcG marks among the hypermethylated gene set, the full array and in the initial 
genome-wide mapping studies is shown in Table 3-10 & Figure 3-16. 
Polycomb repressor target genes were significantly overrepresented in the 
hypermethylated group compared to the entire set of autosomal genes analysed 
on the array (Fisher‘s exact test p<0.0001): genes demonstrating all three PcG 
marks were overrepresented (30% (36/121)) in the hypermethylated group 
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compared to 9.5% (64/674) of all genes included for analysis. Similarly, genes 
showing at least one of the three PcG marks were overrepresented in the 
hypermethylated group (55% (66/121)) compared to 22% (145/674) of all 
genes included for analysis. Thus, in addition to being preferentially located 
within CGIs, the hypermethylated genes are frequently targets of PRC2 in ES 
cells (Figure 3-17). 
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 Hypermethylated  
Gene Set 
GoldenGate  
Array Set 
Genome-wide 
 Number 
of genes 
% genes Number 
of genes 
% genes Number 
of genes 
% genes 
1 mark 13 10.7 46 6.8 609 3.6 
2 marks 17 14 35 5.2 328 2 
3 marks 36 29.8 64 9.5 654 3.9 
No marks 55 45.5 529 78.5 15119 90.5 
       
TOTAL 121 100 674 100 16710 100 
       
EED 53 43.8 100 14.8 1066 6.4 
SUZ12 52 43 69 10.2 1040 6.2 
H3K27Me3 50 41.3 105 15.6 1121 6.7 
 
Table 3-10 PcG mark distribution 
 
Details of number of genes that are marked by individual PcG marks in ESCs 
of PcG marks in genes within hypermethylated gene set, GoldenGate array and 
in genome-wide studies. 
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Figure 3-16 PRC2 target genes and hypermethylated genes 
 
Overrepresentation of Polycomb Repressor Complex 2 target genes within the 
hypermethylated gene set. Polycomb group (PcG) marks are based on the study 
of Lee and colleagues who examined for 3 PcG marks (occupancy by 
Polycomb group proteins SUZ12 and EED and association with trimethylation 
of Lysine 27 of Histone H3) in 16710 genes in embryonic stem cells. The 
hypermethylated gene set is significantly (p<0.0001; Fisher‘s exact test) 
enriched for genes showing PcG marks compared to the entire GoldenGate 
array gene set. This enrichment applies to both genes showing all 3 PcG marks 
and those showing at least 1 of 3 PcG marks. 
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Figure 3-17 PRC2 target genes and DNA methylation 
 
Illustration of enrichment of aberrantly hypermethylated genes for genes that 
are PRC2 targets in ES cells. Heat map shows unsupervised clustering as per 
Figure 3-8. The vertical colour bar on the left indicates genes occupied by the 
PcG proteins EED and SUZ12 or bound by H3K27Me3. The black box 
indicates those genes showing the highest levels of aberrant methylation, their 
typical location within CGIs and their enrichment for PcG target genes in ES 
cells. 
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3.5.6 Comparison with Gene Expression  
 
In order to identify genes where methylation resulted in transcriptional 
silencing and reduction in gene expression, we correlated methylation results 
with previously established gene expression profiles (Dave, et al 2004). Of the 
1264 probe sets measuring methylation, 819 had well measured gene 
expression available across the FL dataset. Of these, 226 loci (27.6%, FDR 
0.30) showed significant (p<0.05) inverse correlation between gene expression 
and methylation, with 77/819 (9.4%, FDR 0.03) being highly significant 
(p<0.001) (Appendix A, Figure 3-18). Loci within CpG islands were 
overrepresented in this group compared with the remaining loci (p=0.016). A 
significant (p<0.05) positive correlation with methylation value was observed 
for 114 of the 819 (13.9%, FDR 0.36) loci, while 30/819 (3.7%, FDR 0.05) had 
a strong positive correlation (p<0.001). CpG loci outside of CpG islands were 
significantly overrepresented in this group (p<0.0001). 
 
The fact that the majority of loci did not show significant inverse correlation 
was not unexpected. Both methylation and gene expression values will likely 
be affected by the tumour cell content percentage, thus confounding definitive 
correlation. There may be a ―threshold effect‖ in regulating gene expression 
whereby gene expression may not be unduly altered until a certain level of 
methylation has arisen (Irizarry, et al 2008, Reinhold, et al 2007). Furthermore, 
other factors involved in methylation-associated gene silencing such as histone 
modifications may also contribute to these results. In order to determine the 
true functional and prognostic significance of methylation on individual genes 
it is clear from our studies that quantitative analysis of purified tumour 
populations are necessary. Perhaps most importantly, a number of other 
recently published studies have shown that many genes methylated in 
lymphoma are expressed at low level in benign haematopoietic tissue (Killian, 
et al 2009, Martin-Subero, et al 2009b, Pike, et al 2008, Wang, et al 2010). 
This is in keeping with the emerging theory of methylation being a widespread 
event occurring by an instructive mechanism rather than functioning 
predominantly to silence individual TSGs (Keshet, et al 2006).  
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Figure 3-18 Correlation between methylation and gene expression.  
 
Gene expression profiling was previously performed on all FL samples studied 
using the Affymetrix U133 A and U133B arrays (Dave, et al 2004). Well 
measured gene expression data was available corresponding to 819 CpG loci (y 
axis) across the FL dataset. Pearson correlation values between gene 
expression and methylation are shown on the x axis with negative values 
representing inverse correlation and positive values representing positive 
correlation. Highly significant (p<0.001) inverse correlation was identified for 
77/819 loci (FDR 0.03) while 30/819 loci (FDR 0.05) had a strong positive 
correlation (p<0.001). 
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3.6 Methylation profiles in paired pre- and post-
transformation samples 
 
Since previous studies of methylation in t-FL had been limited to non-
quantitative methylation-specific PCR in a small series of patients (Rossi, et al 
2004), we analysed paired pre-t-FL and t-FL biopsies to determine whether 
there was dynamic alteration in methylation status over time with disease 
treatment and transformation.  
 
Given the influence of non-tumour tissue on methylation results, analysis of 
paired samples was restricted to the 10 pairs that demonstrated SNP 
abnormalities as this indicated that the sample contained at least 70% tumour 
content. Of the 10 pre-t-FL samples, 2 were obtained at diagnosis, 1 at 
progression after ―watch and wait‖ management, 3 at first relapse, 3 at second 
relapse and 1 at seventh relapse.  
 
Cluster analysis of the paired samples and non-tumour samples demonstrated 
discrete separation of the 20 lymphoma samples from the non-tumour samples, 
validating the discriminative ability of the assay (Figure 3-19). Significant 
increases in methylation relative to controls (p<0.00001; ∆ß ≥0.34) were 
demonstrated in 213 loci (corresponding to 142 genes) in the pre-t-FL group 
and 256 loci (163 genes) in the t-FL group. The number of hypermethylated 
genes in these groups is marginally higher than the u-FL group, which may 
reflect our efforts to limit the effects of contaminating non-tumour tissue by 
restricting analysis to samples with an abnormal SNP profile. There was 
extensive overlap between the hypermethylated CpG loci in all three groups ( 
Figure 3-20). While 36 loci were unique to the t-FL group, further analysis 
demonstrates that this likely relates to the threshold value we set rather than to 
a distinct biological difference.  Of the 36 loci unique to the t-FL group, 36/36 
(100%) in the pre-t-FL group and 33/36 (92%) in the u-FL group showed 
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hypermethylation at the less stringent criteria of (1) a  of at least 0.17 
between the reference and the tumour groups and (2) a P-value of 0.004 as 
determined by the two-sided t-test.  
 
Methylation patterns were more strongly related to the individual than to 
transformation status with predominantly similar profiles in patients pre- and 
post-transformation. Pre-t-FL and t-FL samples from 6 pairs clustered adjacent 
to each other (Figure 3-19). Analysis of variation (ANOVA) carried out by Dr. 
Gavin Kelly (Cancer Research UK Bioinformatics & Biostatistics) confirmed 
that the ‗patient effect‘ was larger than the ‗transformation status effect‘: 876 
loci were differentially methylated between individuals across transformation 
status with 413 loci differentially methylated between transformation status 
groups across individuals (False Discovery Rate = 0.01). Taken together, these 
data suggest that methylation has little role in the key clinical event of 
transformation of FL to an aggressive lymphoma. 
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Figure 3-19 DNA Methylation in transformed FL 
 
Hierarchical clustering of methylation values (ß) from 1264 CpG loci from 10 
pairs of pre- and post- transformation Follicular Lymphoma samples and 
control non-tumour samples. Horizontal colour bar indicates pre-
transformation follicular lymphoma samples (Light blue; n=10), transformed 
FL samples (Dark blue; n=10), benign haematopoietic samples (Yellow; n=24), 
human genomic DNA and human fetal cell line DNA (Orange; n=2), 
enzymatically methylated human DNA (Brown; n=1). The enzymatically 
methylated DNA clusters separately from all other samples. The remaining 
samples separate into two distinct groups consisting of malignant samples and 
benign controls.  Individual samples from six pairs cluster adjacent to each 
other (purple bars of dendrogram). 
Chapter 3      
 
 142 
 
 
 
 
 
Figure 3-20 Hypermethylated loci in u-FL, pre-t-FL and t-FL groups 
 
This figure shows a Venn diagram showing overlap of hypermethylated CpG 
loci among u-FL samples (n=199 CpG loci) and the pre-t-FL (n=212) and t-FL 
(n=256) paired samples. Hypermethylation defined as (1) a ß value difference 
(Delta Beta (∆ß)) of at least 0.34 between the reference and tumour groups and 
(2) a P value of < .00001 as determined by two-sided t-test. Of the 36 loci 
unique to the t-FL group, 36/36 (100%) in the pre-t-FL group and 33/36 (92%) 
in the u-FL group showed hypermethylation at less stringent criteria of  (1) a 
∆ß of at least 0.17 between the reference and tumour groups and (2) a P value 
of < .004 as determined by two-sided t-test. 
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3.7  Discussion 
 
The study of methylation in FL to date has been predominantly restricted to 
analysis of small patient cohorts or focused on individual candidate tumour 
suppressor genes, using locus-specific non-quantitative methods. In this study I 
used array technology to quantitatively assess methylation profiles in a large, 
well-characterised cohort of newly diagnosed FL patients and sequential 
biopsies from patients who underwent transformation to DLBCL. 
 
This approach generated a methylation profile which demonstrated extensive 
methylation changes between FL and benign lymph node allowing separation 
of tumour samples from non-tumour samples with a single exception (Figure 
3-8). This discriminatory ability was based primarily on tumour-specific gains 
of methylation within CpG islands. While many CpG loci were noted to have 
similar methylation levels across all tumour samples, the pattern of methylation 
at a number of loci was heterogeneous within the u-FL group. Our studies 
suggest that the degree of change in methylation relative to the control group 
may reflect not only heterogeneity of methylation within tumour cells but also 
the relative proportions of neoplastic B cells and non-neoplastic infiltrating 
immune cells contained within the biopsies. 
 
Despite numerous studies linking presence or absence of methylation of 
individual genes with outcome across a range of human tumours, few of these 
studies have attempted to separate out tumour cellular components in order to 
provide purified tumour samples. While haematological malignancies often 
contain a relatively high proportion of non-neoplastic inflammatory cells, this 
consideration will also apply to epithelial malignancies that have varying and 
often substantial amounts of accompanying stroma, vasculature and 
inflammatory cells. Studies involving microdissection of samples have shown 
differing levels of methylation between tumour epithelium and its associated 
stroma (Hanson, et al 2006, Rodriguez-Canales, et al 2007) emphasising the 
importance of purified tumour populations in future attempts to define the 
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epigenome of various cancers. Indeed, I believe that in my study the apparent 
link between tumour content and methylation values means that definitive 
correlation with clinical outcome and indeed other variables such as gene 
expression is not possible. This optimal requirement for purified tumour 
populations may limit the practical potential of methylation studies to test for 
methylation as a clinical outcome predictor in cancer. They are also an 
important consideration with the expansion of methylation profiling efforts 
including international collaborations such as the Human Epigenome Project. 
 
Despite these considerations, our study was able to discriminate all but 1 of 
164 tumours from non-tumour tissue, indicating that changes in methylation in 
FL are sufficient to distinguish FL from benign samples regardless of any 
potential effect of tumour content in the vast majority of cases. This has 
important practical applications as it suggests the potential for methylation-
based discriminators in cancer e.g. as a less invasive method of confirming 
disease recurrence (e.g. by fine needle aspiration rather than core needle or 
open biopsies) or as an adjunct to diagnosis when material is limited.  
 
The hypermethylated CpG loci identified in this study include both previously 
reported and novel methylated genes with a wide range of functions. While 
numerous studies have identified methylated genes in a range of human 
tumours, it is unclear if these changes are causal events in tumourigenesis or 
are merely a consequence of tumour development (Suzuki, et al 2002)– what 
have been referred to as ‗epipolymorphisms‘ (Martin-Subero, et al 2006). 
Indeed, despite the explosion in epigenetic studies in recent years, only 
recently has DNA methylation been shown, in vivo, to induce malignancy 
(Linhart, et al 2007). In this series it seems likely that many of the 199 CpG 
loci hypermethylated in u-FL will represent part of widespread epigenetic 
change brought about through instructive mechanisms rather than individual 
random methylation events leading to gene silencing, particularly given the 
relatively low inverse correlation between gene expression and methylation. 
 
Sequential analysis of biopsy material from 10 paired samples provides further 
insights into the timing of methylation changes in lymphomagenesis. These 
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changes appear to be acquired early in the process of lymphomagenesis and 
conserved with treatment since no significant differential methylation was 
noted between u-FL, pre-t-FL and t-FL samples. There was significant overlap 
between hypermethylated gene sets in the u-FL and paired pre-t-FL and t-FL 
groups indicating no apparent role of methylation in transformation, at least for 
those genes present on this array. Indeed, methylation profiles were more 
dependent on the individual patient than on transformation status. 
 
Our data resonate with other groups‘ research findings published in 2009. In 
particular, it was reassuring that a collaboration between a National Institute of 
Health (NIH) group with Illumina Inc. using the same GoldenGate platform 
showed similar findings to our own study (Killian, et al 2009). Moreover, they 
showed excellent reproducibility between matched frozen tissue and formalin-
fixed, paraffin embedded tissue from individuals with FL, confirming the 
potential clinical application of this methylation technology. In their analysis of 
21 FL and 24 FH cases, they also noted how methylation profiles of CpGs 
were dependent on location inside or outside of CpG islands, which they 
referred to as ‗on-island/off-island epigenotype‘. They also showed low 
correlation between gene expression and methylation – in fact, no association 
was identified between ―differentially expressed genes and the differential 
methylation state‖. Hypermethylated genes were found to link to those genes 
showing the least differential expression between FL and FH with many of 
these genes showing weak expression in both FL and FH.  
 
Taking the studies together, we now know that aberrant hypermethylation 
affects over 100 genes in FL, typically occurs at CGIs of genes marked by 
PRC2 in ES cells, many of which show low expression in both reactive and 
neoplastic states. Such findings also appear to apply to the other germinal 
centre neoplasms. Pike and colleagues showed that aberrant methylation in 
DLBCL typically occurred in genes expressed at low levels in the 
corresponding normal tissue (Pike, et al 2008). Martin-Subero and colleagues 
also published in 2009 on methylation profiles of a series of mature aggressive 
B cell lymphomas (the germinal centre B cell lymphomas Burkitt‘s lymphoma 
and DLBCL) using the GoldenGate system (Martin-Subero, et al 2009b). They 
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also identified this overrepresentation of PRC2 targets among hypermethylated 
genes. 
 
While other authors have suggested that such findings support a stem cell 
origin for cancer, it is difficult at present to fit this model in with the currently 
accepted model of lymphoma subtypes corresponding to their normal benign 
counterpart (Chapter 1.1.2).  
 
In summary, this part of my studies confirmed frequent aberrant tumour-
specific methylation changes in FL and highlighted some caveats in 
interpretation of methylation data. The similarities in the methylation profiles 
observed in sequential FL and t-FL biopsies and the overrepresentation within 
the hypermethylated gene set of genes that are targets for epigenetic repression 
by PRC2 in stem cells suggests that the widespread methylation may represent 
an early event in lymphomagenesis. Nonetheless, only a small proportion of all 
CGIs become aberrantly methylated, many through an as yet undetermined 
mechanistic link with PRC2 target status in ES cells. The question remained 
whether these findings were valid on a wider scale and what other factors 
determine susceptibility to methylation. 
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Chapter 4. Epigenome wide profiling of high 
tumour content FL and lymphoid cell lines 
 
4.1  Introduction  
 
Our initial expectation was that the GoldenGate array would act as a discovery 
tool to identify candidate tumour suppressor genes silenced by methylation. 
The research demonstrated hypermethylation at a large number of loci, with 
over half of these genes representing Polycomb Repressor Complex 2 targets in 
ES cells. This finding in light of emerging data led us to conclude that 
methylation, rather than a rare event silencing key tumour suppressor genes, 
was instead predominantly a pre-programmed mechanism targeting genes 
controlled by histone methylation at the embryonic stem cell stage. Indeed this 
observation seems to be a feature of several cancers. 
 
Since the GoldenGate platform contains a relatively limited, highly selective 
group of cancer loci we next sought to validate the findings from the 
GoldenGate study by interrogating methylation on an epigenome wide scale. 
At the beginning of my studies the GoldenGate array represented the highest 
genomic coverage of any ‗bisulphite genotyping‘ type assay. In the meantime, 
methylation profiling technology had improved substantially allowing an 
increased number of CpG sites to be studied at manageable costs. We chose to 
utilise the Illumina Infinium methylation array which contains over 27,000 
CpG loci representing >14,000 genes. While commercially available since 
2008, it was first described in a technical report in the Epigenomics journal in 
late 2009 (Bibikova, et al 2009) with only a few publications describing its 
application since in a number of cancers (Brunner, et al 2009, Kanduri, et al 
2010, Martin-Subero, et al 2009b).  
 
Using this latest epigenome-wide technology, we wished to consider what 
factors were involved in determining susceptibility of CGIs to aberrant 
methylation. The initial global mapping studies of promoters occupied by 
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H3K27me3 in ES cells by Lee and colleagues provided the foundation for 
identifying the link between hypermethylation in FL and PRC2 target genes 
(Lee, et al 2006b). However, even this apparent link with repressive marking 
of genes in ES cells is not as simple as it first seemed. Bernstein and colleagues 
had made an intriguing observation noting a coincidence of the inhibitory 
H3K27Me3 mark with the active histone modification H3K4Me3 (Bernstein, et 
al 2006). These genes are referred to as having ―bivalent chromatin domains‖ 
which leave pluripotent cells in a state of readiness for differentiation, by 
introducing a balancing act between active and repressive signals to facilitate 
control of individual gene expression and differentiation along a particular 
lineage (Figure 4-1). This initial finding based on a study of individual genes 
was followed by genome–wide mapping studies that assessed the global pattern 
of bivalent domains in ES cells (Ku, et al 2008, Pan, et al 2007, Zhao, et al 
2007). These studies identified that 14% of genes are held in this poised state 
and that these genes have key roles in development.  
 
Part of the driving force behind epigenetic research has been its therapeutic 
potential as demethylating agents have entered into clinical practice, 
particularly in the treatment of haematological conditions. As we have seen 
however, the link between methylation and gene expression is complicated. 
Ultimately, functional studies will be required to examine the link between 
gene expression and DNA and histone methylation and the potential for 
therapeutic intervention. I also aimed to assess whether the methylation 
profiles of lymphoid cell lines reflect those of their equivalent primary 
lymphoid tissue and whether treatment with demethylating agents could indeed 
alter expression of aberrantly hypermethylated genes.  
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Figure 4-1 Bivalent chromatin and differentiation 
 
Certain key genes are held in a ―bivalent‖ state at the ESC stage, being marked 
by both the repressive H3K27Me3 mark and the activating H3K4Me3 mark. 
Selective release of these marks allows for differentiation along the intended 
lineage. 
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4.2  Materials & Methods 
 
The Illumina Infinium Human Methylation 27 array provides quantitative 
methylation values at 27578 CpG loci. While it may be broadly characterised 
as a ‗bisulphite genotyping‘ assay as with the GoldenGate assay, the chemistry 
involved in both arrays differs significantly (Chapter 2). 
 
4.2.1 Samples tested 
 
The primary samples included for analysis represented a smaller subset of 
those examined using the GoldenGate platform. These 16 samples were located 
within the ―high change‖ group as they represented samples with probable high 
tumour content. In addition 4 benign lymph nodes were randomly selected 
from the 19 previously examined to act as the control group, given the 
homogenous nature of methylation profiles across the initial group of 24 
haematopoietic control samples (Chapter 3.4). As with the previous 
GoldenGate array, enzymatically methylated human genomic DNA (Universal 
CpGenome Methylated; Chemicon, Temecula, CA, U.S.A.) was used as a 
methylated control. A single FL tumour DNA was included on each of three 
separate 12-sample arrays to assess inter-array reproducibility as well as being 
tested in duplicate on a single individual array to assess intra-array 
reproducibility. Details of primary samples are listed in Table 4-1. Six 
lymphoid cell lines were also tested to assess whether methylation patterns 
were comparable to their corresponding primary tumour samples; these 
represented 2 benign EBV transformed lymphoblastoid cell lines (HRC-57 and 
Nc-Nc) and 4 malignant B cell lymphoma cell lines (DoHH2, Karpas-422, RL 
and Wsu-NHL). A detailed profile of these cell lines is provided in Table 2-1. 
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Sample ID Diagnosis Age Gender 
BLN6  Reactive lymphoid hyperplasia 28 Male 
BLN 10  Granulation tissue, lymphadenitis 16 Male 
BLN16  
Necrotising granulomatous 
lymphadenitis, possible PTLD 
10 Female 
BLN17  Reactive lymphoid hyperplasia 10 Female 
878 FL Grade I 77 Female 
888 FL Grade II 74 Female 
1073 FL Grade II 78 Male 
1075 FL Grade I 49 Male 
1076 FL Grade III 68 Male 
1081 FL Grade I 69 Female 
1098 FL Grade II 46 Female 
1440 FL Grade I 41 Male 
1472 FL Grade III 35 Male 
1598 FL Grade I 43 Male 
1622 FL Grade II 61 Male 
1626 FL Grade I 66 Male 
1732 FL Grade I 69 Female 
1735 FL Grade II N/A N/A 
1830 FL Grade III 72 Male 
1880 FL Grade II 47 Male 
Meth  
Enzymatically methylated 
genomic DNA 
N/A Male 
 
Table 4-1 Samples examined with Infinium array 
 
Details of primary tissue samples examined using Illumina Infinium Human 
Methylation 27 array. BLN = Benign Lymph Node; Meth = Enzymatically 
methylated human male genomic DNA. PTLD = Post-transplant 
lymphoproliferative disorder. N/A = Not available. 
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4.2.2 Methylation analysis 
 
Sample Methylation Analysis 
Methylation values were analysed using BeadStudio software using the 
algorithms as for the GoldenGate arrays in Chapter 3. Quantitative methylation 
values were obtained for each sample at each CpG locus. Initial analysis was 
by unsupervised hierarchical clustering of beta values.  
 
Group Methylation Analysis 
For the purposes of identifying CpG loci differentially methylated in FL 
relative to benign lymph nodes, the 16 primary FL samples and the 4 benign 
lymph nodes were grouped separately. Differential methylation analysis was 
performed as described for the GoldenGate platform. CpG loci were 
considered to be differentially methylated when comparison of beta values 
between the two groups demonstrated a p value significance level of <0.00001 
(t-test) and an absolute difference in beta value of 0.34 between the two 
groups. 
 
4.2.3 Comparison of hypermethylated genes with list of genes marked by 
bivalent domains in ES cells 
 
The histone modification patterns in ES cells at 18,216 gene promoters were 
obtained from a previous study (Ku, et al 2008). Genes were listed within a 
supplementary table accompanying this study as belonging to one of four 
categories: (a) marked by H3K27me3 alone; (b) marked by H3K4Me3 alone; 
(c) marked by H3K4Me3 and H3K27Me3 (bivalent domains) or (d) marked by 
neither H3K4Me3 nor H3K27Me3. These data were correlated with the list of 
27,578 CpG loci analysed on the Infinium platform. The frequency of genes 
belonging to each category was compared between the hypermethylated gene 
set and all genes examined on the array. Testing of the significance of changes 
Chapter 4 
 153 
between the groups was performed using 2x2 contingency tables and Fisher‘s 
exact test using GraphPad Prism software. 
 
4.2.4 Assessment of hypermethylated genes in relation to CpG density of 
CpG Island 
 
Information on density of CpGs within CGIs of 18,210 genes was also 
available as supplementary information from the manuscript of Ku and 
colleagues (Ku, et al 2008). CGIs were classified as having high (HCP), 
intermediate (ICP) or low (LCP) CpG density. Data was matched with the list 
of 27,578 CpG loci analysed on the Infinium platform and the distribution of 
each category compared between the hypermethylated gene set and all genes 
examined on the array. Testing of the significance of changes between the 
groups was performed using 2x2 contingency tables and Fisher‘s exact test 
using GraphPad Prism software. 
 
4.2.5 Identification of reported functions of hypermethylated genes by 
Gene Ontology analysis 
 
Gene Ontology (GO) provides a platform for scientists to assign human genes 
to various categories according to their reported function. A number of 
software programs and web-based tools allow comparison of two gene lists to 
assess which GO terms are enriched within one list relative to the other. The 
web-based tool at www.fatigo.org (Al-Shahrour, et al 2004) was used to test 
for enrichment of genes with particular assigned GO terms in the 
hypermethylated gene set compared to all genes examined. This tool uses 2x2 
contingency tables and Fisher‘s exact test to assess for significant enrichment 
of genes with GO terms in one group relative to another. False Discovery Rate 
correction was set at 0.01. 
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4.2.6 Treatment of cell lines with 5-aza-2’-deoxycytidine (DAC) 
 
5-aza-2‘-deoxycytidine (DAC)  (C8H12N4O4) has been widely used as a 
methylation inhibitor. DAC (A3656, Sigma Aldrich, Saint Louis, Missouri, 
U.S.A.) was aliquoted into 0.1M stock solutions in Dimethyl Sulfoxide 
(DMSO). Cells were collected by centrifuging 10-15 x 10
6 
cells at 1300rpm for 
5 minutes. The resultant supernatant was discarded and the cell pellet was 
resuspended in 3mls PBS and divided into 3 separate 1ml aliquots. These were 
then centrifuged at 1300rpm for 5 minutes and the supernatant was removed 
and the cell pellet stored at -20ºC for future analysis. 
 
Cells were treated by resuspending in 40mls of a 5µM solution of DAC in 
standard media (2µl 0.1M DAC in 40mls media). Cells were collected at 24, 48 
and 72 hours with DAC treatment repeated at 24 and 48 hours. Control cell 
lines were treated identically except that they were treated with standard media 
to which DMSO only had been added. Cell viability was assessed at 0, 24, 48 
and 72 hours.  
 
4.2.7 cDNA synthesis 
 
One microgram (µg) RNA was added to 1.5l Random Hexamers (50M) in a 
0.2ml PCR reaction tube and the final volume was adjusted to 12l with 
ddH2O. Samples were incubated in a thermal cycler at 72ºC for 5 minutes 
before the reverse transcription step with 18µl of a reaction mix consisting of 
1µl Reverse Transcriptase enzyme (M368A, Promega, Madison, Wisconsin, 
USA), 10µl dNTPs (2.5mM), 6µl of 5x Buffer (M531A, Promega) and 1µl of 
ddH2O. The 30µl samples were placed in a thermal cycler at 42ºC for 60 
minutes and 95ºC for 5 minutes. A sample containing ddH2O instead of RNA 
was included as a control.  
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4.2.8 Quantitative Real-time PCR measurement of gene expression 
 
Gene expression was measured by real time quantitative PCR (RTQ-PCR) 
using commercially available Individual Assays on Demand (Applied 
Biosystems) which contained primers and probe in a single mixture for the 
following genes: CDH1, DAPK, FAT and SLIT2. Assay details are shown in 
Table 4-2. GAPDH Assay-on-Demand was used as the endogenous reference 
control sample. All assays were designed across exonic borders so as genomic 
DNA would not be amplified. All samples were run in duplicate.  
 
A reaction mix consisting of 5µl TaqMan 2x Fast Universal PCR MasterMix, 
0.5µl of assay on demand and 3.5µl of ddH2O was added to an individual well 
of a Fast Optical 96-well Reaction Plates with Barcode (0.1ml) (Catalogue 
Number 4346906, Applied Biosystems). One µl of the individual cDNA to be 
studied was added to the reaction mix. The plate was sealed with an optical 
adhesive cover, briefly centrifuged at <100xg to remove any bubbles and then 
the plate was loaded on to the ABI Prism 7900HT (Applied Biosystems) 
machine. Quantitative fast real-time PCR was performed with an initial step at 
95ºC for 10 minutes followed by 40 cycles at 95ºC for 1 second ramping down 
to 60ºC for 20 seconds. 
 
As amplification proceeds, fluorescent reporter molecules are released in 
proportion to amount of product produced and fluorescence intensity is 
measured. The cycle at which this intensity is statistically increased over 
background is known as the cycle threshold (Ct). Samples with very low or 
undetectable gene expression may have undetectable Ct values. As it is 
considered that 35-40 cycles is generally sufficient to amplify single molecules 
of cDNA to a detectable level, those with undetermined Ct values are given a 
Ct value of 40. Mean Ct values are calculated from the duplicate reaction. Ct 
values of individual genes were assessed relative to those of the reference 
endogenous control gene (GAPDH). These Ct values can then be used to 
compare relative expression between two samples, for instance comparing gene 
expression of a sample which has been treated with DAC to a reference level 
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from one which has not (calibrator sample). These values can then be used to 
derive the fold change in expression between two samples. 
 
These steps can be summarised as follows: 
∆Ct    = (Ct SAMPLE – Ct REFERENCE) 
∆∆Ct  = (∆Ct SAMPLE - ∆Ct CALIBRATOR ) 
Expression fold change = 2
-∆∆Ct
 
 
Along with the cDNA samples being analysed, control samples included the no 
RNA control (NRC) from the cDNA synthesis step and a no template control 
(NTC). 
 
Gene 
Name 
Assay ID Exon 
Boundary 
Reporter Quencher 
CDH1 Hs01023895_m1 6-7 FAM Non-Fluorescent 
DAPK1 Hs00234480_m1 18-19 FAM Non-Fluorescent 
FAT Hs00170627_m1 6-7 FAM Non-Fluorescent 
SLIT2 Hs00191193_m1 3-4 FAM Non-Fluorescent 
GAPDH 43100884E  VIC TAMRA 
 
Table 4-2 Gene expression study detail  
Details of Applied Biosystems Assays-on-Demand used to examine gene 
expression by real-time quantitative PCR.  GAPDH was used as the 
endogenous reference control sample. 
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4.3  Infinium analysis – quality control and validation  
 
4.3.1 Exclusion of CpG loci 
 
Given the confounding effects of methylation profiles of genes on the sex 
chromosomes on overall analysis, only autosomal CpG loci were included for 
cluster analysis of sample methylation profiles. In total, 26,486 autosomal CpG 
loci were examined following exclusion of 1092 CpG Loci on X and Y 
chromosome. 
 
4.3.2 Exclusion of samples / analysis of internal controls 
 
The Infinium assay contains a number of probes designed to provide quality 
control for a number of steps in the assay process. These examine for the 
efficiency of staining, nucleotide extension, post-extension target removal and 
the hybridisation steps. The efficiency of bisulphite conversion is tested by a 
set of control probes as is the specificity of values obtained. A set of negative 
control probes establishes the background signal while a final set of control 
probes tests the overall assay performance. Control probe profiles were 
inspected for each of the samples examined and compared with the expected 
profile pattern. A single sample failed quality control. This was on the basis of 
an abnormal profile for the Bisulphite Conversion control probes (Figure 4-2).  
 
4.3.3 Reproducibility (inter and intra-array correlation) 
 
In order to test reproducibility of results, a single sample (Sample ID 1626) 
was tested on all three 12-sample BeadChips as well as being duplicated on a 
single array. Pearson correlation coefficients for all paired replicates (Intra- and 
inter-array) are listed in Table 4-3 with corresponding scatter plots in Figure 
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4-3. Pearson correlation coefficients (r) ranged from 0.94 to 0.99 indicating 
excellent reproducibility of results with this array. 
 
4.3.4 Validation  
 
To assess whether the values obtained using the Infinium were valid, the 
correlation with results obtained for the same samples using a different analysis 
method was assessed. Beta values at 100 CpG loci common to both 
GoldenGate and Infinium arrays were correlated for 21 samples examined on 
both platforms (16 FL, 4 benign lymph node, methylated control). All 21 
samples had been independently bisulphite converted for each array method. 
Pearson correlation coefficients for all 21 samples are listed in Table 4-4. 
Correlation was very good for all primary benign and FL samples (r range = 
0.83-0.92). Correlation was poorer for the enzymatically methylated control 
sample, most probably reflecting the skewed distribution of values towards 
high beta values. Sample scatter plots are shown in Figure 4-4. As there was 
good concordance between both methods, this confirmed the validity of the 
Infinium array findings.  
 
4.3.5 Correlation across adjacent bases  
 
A reputed drawback of bisulphite genotyping methods such as the Infinium 
assay is the use of a small number of selected CpGs to establish methylation 
status of a CpG island (Feinberg 2010). While the CpG probes on the Infinium 
array still represent a small fraction of all CpG nucleotides, previous studies 
have shown that CpG methylation state is highly correlated over hundreds of 
bases (Eckhardt, et al 2006) so results from individual CpG loci broadly reflect 
the methylation status of adjacent CpG loci. It is worth noting that this 
assumption also provides the basis for the design of most other methylation 
assays such as MSP. Indeed, computational algorithms for methylation analysis 
of genome-wide methods such as BaTMAn analysis of MeDIP (Down, et al 
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2008) are based on findings that methylation state is generally highly 
correlated across hundreds of bases. 
 
The Pyrosequencing results outlined in Chapter 3 would also suggest that 
methylation values across 4-5 adjacent CpG sites differ little in their 
methylation status. It is notable that even where differences in absolute 
methylation do occur, the differential methylation between benign and 
malignant samples is generally maintained. Nonetheless, I tested to see whether 
values correlated across hundreds of base pairs in FL. All CGIs studied with 6 
or more individual probes were examined to assess whether values were 
similar across the CGI. In total, 110 CGIs from 99 genes fulfilled these criteria. 
Average methylation values in the FL and benign lymph node group and the 
average ∆ß are detailed in Appendix D. Standard deviation of values across all 
probes showed generally good correlation across bases suggesting that values 
from a relatively small number of probes are broadly representative of the 
entire CGI status. 
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Figure 4-2 Bisulphite conversion control profile.  
 
Exclusion of sample based on bisulphite conversion control profile. Probe 
signal intensity is displayed on the y axis with all samples from 3 arrays 
arranged on the x axis. The expected profile is of high signal intensity for 
bisulphite conversion probes C1 and C2 (green and blue dots) with low 
intensity for bisulphite conversion probes U1 and U2 (red and purple dots). 
The black box highlights the single sample (enzymatically methylated DNA 
sample in Array 1) that does not display the expected profile.  
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Sample ID 
of correlated pairs Pearson r 
95% Confidence 
Interval 
P value 
(two-tailed) r
2
 
1626-1A 1626-1B 0.9755 0.9749 to 0.9761 < 0.0001 0.9516 
1626-1A 1626-2 0.9783 0.9778 to 0.9788 < 0.0001 0.9571 
1626-1A 1626-3 0.9763 0.9757 to 0.9768 < 0.0001 0.9531 
1626-1B 1626-2 0.9451 0.9438 to 0.9463 < 0.0001 0.8931 
1626-1B 1626-3 0.9419 0.9405 to 0.9432 < 0.0001 0.8871 
1626-2 1626-3 0.9921 0.9919 to 0.9923 < 0.0001 0.9843 
 
Table 4-3 Correlation of replicate sample values 
Pearson correlation coefficients for intra- and inter-array replicates of FL 
sample 1626. The number following the sample ID refers to the array on which 
the sample was examined. The lettering distinguishes replicates on the same 
array. 
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Figure 4-3  Inter- and intra-array reproducibility 
 
Scatter plots demonstrating Inter- and intra-array reproducibility. Values on x 
and y axes correspond to methylation beta values between 0 and 1. Each dot 
represents a beta value for one of the 27,578 CpG loci examined. Pearson 
correlation coefficient values corresponding to the individual scatter plots are 
shown in the inset table. 
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Sample ID Pearson r 95% confidence interval 
P value 
 (two-tailed) r2  
BLN6  0.9162 0.8777 to 0.9429 < 0.0001 0.8393 
BLN 10  0.9152 0.8762 to 0.9422 < 0.0001 0.8375 
BLN16  0.9114 0.8709 to 0.9396 < 0.0001 0.8307 
BLN17  0.9188 0.8815 to 0.9447 < 0.0001 0.8442 
878 0.8979 0.8517 to 0.9303 < 0.0001 0.8063 
888 0.8795 0.8258 to 0.9175 < 0.0001 0.7736 
1073 0.8262 0.7517 to 0.8798 < 0.0001 0.6826 
1075 0.8942 0.8464 to 0.9277 < 0.0001 0.7996 
1076 0.8329 0.7610 to 0.8846 < 0.0001 0.6938 
1081 0.8386 0.7688 to 0.8887 < 0.0001 0.7033 
1098 0.8693 0.8114 to 0.9103 < 0.0001 0.7556 
1440 0.9013 0.8564 to 0.9326 < 0.0001 0.8123 
1472 0.877 0.8221 to 0.9157 < 0.0001 0.7691 
1598 0.91 0.8688 to 0.9386 < 0.0001 0.8281 
1622 0.8795 0.8257 to 0.9175 < 0.0001 0.7736 
1626 0.8654 0.8059 to 0.9075 < 0.0001 0.7489 
1732 0.8995 0.8540 to 0.9314 < 0.0001 0.8091 
1735 0.8977 0.8515 to 0.9302 < 0.0001 0.8059 
1830 0.9091 0.8676 to 0.9380 < 0.0001 0.8264 
1880 0.9006 0.8555 to 0.9321 < 0.0001 0.8111 
Meth  0.3707 0.1879 to 0.5287 0.0001 0.1374 
 
Table 4-4 Correlation between GoldenGate and Infinium  
Correlation coefficients (r) of 21 samples of methylation values at 100 CpG 
loci measured by both the GoldenGate and Infinium arrays. BLN = Benign 
lymph node; Meth = Enzymatically methylated human genomic DNA control.
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Figure 4-4 Correlation between Infinium and GoldenGate results 
Sample scatter plots of correlation of beta values for 100 CpG loci obtained 
with both Infinium and GoldenGate methylation assays. Each dot represents a 
beta value at an individual CpG locus. Values obtained with Infinium assay are 
represented on the y axis with GoldenGate values on the x axis. (A) Benign 
Lymph node – Sample ID BLN17 (B) FL – Sample ID 1880 (C) Methylated 
control.  
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4.4  Infinium Analysis  
 
4.4.1 Sample Methylation profiles 
 
Sample methylation profiles were analysed by unsupervised hierarchical 
clustering using the Manhattan method. Clustering of primary samples 
identified similar methylation profiles to that of the smaller scale GoldenGate 
array (Figure 4-5) with the majority of CpG loci showing similar methylation 
profiles in both benign and malignant lymphoid tissue while a distinct subset of 
loci showed FL-specific hyper- and hypo-methylation (orange and yellow 
boxes in Figure 4-5 respectively). Separate analyses of loci located within or 
outside of CpG islands confirmed the distinct pattern of tumour-specific 
hypermethylation occurring within CGIs with tumour-specific 
hypomethylation occurring outside of CGIs (Figure 4-6 & Figure 4-7). An 
analysis of cell line samples is provided in Section 4.5. 
 
4.4.2 Differential methylation of FL relative to benign lymph nodes 
 
Differential methylation was assessed in the group of 16 u-FL samples relative 
to the 4 benign lymph nodes according to the same criteria used for the 
GoldenGate assay (Chapter 3.2.1.3). In total, 1074 (4%) autosomal CpG loci 
demonstrated significant FL-specific hypermethylation relative to the control 
group, of which 1063 loci (99%; corresponding to 788 genes) were within 
CGIs. Of 388 loci demonstrating significant tumour-specific hypomethylation, 
89% (344) were located outside of CGIs. As our primary focus is on those 
genes demonstrating tumour-specific hypermethylation, examination of 
hypermethylated loci is furthermore confined to those loci within CGIs. 
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Figure 4-5 DNA Methylation in FL and benign lymph nodes 
 
Unsupervised hierarchical clustering of methylation values at all autosomal 
loci examined of 16 FL samples, 4 benign lymph nodes and methylated control 
DNA. Columns represent samples; rows represent CpG loci. Colour represents 
methylation level (ß) from 0 – 1 as per colour bar (Red = high methylation 
level; Green= Low methylation level). Horizontal colour bar indicates nature of 
benign sample as per figure legend. The enzymatically methylated DNA 
clusters separately from all other samples. The next major cluster divides 
benign from malignant samples. The orange box demonstrates loci showing 
FL-specific hypermethylation while the yellow box highlights loci showing 
FL-specific hypomethylation. 
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Figure 4-6 DNA Methylation within CpG islands 
 
Unsupervised hierarchical clustering of methylation values at autosomal loci 
within CGIs of 16 FL samples, 4 benign lymph nodes and methylated control 
DNA. 
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Figure 4-7 DNA Methylation outside CpG islands 
 
Unsupervised hierarchical clustering of methylation values at autosomal loci 
outside of CGIs of 16 FL samples, 4 benign lymph nodes and methylated 
control DNA. 
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4.4.3 MicroRNAs and DNA Methylation 
  
MicroRNAs are short sequences of RNA that control gene expression by 
binding to complementary sequences on mRNA. It is worth noting here that 
255 of the CpG loci were located within CpG islands reported to be involved in 
control of microRNA expression. Examination of these 255 loci 
(corresponding to 110 different CpG islands regulating 74 individual 
microRNAs) showed a similar pattern to that of all CpG loci within CGIs. 
Cluster analysis showed discrimination between benign and malignant samples 
on the basis of methylation profiles of these highly selective CpGs (Figure 
4-8).  The majority of CpG loci were unmethylated in both malignant and 
benign tissue with only a minority of CpG loci showing aberrant 
hypermethylation. It should be noted that all of these CpGs are within CGIs 
also associated with known genes so it may be that the effect of 
hypermethylation is on expression of these known genes rather than the 
microRNAs.  
 
4.5  Methylation profiles in cell lines 
 
As a first step towards establishing the applicability of using cell lines as a 
mechanism to investigate epigenetic mechanisms, I wished to establish whether 
lymphoid cell lines represented the methylation status of benign and malignant 
primary samples. The promise of investigating these epigenetic mechanisms 
lies in their therapeutic potential - ‗demethylating‘ agents are in frequent use in 
both the clinical situation in AML/MDS and are currently being evaluated in 
clinical trials in FL. In this series of experiments I assessed whether genes 
identified as methylated using the Infinium platform could be re-expressed by 
treatment with demethylating agents. This was of particular interest given the 
relatively low inverse correlation between methylation and gene expression in 
both our own and other studies. 
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Figure 4-8 DNA Methylation and MicroRNAs 
 
Unsupervised hierarchical clustering of methylation beta values for primary 
samples and methylated control DNA of 255 CpG loci located within CGIs 
reported to control microRNA expression status. The majority of CpGs are 
unmethylated in both benign and malignant samples. The base of the heat map 
is magnified to demonstrate a number of CpG loci that show FL-specific 
methylation. 
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Few previous studies have examined whether cell lines are representative of 
primary samples. A number of studies had identified higher levels of 
methylation in cell lines as compared to primary malignant samples (Paz, et al 
2003, Smiraglia, et al 2001). Ehrich and colleagues performed methylation 
profiling on a series of cell lines from the National Cancer Institute (NCI) 
(Ehrich, et al 2008). Their validation studies using primary colorectal samples 
suggested that findings from cell lines are applicable to primary samples. 
While quantitative methylation values were generally higher in the cell line 
samples, the authors suggested that this was most likely a function of the 
heterogeneity of primary samples. 
 
4.5.1 Comparison with primary sample data 
 
In order to compare methylation profiles of cell lines and primary sample data, 
unsupervised hierarchical clustering was performed. Clustering of all 26,486 
autosomal loci shows that methylation provided a robust discriminator between 
benign and malignant samples (Figure 4-9), regardless of whether the samples 
were primary tissue samples or cell lines. Similarly, analysis restricted to those 
loci within CGIs showed a similar pattern (Figure 4-10), confirming that 
malignancy exerts a greater effect on methylation profiles of lymphoid tissue 
than cell culture. However, analysis restricted to those loci outside of CGIs 
showed a different pattern (Figure 4-11). In this case, the major division of 
methylation profiles was between primary samples and cell lines, regardless of 
whether they were benign or malignant. This suggests that the major 
differences occurring with cell culture in lymphoid cell lines may occur at 
those loci outside of CGIs, while methylation patterns in cell lines at loci 
within CGIs are broadly representative of primary samples. 
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Figure 4-9 DNA Methylation of cell lines and primary samples 
 
Unsupervised hierarchical clustering of methylation beta values for primary 
samples, cell lines and methylated control DNA for all autosomal CpG loci. 
The horizontal colour bar indicates the nature of the sample tested – blue 
samples are malignant while yellow samples are benign with the heavier shade 
representing cell lines. The enzymatically methylated DNA clusters separately 
from all other samples. The next major cluster divides benign from malignant 
samples. 
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Figure 4-10 DNA Methylation of cell lines and primary samples within 
CpG islands. 
 
Unsupervised hierarchical clustering of methylation beta values for primary 
samples, cell lines and methylated control DNA for autosomal CpG loci 
located within CGIs. The horizontal colour bar indicates the nature of the 
sample tested – blue samples are malignant while yellow samples are benign 
with the heavier shade representing cell lines. The enzymatically methylated 
DNA clusters separately from all other samples. The next major cluster divides 
benign from malignant samples. 
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Figure 4-11 DNA Methylation of cell lines and primary samples outside 
CpG islands. 
 
Unsupervised hierarchical clustering of methylation beta values for primary 
samples, cell lines and methylated control DNA for autosomal CpG loci 
located outside of CGIs. The horizontal colour bar indicates the nature of the 
sample tested – blue samples are malignant while yellow samples are benign 
with the heavier shade representing cell lines. It is notable that, in contrast to 
the overall analysis and that restricted to loci within CpG islands, the principal 
cluster separation is between cell lines and primary samples rather than 
between benign and malignant samples. 
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4.5.2 Treatment with demethylating agents 
 
Our initial studies had shown relatively low inverse correlation between gene 
expression and methylation. The benign lymphoblastoid cell line HRC57 and 
the malignant lymphoma cell lines DoHH2 and RL were treated with the 
―demethylating‖ agent DAC in order to assess whether such agents could 
influence gene expression. Expression of four genes were examined – CDH1, 
DAPK1, FAT and SLIT2. Each had been shown to be aberrantly 
hypermethylated in FL samples by both the GoldenGate and Pyrosequencing 
technologies with similar aberrant hypermethylation in malignant lymphoid 
cell lines relative to lymphoblastoid cell lines (Table 4-5). Furthermore, each 
had been among those genes whose expression showed significant inverse 
correlation with methylation (Chapter 3.5.6, Appendix A). 
 
Cell lines were treated as described in Chapter 4.2.6. Initial experiments 
showed that treatment with DAC increased expression of the 4 genes tested at 
48 hours with a further increase at 72 hours (Table 4-6, Figure 4-12). Two 
further independent experiments were performed to examine the effect of DAC 
following 72 hours of treatment. Cell lines treated with DMSO only were used 
as control samples. The effect of DAC treatment on CDH1, DAPK1, FAT and 
SLIT2 gene expression in the benign lymphoblastoid cell line HRC57 and the 
malignant lymphoma cell lines DoHH2 and RL are shown in Figure 4-13 with 
details of log
10
 fold change in Table 4-7. The effect of DAC treatment on cell 
viability in these three cell lines is shown in Figure 4-14. 
 
Exposure to DAC resulted in a profound increase in expression of all 4 studied 
genes in all 3 cell lines examined. In general, these changes were more 
pronounced in the more highly methylated malignant cell lines rather than the 
partially methylated benign lymphoblastoid cell line, suggesting that the 
increase in gene expression may occur through release of the repressive effect 
of methylation on expression. However, further studies involving a range of 
genes with varying methylation values will be required to assess whether these 
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marked changes in gene expression are the result of demethylation or an 
alternative mechanism. For instance, if such a marked increase in expression 
were identified for unmethylated genes, this may suggest an alternative 
mechanism other than inhibition of methylation. Additional studies would also 
be required to clarify the effects of DMSO on gene expression given the 
reduction in gene expression noted in some cases with DMSO treatment.  
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 CDH1 DAPK1  FAT  SLIT2  
HRC57 0.37 0.22 0.34 0.27 
DoHH2 0.81 0.7 0.87 0.60 
RL 0.81 0.58 0.86 0.60 
 
Table 4-5 Individual gene methylation in cell lines 
Quantitative methylation values for 4 genes assessed for expression change 
with DAC treatment in the lymphoblastoid B cell line HRC57 and the 
malignant lymphoma cell lines DoHH2 and RL. Values are an average value of 
all loci examined on the Infinium array. 
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 CDH1 DAPK1 FAT SLIT2 
 48 hrs 72 hrs 48 hrs 72 hrs 48 hrs 72 hrs 48 hrs 72 hrs 
HRC57 1.23 
(16) 
1.87 
(74) 
0.33 
(2) 
0.89 
(8) 
1.66 
(45) 
2.27 
(188) 
0.26 
(2) 
0.66 
(5) 
DoHH2 2.94 
(877) 
3.34 
(2166) 
1.93 
(86) 
2.52 
(336) 
1.1 
(12) 
1.81 
(65) 
1.18 
(15) 
1.36 
(23) 
RL 2.33 
(213) 
2.72 
(533) 
1.66 
(45) 
2.15 
(140) 
0.82 
(7) 
1.85 
(71) 
2.12 
(133) 
2.93 
(854) 
 
 
 
Table 4-6 Effect of DAC on gene expression at 48 and 72 hours 
Figure 4-12 Effect of DAC on gene expression at 48 and 72 hours 
Table and figure show effect of 5‘-aza-2-deoxycytidine treatment on gene 
expression after 48 hours and 72 hours treatment. Figures are for log
10
 fold 
expression change relative to pre-treatment (Time 0) expression. Absolute fold 
expression change is shown in parentheses in the table. Log fold expression 
change with DAC treatment is shown on the y axis in the figure.  
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 DAC DMSO 
CDH1 1 2 1 2 
HRC57 1.32 (21) 1.45 (28) -0.22 (0.6) -0.39 (0.40) 
DoHH2 2.41 (260) 2.46 (286) -0.95 (0.11) -1.35 (0.04) 
RL 2.24 (174) 2.38 (242) -0.41 (0.38) -0.43 (0.37) 
 
 DAC DMSO 
DAPK1 1 2 1 2 
HRC57 0.61 (4) 0.63 (4) -0.1 (0.80) -0.13 (0.74) 
DoHH2 1.02 (10) 1.96 (91) -1.3 (0.05) -1 (0.1) 
RL 1.68 (48) 2.02 (105) -1.08 (0.08) -0.2 (0.58) 
 
 DAC DMSO 
FAT 1 2 1 2 
HRC57 2.26 (183) 2.18 (150) 0.31 (2.06) 0.39 (2.46) 
DoHH2 0.8 (6.26) 1.06 (11.4) -0.25 (0.55) -0.6 (0.25) 
RL 1.81 (65) 2.37 (233) -0.26 (0.54) -0.07 (0.85) 
 
 DAC DMSO 
SLIT2 1 2 1 2 
HRC57 0.47 (2.94) 0.52 (3.32) 0.18 (1.51) -0.63 (0.23) 
DoHH2 0.45 (2.8) 0.98 (9.57) 0.02 (1.04) -0.2 (0.62) 
RL 3.29 (1941) 3.35 (2240) 0 (1) -0.25 (0.56) 
 
Table 4-7 Effect of DAC and DMSO on gene expression 
Effect of treatment of cell lines with 5‘aza-2-deoxycytidine on expression of 4 
genes (CDH1, DAPK1, FAT, SLIT2). Measurements are given as log-fold 
change in expression after 72 hours treatment with DAC or DMSO only 
control relative to untreated (Time 0) expression. Absolute fold change is in 
parentheses. Results are given for two separate experiments.  
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Figure 4-13 Effect of DAC and DMSO on gene expression 
Effect of 5‘-aza-2-deoxycytidine treatment on gene expression after 72 hours 
compared to treatment with DMSO alone in the benign lymphoblastoid cell 
line HRC57 and the malignant lymphoma cell lines DoHH2 and RL. Results 
are given for two separate experiments and are expressed as log
10
 fold change 
(shown on y axis). 
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Figure 4-14 Effect of DAC treatment on cell line viability. 
 
Percentage of cells viable at 24, 48 and 72 hours after treatment with DAC is 
shown. 
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4.6  Identification of features of CpG islands 
susceptible to aberrant hypermethylation 
 
My initial studies suggested that aberrant methylation of numerous genes in 
cancer may be linked to a pre-programmed mechanism. The next step was to 
examine how many genes were susceptible to aberrant hypermethylation and to 
identify what factors discriminated between CGIs prone to hypermethylation in 
cancer and those resistant to hypermethylation. In all cases, the 
hypermethylated gene set was compared to both genome-wide data (Genome 
Wide Set) and to data on all genes on the array (Infinium Array Set). Given the 
finding that significant hypermethylation was restricted to CpG loci within 
CGIs and our previous findings of distinct methylation profiles based on 
whether CpG loci were located within a CGI, we included only CpG loci 
within CpG islands as the reference Infinium array set.  
 
4.6.1 PRC2 target genes in ES cells  
 
Firstly, we set out to confirm, on a wider scale, our finding that those genes 
that become hypermethylated in FL are enriched for genes targeted by PRC2 in 
ES cells. Of the 788 genes hypermethylated in FL, data on PRC2 component 
occupancy was available for 723. Of these, 347 (48%) were marked by at least 
one of the three PRC2 marks in ES cells, a significant overrepresentation 
(p<0.0001; chi-square test; RR 3.67; OR 6.17) when compared to all genes in 
the Infinium Array Set. Similarly, genes with all 3 PcG marks were 
significantly overrepresented in the hypermethylated gene set (p<0.0001; chi-
square test; RR 4.75; OR 6.2) (Table 4-8, Figure 4-15). This significant 
overrepresentation also applied to each of the individual marks (EED, SUZ12, 
H3K27Me3) when examined in isolation (Table 4-8 & Table 4-9, Figure 
4-16). 
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Of note, of the 508 genes with all 3 PcG marks which were examined on the 
array, 38% (192) were aberrantly hypermethylated in FL suggesting that not 
only are a large proportion of hypermethylated genes PRC2 target genes but 
also that a substantial proportion of PRC2 target genes become methylated in 
FL. 
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 Hypermethylated Set Infinium Array Set Genome-wide 
 n= % n= % n= % 
1 mark 86 11.9 436 4.8 609 3.6 
2 marks 69 9.5 245 2.7 328 2 
3 marks 192 26.6 508 5.6 654 3.9 
0 mark 376 52 7900 86.9 15119 90.5 
       
TOTAL 723 100 9089 100 16710 100 
       
EED 257 35.5 815 9 1066 6.4 
SUZ12 272 37.6 777 8.5 1040 6.2 
H3K27Me3 273 37.8 858 9.4 1121 6.7 
 
Table 4-8 Distribution of PRC2 marked genes 
Frequency of genes marked by PRC2 components within hypermethylated 
gene set, Infinium array and genome-wide studies. 
 
 P value Relative Risk (RR) Odds Ratio (OR) 
EED <0.0001 3.96 (3.52-4.46) 5.6 (4.73-6.62) 
SUZ12 <0.0001 4.4 (3.92-4.94) 6.45 (5.46-7.62) 
H3K27Me3 <0.0001 4 (3.58-4.48) 5.83 (4.94-6.88) 
 
Table 4-9 Significance of distribution of PRC2 marked genes 
The table demonstrates significant overrepresentation of each of the PcG mark 
target genes in the Hypermethylated Gene Set compared to the Infinium Array 
Set (Fishers exact test). 
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Figure 4-15 Distribution of PRC2 target genes  
 
Distribution of PRC2 target genes within hypermethylated gene set, Infinium 
array gene set and genome-wide studies. 
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Figure 4-16 Distribution of individual PcG marks 
 
Distribution of PRC2 target genes within hypermethylated gene set, Infinium 
array gene set and genome-wide studies according to each individual PcG mark 
(EED, H3K27Me3 and SUZ12). 
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4.6.2 Genes marked by bivalent chromatin domains in ES cells 
 
Recent work has shown that not only is cell differentiation controlled by the 
repressive H3K27Me3 mark but that both H3K27Me3 and the activating mark 
H3K4Me3 mark many genes (Figure 4-1). Such pluripotent cells marked both 
by repressive H3K27Me3 and activating H3K4Me3 histone marks are 
described as being held in a ―bivalent‖ chromatin state (Bernstein, et al 2006). 
Alteration of these marks in various key developmental genes allows cells to 
differentiate along a particular pathway. Ku and colleagues previously 
examined 18216 promoters in embryonic stem cells with respect to whether 
they were occupied by H3K27Me3 or H3K4Me3 (Ku, et al 2008). They 
identified a subset of genes (14.3%) that were marked by both histone 
modifications. A smaller number (1.2%) were marked by the repressive mark 
alone.  
 
Of the 788 hypermethylated CGI genes, data was available for 684 genes 
(87%). Data on occupancy for either of these histone marks for the genome-
wide studies, all genes within CGIs on the array (Infinium Array Set) and the 
hypermethylated gene set are presented in Table 4-10. For purposes of 
consistent comparison, only autosomal promoters were included in the 
analysis. 
 
The hypermethylated gene set was significantly enriched for genes with 
bivalent marks when compared with the Infinium Array Set (Table 4-11, 
Figure 4-17). The relatively small amount of genes marked by H3K27Me3 
alone suggests that the majority of those genes shown to be marked by PRC2 
components in ES cells in the initial studies of Lee and colleagues (Lee, et al 
2006b) will also be marked by H3K4Me3. While such genes marked by 
H3K27Me3 alone were much less frequent, these were also significantly 
overrepresented among the hypermethylated gene set (Table 4-12). 
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 Hypermethylated  Infinium Array  Genome Wide  
 n= % n= % n= % 
No Marks 28 4.1 737 8.2 4600 26.2 
K4 233 34.1 6524 72.2 10218 58.3 
K27 37 5.4 116 1.3 213 1.2 
K4 and K27 386 56.4 1660 18.4 2510 14.3 
TOTAL 684 100 9037 100 17541 100 
 
Table 4-10 Genes marked by histone modifications in ESCs 
Data on distribution of genes with known histone modification profiles in 
ESCs. Data was available from mapping studies performed by Ku et al. on the 
occupancy of 18216 genes by the repressive mark H3K27Me3 and the active 
mark H3K4Me3 in ESCs. Data was available for 9037 of the 10371 autosomal 
genes within CpG islands examined on the array and for 684 of the 788 genes 
within CGIs identified as being aberrantly hypermethylated in FL. Statistical 
comparison of frequencies of these marks is provided in (Table 4-11-Table 
4-13).  
 
 K4 and K27 Other 
Hypermethylated Gene Set 386 298 
Infinium Array Set 1660 7377 
P Value <0.0001  
 
Table 4-11 Genes marked by H3K27Me3 and H3K4Me3 
Frequency of genes marked by both H3K27me3 and H3K4Me3 in ES cells 
among hypermethylated gene set relative to all genes on the Infinium array. 
Genes with bivalent chromatin domains were significantly overrepresented in 
the hypermethylated gene set. 
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 K27 Other 
Hypermethylated Gene Set 37 647 
Infinium Array Set 116 8923 
P Value <0.0001  
 
Table 4-12 Genes marked by H3K27Me3 only 
Frequency of genes marked by H3K27me3 alone in ES cells among 
hypermethylated gene set relative to all genes on the Infinium array. 
H3K27Me3 target genes were significantly overrepresented in the 
hypermethylated gene set. 
 
 K4 Other 
Hypermethylated Gene Set 233 451 
Infinium Array Set 6524 2513 
P Value <0.0001  
 
Table 4-13 Genes marked by H3K4Me3 only 
Frequency of genes marked by H3K4me3 alone in ES cells among 
hypermethylated gene set relative to all genes on the Infinium array. H3K4Me3 
target genes were significantly underrepresented in the hypermethylated gene 
set. 
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Figure 4-17 Distribution of genes with bivalent domains in ESCs 
 
Distribution of genes marked by H3K4Me3 and H3K27Me3 within 
hypermethylated gene set, Infinium array gene set and genome-wide studies. 
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4.6.3 Genes with high CpG density  
 
Data was available on promoter CpG density for 16290 of the 19237 autosomal 
CpG CGI loci on the Infinium array. This corresponded to 9037 unique genes. 
Promoters were classified as being of low, intermediate or high CpG density. 
Frequency of each class of promoter density within the hypermethylated gene 
set, the Infinium array and the genome-wide studies is shown in Figure 4-18 & 
Table 4-14 - Table 4-16. As can be seen from the table, the selection bias for 
high-density CpG promoters (HCPs) in the Infinium array set compared to the 
genome wide set is pronounced (86% in Infinium array set compared to 66% in 
genome-wide set). Despite this, HCPs are significantly overrepresented within 
the hypermethylated gene set compared to the Infinium array set. Low CpG 
density promoters (LCPs) and intermediate CpG density promoters (ICPs) are 
underrepresented in the hypermethylated gene set. When HCPs and ICPs are 
grouped together they remain overrepresented suggesting that DNA 
methylation preferentially affects promoters with higher CpG content. It is 
worth noting that high density CpG promoters have previously been linked 
with both housekeeping genes and key development genes (Saxonov, et al 
2006) with the housekeeping genes being highly expressed in ES cells and 
univalent while developmental genes have bivalent chromatin domains 
(Bernstein, et al 2006, Mikkelsen, et al 2007). 
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 Hypermethylated Gene Set  Infinium Array Set Genome Wide Set 
 n= % n= % n= % 
LCP 9 1.3 260 2.9 3109 17.7 
ICP 44 6.4 1045 11.6 2746 15.7 
HCP 631 92.3 7732 85.6 11686 66.6 
TOTAL 684 100 9037 100 17541 100 
 
Table 4-14 Density of CpG promoters 
Distribution of low, intermediate and high CpG density promoters within the 
hypermethylated gene set, the Infinium array and genome-wide studies (Ku, et 
al 2008). 
 
 HCP Other 
Hypermethylated Gene Set 636 53 
Infinium Array Set 7732 1305 
P Value <0.0001 
 
Table 4-15 Distribution of genes with high-density CpG promoters 
Frequency of high-density CpG promoters among hypermethylated gene set 
relative to genes on Infinium array set. High-density promoters are 
significantly overrepresented in the hypermethylated gene set. 
 
 HCP & ICP Other 
Hypermethylated Gene Set 675 9 
Infinium Array Set 8777 260 
P Value 0.0227  
 
Table 4-16 Distribution of genes with high- and intermediate density CpG 
promoters 
Frequency of high- and intermediate density CpG promoters among 
hypermethylated gene set relative to genes on Infinium array.
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Figure 4-18 CpG density of hypermethylated genes 
 
Distribution of genes with high, intermediate or low density of CpGs in their 
promoter regions within the hypermethylated gene set, Infinium array gene set 
and genome-wide studies. 
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4.6.4 Assessment of GO terms assigned to hypermethylated genes. 
 
My data demonstrated that the hypermethylated gene set was enriched for a 
unique subset of genes in embryonic stem cells marked by both the repressive 
H3K27me3 and activating H3K4me3 marks. Based on the ‗state of readiness‘ 
associated with bivalent domains in ES cells these genes could potentially be 
involved in differentiation through control of their expression by manipulation 
of these histone marks. To examine this further, I compared GO terms assigned 
to the 788 genes in the hypermethylated gene set with those of the 10371 genes 
on the Infinium array set to assess whether genes with particular cellular 
functions were more susceptible to cancer-related methylation.  
 
Examination was conducted for two categories of GO terms - biological 
processes and molecular function. GO terms within the biological processes 
category that are significantly overrepresented within the hypermethylated 
gene set list compared to the overall Infinium array set are listed in Table 4-17 
(Full list in Appendix D). Notably, genes with development-related functions 
were highly significantly overrepresented within the hypermethylated gene set. 
 
GO terms within the molecular function category that are significantly 
overrepresented within the hypermethylated gene set list compared to the 
overall array Infinium array set are listed in Appendix D. The most significant 
enrichment within the hypermethylated gene set in this category was for genes 
reported to function in ―sequence-specific DNA binding‖ and ―transcription 
factor activity‖.  
 
The overrepresentation of genes with developmental function was supported by 
a separate analysis of the protein terms using the InterPro database. The most 
significantly overrepresented genes within the hypermethylated gene set were 
those whose protein products were assigned to the homeobox and POU 
families (Appendix D). We have already described the key role of homeobox 
genes such as the HOX family genes in development and their targeting by 
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Polycomb proteins. The POU protein family consists of transcription factors 
with a wide variety of functions, all of which are related to organism 
development – in fact, each protein consists of two subunits, one of which is a 
homeobox domain. 
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GO term Hypermethylated 
gene set (%) 
Infinium 
array set 
(%) 
Adjusted 
P value 
Multicellular organismal 
development 
38.1 18.5 2.05 x10
-25
 
Anatomical structure 
development 
34.5 17.2 2.79 x10
-21
 
System development 30.4 14.4 3.01 x10
-19
 
Nervous system 
development 
18.45 7.1 1.18 x10
-14
 
Cell-cell signalling 15.1 5.5 8.77 x10
-14
 
Organ development 22.3 10.9 2.46 x10
-11
 
 
Table 4-17 Gene Ontology analysis  
List of GO terms (within the biological processes GO category) most 
significantly overrepresented within the hypermethylated gene set. Full list in 
Appendix D. 
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4.7  Discussion 
 
Our initial study had suggested that aberrant DNA methylation affected many 
genes in FL and that a large proportion of these genes were already repressed 
in embryonic stem cells through trimethylation of H3K27 mediated by the 
Polycomb Repressor Complex 2. This suggested a degree of pre-programming 
of methylation changes. To gain a better understanding of the factors driving 
methylation in FL, global methylation profiles were obtained on a subset of FL 
and benign lymph node samples using a recently developed high coverage 
array. The analysis was focused on CpG loci located within CGIs as our initial 
study had confirmed that this was where the vast majority of aberrant 
hypermethylation occurred.  
 
These Infinium experiments demonstrated that aberrant methylation affects 
almost 800 genes in FL and confirmed the link with PRC2 targets in ES cells. 
However, many of those genes targeted by H3K27Me3 in ES cells are also 
marked by the activating histone modification H3K4Me3 – the so-called 
bivalent chromatin domain. These bivalent domains allow genes to be held 
poised in a low transcription state until they undergo lineage-specific 
differentiation and their bivalent state is resolved. Indeed, the hypermethylated 
gene set was significantly enriched for genes marked by bivalent domains in 
embryonic stem cells. While this subset of genes with bivalent domains 
represents just 14% of all genes on the array, they represented 56% of all genes 
hypermethylated in FL. Based on the striking enrichment for genes with 
bivalent domains I next sought to determine whether these loci had distinct 
functions. GO analysis demonstrated that the hypermethylated genes were 
significantly enriched for genes classed as being involved in development. In 
keeping with this, the gene set was also significantly enriched for those genes 
with CpG islands containing a high density of CpGs. These findings confirmed 
that CGI methylation in FL preferentially affects a distinct subset of genes 
linked with development and differentiation in embryonic stem cells.   
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An issue to be considered is whether some of these changes are age-related. In 
2010, two groups used the same Infinium platform to examine for changes in 
methylation with aging, in benign T cells, monocytes (Rakyan, et al 2010) and 
whole blood samples (Teschendorff, et al 2010). Rakyan and colleagues 
suggested that aging-associated DNA hypermethylation occurred preferentially 
at bivalent chromatin domains. They noted that increased methylation occurred 
with aging at PcG target / bivalent genes and suggested that such 
hypermethylation may act as one of the hits required for cancer development in 
the elderly, possibly by ―irreversibly stabilising stem cell features‖. The 
question therefore arises as to how much of the changes we have described are 
aging-related. While our benign and malignant groups differed in their age 
profile in the Infinium study, the GoldenGate study had shown no discernible 
difference in methylation profiles in benign samples from patients aged 4-55 
years. Nor had any correlation between age and extremes of methylation been 
identified in the FL group. Notably, the differences in beta values described in 
these studies with age are far less than the beta value threshold of 0.34 for 
significant differential methylation change in our study. Perhaps, aging 
predisposes to such changes and these become more pronounced with 
malignant transformation.  
 
One of these studies had also noted that similar changes occurred with cell 
culture. In order to establish the validity of using lymphoid cell lines for future 
experiments I analysed a number of lymphoid cell lines and showed that their 
methylation patterns were similar to their primary sample equivalents, at least 
for those CpG loci located within CGIs. Treatment of cell lines with a 
‗demethylating‘ agent was able to significantly increase expression of 
aberrantly methylated genes (4/4) in malignant cell lines supporting a role for 
methylation in control of gene expression. It is worth noting that many studies 
using ‗demethylating‘ agents show re-expression of genes with treatment, yet 
few have gone on to confirm that there is corresponding demethylation of the 
target genes. Indeed, in the clinical setting, such agents are most used in AML / 
MDS which has been shown to have relatively low levels of aberrant 
methylation in AML compared to B cell lymphomas, particularly germinal 
centre lymphomas (Martin-Subero, et al 2009a). It has been suggested that this 
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provides support for ―demethylating‖ agents acting through cytotoxicity rather 
than direct demethylation of target genes – alternatively, if the promise of these 
agents is indeed through a true demethylating mechanism, then germinal centre 
lymphomas such as FL would seem to be ideal candidates given the extent of 
aberrant methylation. 
 
Our studies resonate with emerging data linking DNA methylation and histone 
methylation pathways. To date, histone modification profiling has focussed on 
ES cells. Much less is known about how these modifications affect 
differentiated, mature cells, be they benign or malignant. Having profiled DNA 
methylation in FL, our next step was to examine the other key repressive 
epigenetic modification, H3K27Me3. 
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Chapter 5. EZH2 and H3K27Me3 in FL 
5.1  Introduction 
 
Our methylation profiling studies in FL supported a role for epigenetic 
deregulation of genes targeted by the polycomb repressor complex 2 (PRC2) in 
embryonic stem cells. This complex comprises 3 proteins including the histone 
methylase EZH2 and is responsible for trimethylation of lysine 27 on histone 
H3 (H3K27Me3), a chromatin mark associated with repression of gene 
expression. In addition, EZH2 has also been implicated in direct control of 
DNA methylation (Vire, et al 2006). Despite these intriguing links between 
histone and DNA methylation, the exact mechanistic link explaining the 
finding of preferential DNA methylation of PRC2 target genes has yet to be 
elucidated.  
 
While the EZH2-H3K27Me3 pathway is a current focus of interest in many 
cancers, previous studies have suggested a potential particular significance in 
germinal centre B cell lymphomas. Conditional Ezh2 knockout mice showed 
defective B cell development and rearrangement of the immunoglobulin heavy 
chain gene (Su, et al 2003) while previous immunohistochemical studies in 
humans showed that the expression of PcG proteins differed according to the 
stage of B cell differentiation, suggesting a role for PcG proteins in germinal 
centre development (Raaphorst, et al 2000). 
 
However, to date, the expression pattern of H3K27Me3 has not been studied in 
FL. Indeed, while the target genes of H3K27Me3 have been profiled on a 
genome-wide scale in embryonic stem cells, far less is known about the 
distribution of H3K27Me3 in mature tissues. H3K27Me3 is enriched at certain 
promoters in cancer (McGarvey, et al 2006) yet systematic genome-wide 
analyses of H3K27Me3 occupancy in cancers are lacking.  
 
There was therefore a need to examine H3K27Me3 in mature lymphoid tissue 
to begin to explore the links between DNA and histone methylation in FL 
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biology. While genome-wide ChIP experiments such as those performed in the 
mapping of PRC2 targets in ESCs were beyond the scope of this project, 
immunohistochemical expression of H3K27Me3 was initially assessed in 
tissue microarrays of FL patient samples.  
 
The importance of the EZH2-H3K27Me3 pathway has been emphasized with 
the recent discoveries of mutations affecting pathway genes in a number of 
human cancers (Morin, et al 2010, van Haaften, et al 2009). Indeed, literature 
published during this final stage of my thesis further supported a key role for 
the EZH2-H3K27Me3 pathway in germinal centre lymphomas (Morin, et al 
2010). These developments, which shaped the course of my investigation, are 
outlined throughout this chapter.  
 
5.2  H3K27Me3 and EZH2 expression in benign and 
malignant lymphoid tissue. 
 
5.2.1 Samples and Methods 
 
Immunohistochemistry was performed on tissue microarrays (TMAs) 
constructed from formalin-fixed paraffin-embedded (FFPE) tissue blocks from 
patients with FL who had undergone transformation to DLBCL. Expression of 
H3K27Me3 and its histone methyltransferase EZH2 were tested in a total of 43 
FL patients. Antibodies and their working dilutions and reaction conditions are 
listed in Table 5-1. Cores were regarded as assessable if at least two replicate 
cores were present and scorable. Sections of benign human tonsil were 
examined as tissue cores on TMAs and as whole sections. To ensure that the 
differential staining between arrays and cores was not due to any artefact of 
processing or fixation, individual samples were represented by triplicate cores, 
staining was duplicated and previous staining performed on these arrays for 
well-established B cell lymphoma markers (CD20, CD10) was reviewed to 
ensure uniform staining across cores. H3K27Me3 scoring was divided into 
three categories: weak, intermediate and strong, based on a combination of 
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intensity of staining and percentage of positive cells. Staining intensity was 
graded as low (weak or no staining), moderate or high (strong intensity 
staining). An overall weak score applied to all cases showing low intensity 
staining with less than 10% of centroblasts positive. An overall strong score 
applied to all cases showing high intensity staining in >30% of centroblasts. 
An overall intermediate score applied to all cases showing intermediate 
patterns of staining insufficient for categorisation as weak or strong. Scoring 
was performed by 2 pathologists independently, myself and Dr. Maria 
Calaminici, Consultant Histopathologist at the Royal London Hospital. In cases 
of discordance, a consensus score was obtained by reviewing slides together at 
a double-headed microscope.  
 
5.2.2 H3K27Me3 expression in benign lymphoid tissue 
 
H3K27Me3 expression showed a distinctive pattern in the normal lymphoid 
structures of human tonsillar tissue (Figure 5-1). Expression was strongest in 
the cells of the mantle zone surrounding the germinal centre. Within the 
germinal centre the centroblasts of the dark zone were predominantly negative 
while some cells within the light zone were positive. These included a number 
of centroblasts, with weaker expression in occasional large centrocytes. 
 
5.2.3 H3K27me3 expression in FL 
 
H3K27me3 staining showed marked variability across all samples studied. In 
total, 28 patients had assessable cores.  Of these, 25 had a pre-transformation 
sample available with 9 corresponding post-transformation samples while 3 
patients had post-transformation samples only.  Of the 25 pre-t-FL samples 
studied, 13 showed weak expression, 5 showed intermediate expression and 7 
showed strong expression (Figure 5-2; Table 5-2). Post-transformation biopsy 
samples were available on 9 of the 25 FL samples (2 weak, 3 intermediate, 4 
strong expression). Post-transformation sample scores reflected pre-
transformation scores for all but one case, which showed intermediate 
expression in the pre-t-FL case and strong expression post-transformation. 
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Antibody Company 
 
Concentration Incubation 
Duration  
Incubation 
Temperature 
EZH2 Invitrogen 1:200 1 hour 24C 
H3K27Me3 Abcam 1:60 16 hours 4C 
 
Table 5-1 Immunohistochemistry details 
Details of primary antibodies and experimental conditions used in examination 
of TMAs. 
 
 Weak (n=) Intermediate 
(n=) 
Strong (n=) 
pre-t-FL cases (n=25) 13 (52%) 5 (20%) 7 (28%) 
t-FL cases (n=9) 2 (22%) 3 (33%) 4 (44%) 
    
EZH2 mutated cases 
(n=6) 
2 (33%) 2 (33%) 2 (33%) 
EZH2 wildtype cases 
(n=7) 
5 (71%) 2 (29%) 0 (0%) 
 
Table 5-2 H3K27Me3 expression 
Summary of H3K27Me3 expression pattern in pre-t-FL and t-FL cases and in 
those cases with and without a mutation in EZH2.  
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Figure 5-1 H3K27Me3 expression in tonsil 
 
A: Low power (x50) image of reactive germinal centre in human tonsil. 
Expression of H3K27Me3 is predominantly confined to the mantle zone and 
the light zone. 
B: Higher power (x400) of dark zone (DZ) area highlighted in part A showing 
occasional cells staining positive for H3K27Me3. 
C: Higher power (x400) of light zone (LZ) area highlighted in part A with the 
surrounding mantle zone to the right of the image. There is strong staining for 
H3K27Me3 in the majority of light zone cells with strong staining in almost all 
mantle zone cells. 
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Figure 5-2 H3K27Me3 expression in FL  
 
A, B: Low (x50) and high (x400) power images of FL core showing weak 
H3K27Me3 expression 
C, D: Low (x50) and high (x400) power images of FL core showing 
intermediate H3K27Me3 expression 
E, F: Low (x50) and high (x400) power images of FL core showing strong 
H3K27Me3 expression 
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5.2.4 EZH2 expression in benign lymphoid tissue and FL 
 
 
We next considered whether expression of EZH2 affected H3K27Me3 
expression. In the previous studies of Raaphorst and colleagues (Raaphorst, et 
al 2000), EZH2 expression in normal lymphoid tissue was mainly restricted to 
the dark zone centroblasts with few cells within the light zone and mantle zone 
staining positive. My own studies of tonsillar tissue showed EZH2 expression 
in most cell types with strongest expression in germinal centre centroblasts 
(Figure 5-3).  
 
Similarly, EZH2 expression was previously reported as confined to 
centroblasts in FL. In my own studies of FL, EZH2 expression was strongest in 
centroblasts with strong expression in the majority of cases: strong EZH2 
expression (strong positive staining in >60% of cells) was identified in 21 of 
24 FL cases (Figure 5-4) with low expression (weak or negative staining in 
<40% cells) in 3 cases. Of these 24 cases, 8 had post-transformation biopsies 
available – all showed similar expression to the pre-transformation biopsies.  
 
Notably, this expression pattern of EZH2 contrasted with the expression of its 
product H3K27Me3 in benign tissue (Section 5.2), with H3K27Me3 expressed 
predominantly in mantle zone cells and the cells of the germinal centre light 
zone while dark zone centroblasts were predominantly negative.  
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Figure 5-3 EZH2 expression in human tonsil  
 
A: Medium power (x200) image of reactive germinal centre in human tonsil. 
Expression of EZH2 is present in the vast majority of cells. 
 
B: Higher power (x400) image showing stronger staining within large 
centroblasts. 
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Figure 5-4 EZH2 expression in FL 
 
A: Medium power (x100) image of FL showing weak EZH2 expression. 
B: Higher power (x200) image of FL showing weak EZH2 expression. 
C: Medium power (x100) image of FL showing strong EZH2 expression. 
D: Higher power (x200) image of FL showing strong EZH2 expression. 
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5.3 EZH2 mutation detection in pre- and post-
transformation Follicular Lymphoma 
 
5.3.1 EZH2 mutations in germinal centre lymphoma 
 
The immunohistochemical studies showed that EZH2 protein is strongly 
expressed in the vast majority of FL cases and that differential EZH2 
expression is not an apparent cause for the differential staining of its product, 
H3K27Me3. However, immunohistochemistry is a relatively crude tool for 
identifying protein expression and subtle differences in expression of various 
proteins may not be identified by this method. Intriguingly, a potential further 
cause for differences in H3K27Me3 expression emerged recently with the 
finding of frequent mutation of EZH2 in GC B cell lymphoma (Morin, et al 
2010). These mutations affected a single codon of EZH2 that encodes a 
tyrosine (Y) and is associated with the catalytic SET domain. Mutations of this 
Y641 codon were identified in 16/225 (7.1%) of pre-treatment FL samples, 
6/52 (11.5%) of transformed-FL and 18/80 (22%) GCB-type de novo DLBCL. 
These mutations appeared to be specific to lymphomas of the GC B cell type as 
no mutations were found in 42 DLBCL of the ABC subtype, 25 mantle cell 
lymphomas, 30 small lymphocytic lymphomas, 25 T cell lymphomas or 23 
reactive tonsils.  The mutations described exerted an apparent functional effect 
as introducing each of the four Y641 mutations into wild-type EZH2 resulted 
in an on average 7-fold reduction in the ability to trimethylate lysine 27 on H3 
peptides in-vitro.  
 
To assess whether mutations affecting EZH2 function may account for 
differences in H3K27Me3 expression, I tested DNA from 40 samples 
corresponding to 20 pairs of pre- and post-transformation FL for the presence 
of mutations in the Y641 codon of EZH2. Direct DNA sequencing was 
performed according to the general protocol in Chapter 2.14 using primers 
flanking the coding region of exon 16 that contains the Y641 codon (Appendix 
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E). To exclude the possibility that the observed sequencing variation might 
represent rare polymorphic variants, germline DNA was also tested from 
unaffected haematopoietic tissue where available. 
 
5.3.2 EZH2 mutations are frequent in both pre- and post-transformation 
FL samples.  
 
Mutations within the Y641 codon were detected in 7 of the 20 (35%) patients 
analysed (Figure 5-5, Table 5-3). All mutations were apparent heterozygous 
mutations. The mutant peak typically had reduced intensity as compared with 
wildtype, most likely a reflection of the occurrence of non-tumour tissue 
present in the sample. Four different point mutations were identified in the 7 
patients with point mutations leading to predicted conversion of Tyrosine (Y) 
to Asparagine (N), Histidine (H), Phenylalanine (F) or Serine (S). In 5 of the 7 
patients, the mutation was detected in both the pre-transformation and the t-FL 
sample (patients 1, 5, 12, 15 and 19). In a single case, the pre-t-FL sample was 
wildtype with the mutation present only in the t-FL sample (patient 17). Of 
note, the remaining affected patient (patient 7) had a mutation present at 
diagnosis of FL but subsequently reverted to wildtype in the transformation 
sample. This may provide further support for some cases of transformed FL 
arising from a common progenitor cell rather than being a result of stepwise 
acquisition of further genetic changes (Carlotti, et al 2009). Unaffected 
haematopoietic tissue was available for 4 of the 7 affected patients and 
demonstrated a wild-type sequence, supporting a somatic origin for these 
mutations. 
 
In addition, a frequent SNP (rs2072407) involving the cytosine base within a 
CpG site 21 bases 5‘ to exon 16 and 105 bases 5‘ from the Y641 codon was 
detected. Of the 20 pairs studied, a single C peak was identified at this position 
in 10 pairs. A heterozygous variant, identified by the presence of C and T 
peaks, was present in 7 pairs while a homozygous SNP (T/T) was identified in 
the remaining 3 pairs (Figure 5-6). As expected, pre-and post-transformation 
SNP status was concordant in all pairs.  
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Figure 5-5 Mutations of EZH2 identified in paired FL biopsies.  
(a) Wildtype EZH2 sequence TAC at codon 641 encoding Tyrosine (Y)  
(b) Y641N: TA leads to predicted conversion to Asparagine (N)  
(c) Y641H: TC leads to predicted conversion to Histidine (H) 
(d) Y641F: AT leads to predicted conversion to Phenylalanine (F)  
(e) Y641S: AC leads to predicted conversion to Serine (S). 
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Patient ID Pre-t-FL t-FL Germline 
1 Y641F Y641F N/A 
5 Y641F Y641F N/A 
7 Y641S wt wt 
12 Y641H Y641H N/A 
15 Y641F Y641F wt 
17 wt Y641N wt 
19 Y641F Y641F wt 
  
Table 5-3 EZH2 mutations in pre- and post-transformation FL.  
 
Details of EZH2 mutations identified in 7 patients from a series of 20 pairs of 
pre- and post-transformation biopsies. Wild type (wt) sequence at codon 641 is 
TAC encoding Tyrosine (Y). N/A = not available. Predicted amino acids 
encoded by mutated codon: F=Phenylalanine, H=Histidine, N=Asparagine, 
S=Serine. 
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Figure 5-6 Frequent SNP within the EZH2 gene. 
 
This SNP involves replacement of the Cytosine base with Thymine (C/T 
Polymorphism) of a CpG locus within the intron 5‘ to codon 16.  
(a) homozygous for the likely major allele Cytosine (in 10/20 pairs)  
(b) heterozygous C/T SNP (present in 7/20 pairs)  
(c) homozygous for Thymine (present in 3/20 pairs). 
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5.3.3 Comparison of EZH2 mutation status with H3K27Me3 expression 
in FL 
 
Of the patients analysed for EZH2 mutation, 13 were included on the TMA 
examined for EZH2 and H3K27Me3 expression. Six of these 13 cases 
contained an EZH2 mutation and these showed a range of H3K27Me3 
expression (weak n=2; intermediate n=2; strong n=2). The 7 wild-type cases 
showed weak expression in 5 cases and intermediate expression in 2 cases 
(Table 5-2). 
 
While all 7 wild-type cases showed strong immunohistochemical expression of 
EZH2, strong expression was identified in 4 of the 6 mutated cases with low 
expression in the remaining two cases. While EZH2 mutation is a potential 
cause for variation in H3K27Me3 expression, it is clear that this relationship 
needs to be assessed in a larger sample set. It is worth noting that the single 
probe examining EZH2 on the Infinium array showed very low methylation 
values for EZH2 in both the benign lymph node and FL groups (0.06 and 0.03 
beta value respectively), suggesting that methylation of EZH2 does not account 
for differences in H3K27Me3 expression. 
 
5.3.4 Comparison of EZH2 mutation status with global methylation 
values in FL  
 
As EZH2 has previously been implicated in direct control of DNA methylation 
(Vire, et al 2006), we next considered whether EZH2 mutation status had any 
effect on DNA methylation profiles. Mutation status was compared with 
methylation values in the 10 pairs of pre- and post-transformation FL samples. 
Mutations were present in 5 of the 10 pairs. Given the distinct patterns of 
methylation at CpG sites within and outside of CGIs, these groups were 
analysed separately. Average methylation beta values differed by 0.02 between 
wildtype and mutated EZH2 cases (Table 5-4). Within CGIs, the mutated 
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EZH2 group showed higher beta values than the wildtype group while for CpG 
loci outside of CGIs lower beta values were observed in the mutated EZH2 
group than the wildtype group.  
 
Given the relatively low numbers of pairs of transformation samples available 
for analysis, it was of interest to assess whether EZH2 mutation status had any 
effect on the larger series of 164 untreated FL samples analysed by the 
GoldenGate array (Chapter 3). The Vancouver group involved in the initial 
EZH2 mutation study (Morin, et al 2010) provided EZH2 mutation status for 
163 of these samples. Twenty-three patients (14%) harboured a mutation in 
Y641. In order to test for any global differences in methylation between the 
mutant group (n=23) and the wildtype group (n=140), the average methylation 
values of all CpG loci were calculated and compared. The results showed a 
similar pattern to the FL-tFL series with a difference of 0.02 in the average 
beta value of CpG loci between the wildtype and mutated groups (Table 5-4).  
 
Distribution of EZH2 mutated cases relative to methylation values is shown in 
the heat map (Figure 5-7). Comparison of high and low change groups showed 
that EZH2 mutated cases were significantly overrepresented (p=0.042) within 
the high change group relative to the low change group. No significant 
difference was identified in the distribution of EZH2 mutated cases between 
either group in comparison to the entire FL sample set (Table 5-5). The 
significance of this observation is as yet unclear. As with the 
overrepresentation of abnormal SNP profiles within the high change group 
(Chapter 3), it may represent a group of samples with extensive epigenetic and 
genetic changes, a detection threshold issue related to tumour burden or a true 
effect of EZH2 mutation on methylation values.  
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 Average Beta Value 
within CpG Island 
Average Beta Value  
outside CpG Island 
 Wildtype  Mutated  Wildtype Mutated 
Paired pre-t-FL 
and t-FL samples 
(n=20) 
0.34 (n=11) 0.36 (n=9) 0.51 (n=11) 0.49 (n=9) 
u-FL samples 
(n=163) 
0.33 
(n=140) 
0.35 
(n=23) 
0.61 (n= 
140) 
 0.59 (n=23) 
 
Table 5-4 Effect of EZH2 mutation on DNA methylation values 
Average methylation (Beta) values in EZH2 wildtype and mutated cases in 
transformation pairs and untreated FL samples. 
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Figure 5-7 Distribution of EZH2 mutations in u-FL samples 
 
Unsupervised hierarchical clustering of untreated FL showing distribution of 
EZH2 wildtype and mutated cases. Heat map is as per Figure 3-8. The upper 
horizontal colour bar indicates sample type (as per legend key). The lower 
horizontal colour bar indicates EZH2 wildtype (purple) and mutated (grey) 
cases. Samples within the low change group are indicated by the green 
coloured dendrogram bars while the red coloured dendrogram bars indicate 
samples within the high change group. 
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Table 5-5 EZH2 mutation in u-FL samples 
 
Contingency tables (2x2) showing the significance (as determined by two-
sided Fisher‘s exact test) of distribution of cases with EZH2 mutation across all 
samples and in low and high change groups. 
 Wildtype EZH2 Mutated EZH2 
Low ∆ß group 33 1 
High ∆ß group 23 6 
P value = 0.042  
 Wildtype EZH2 Mutated EZH2 
Low ∆ß group 33 1 
All samples 140 23 
P value = 0.086  
 Wildtype EZH2 Mutated EZH2 
High ∆ß group  23 6 
All samples 140 23 
P value = 0.4  
Chapter 5 
 219 
 
5.4  Discussion 
 
DNA methylation and histone methylation have increasingly been linked in 
recent years. A 2006 study suggested that EZH2 has a direct effect on DNMT 
recruitment and consequent hypermethylation (Vire, et al 2006). Meanwhile, 
our study of DNA methylation in FL (O'Riain, et al 2009) was one of a number 
of recent studies to show extensive overlap between aberrantly 
hypermethylated genes in cancer and those genes targeted for repression at the 
stem cell stage by H3K27Me3 (Ohm, et al 2007, Schlesinger, et al 2007, 
Widschwendter, et al 2007).  
 
Other recent findings have reinforced the potential importance of deregulation 
of trimethylated H3K27Me3 in cancer and in haematological malignancies in 
particular, with the identification of mutations of the histone methylase EZH2 
in germinal centre lymphomas. Even before these recent findings, earlier 
studies had hinted at a potentially important role for the EZH2-H3K27Me3 
pathway in B cell development and malignancy. Mice studies had shown 
defective B cell development upon knockout of Ezh2 (Su, et al 2003) while 
immunohistochemical studies had shown specific expression patterns of 
Polycomb proteins, including EZH2, in human B cell lymphomas (Raaphorst, 
et al 2000). Despite these findings, no attempt has yet been made to examine 
the pattern of H3K27Me3 expression in normal B cells and B cell lymphomas. 
 
In the final experiments, I examined our series of paired FL and t-FL cases for 
H3K27Me3 expression and expression of its histone methylase EZH2. The 
mutation status of EZH2 in FL was evaluated and correlated with 
immunohistochemical EZH2 expression and DNA methylation values.  
 
Our studies in normal tonsil showed that H3K27Me3 expression varies 
according to the stage of differentiation of B cells with highest expression 
within the mantle zone and the light zone of the germinal centre. Somewhat to 
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our surprise, a wide variation in H3K27Me3 expression across FL samples was 
identified. We examined for a potential cause of this differential expression. 
Despite confirmation of frequent mutation of EZH2 in FL, EZH2 remains 
strongly expressed in the vast majority of FL cases. Further studies are 
required to draw conclusions on the links between EZH2 mutation status, 
EZH2 protein expression and H3K27Me3 expression. It will also be of interest 
to examine the link between H3K27Me3 expression and clinical outcome as a 
previous study had suggested that loss of H3K27Me3 was associated with 
worse outcome in breast, ovarian and pancreatic cancer (Wei, et al 2008). 
 
As well as examining larger patient series, such studies will have to take into 
account myriad other factors that have recently been shown to have the 
potential to deregulate the EZH2-H3K27Me3 pathway. For example, cells with 
high levels of phosphorylated Akt have been found to have lower levels of 
H3K27Me3 (Cha, et al 2005) while a role for microRNAs has also been 
suggested with miR-101 and miR-26a being implicated in the repression of 
EZH2 (Friedman, et al 2009, Sander, et al 2008, Varambally, et al 2008). In 
the latter case, there are intriguing links with a key lymphoma-related 
oncogene, MYC, which has been reported to stimulate EZH2 expression 
through repression of miR-26a (Sander, et al 2008). Along with alterations 
directly affecting the histone methylase EZH2, changes in histone 
demethylases may also be important. Frequent mutation of UTX, which 
demethylates H3K27Me3, has recently been reported in a number of human 
cancers including the haematological malignancy multiple myeloma (van 
Haaften, et al 2009). Even our finding of a frequent C/T SNP within an 
intronic CpG site adjacent to the site of EZH2 mutation is intriguing in light of 
recent research showing that allele-specific methylation may be affected by the 
presence of an adjacent SNP within a CpG locus (Shoemaker, et al 2010). 
Subsequent studies within our group following on from my work have begun 
to examine these potential mechanisms of alteration of the EZH2-H3K27Me3 
pathway.  
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Chapter 6. Discussion 
 
Changes in cell behaviour and the development of a malignant phenotype are 
derived from changes in individual gene expression. In FL, the critical change 
in gene expression is the overexpression of BCL2 due to a t(14;18) 
translocation, which occurs in the majority of FL cases (Horsman, et al 1995, 
Rowley 1988). Yet this change alone is insufficient to cause lymphoma and 
despite extensive genetic studies, the other changes required to drive 
lymphomagenesis remain undiscovered. To date, any secondary genetic 
changes have been identified in only small subsets of patients while the exact 
impact of the tumour microenvironment on gene expression is still unclear. 
Studies of the epigenetic effects on gene expression in FL have thus far lagged 
further behind genetic studies and have been predominantly confined to studies 
of individual genes in small patient series. 
 
We set out to gain the first global view of DNA methylation and its effect on 
gene expression in FL. Our initial study of 164 FL patients using the 1505 CpG 
GoldenGate platform confirmed that frequent aberrant hypermethylation and 
hypomethylation occurred in FL. For a subset of CpG loci, DNA methylation 
values differed substantially across the patient cohort. Our studies suggested 
that this difference was not due to any significant influence of age or stage, nor 
did these groups differ in clinical outcome. Instead, correlation with previous 
genetic profiles and studies of purified cell populations suggested that this 
heterogeneity was predominantly due to the percentage tumour content in the 
samples. The issue of sample purity is often overlooked in epigenetic studies 
and represents an important consideration in future studies delineating 
epigenetic changes, such as the Human Epigenome Project (Anonymous 2008). 
 
Nevertheless, methylation profiles were a powerful discriminator between 
benign and malignant lymphoid tissue, predominantly due to widespread gains 
of methylation in FL at CpG islands and loss of methylation outside of CpG 
islands. This discriminative ability was validated in a separate series of St. 
Barts Hospital patients who had undergone transformation to DLBCL. This 
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key event has been a focus of study in an attempt to identify those factors that 
lead to disease progression. Our studies suggested that methylation was largely 
unchanged during the transformation process. 
 
While methylation has conventionally been viewed as a potential required ‗hit‘ 
in silencing TSGs (Herman 1999), the very frequency of hypermethylation in 
FL suggests that not all hypermethylation events result in individual silencing 
of critical TSGs. Studies from other groups have shown that hypermethylated 
genes in lymphoma are often expressed at low levels in normal tissue (Pike, et 
al 2008, Wang, et al 2010). In our own study, methylation values showed a 
relatively low inverse correlation with gene expression. This suggests that the 
aberrant methylation of many genes in cancer may represent a bystander effect 
rather than a mechanism of providing selective growth advantage to the cancer 
cell. However, it seems plausible that a small number of genes undergo true 
TSG silencing by methylation and play a role in tumour development and 
progression. Distinguishing these critical events from bystander effects 
represents one of the major challenges for epigenetic research (Kalari and 
Pfeifer 2010). 
 
The theory that widespread methylation may be largely brought about by an 
―instructive‖ mechanism (Keshet, et al 2006) is supported by data published 
during the course of my thesis, which have shown intriguing links between 
DNA methylation and another key mechanism implicated in gene repression, 
the trimethylation of H3K27 by the histone methyltransferase EZH2. A 2006 
study had suggested that EZH2, as part of the PRC2, may directly control DNA 
methylation through recruitment of DNMTs (Vire, et al 2006). The following 
year, a number of studies showed that DNA hypermethylation in carcinomas 
preferentially targeted genes that are marked by the repressive H3K27Me3 
mark at the ESC stage (Ohm, et al 2007, Schlesinger, et al 2007, 
Widschwendter, et al 2007). Our studies confirmed overrepresentation of ESC 
PRC2 targets among hypermethylated genes in FL, while other groups showed 
similar findings using the same GoldenGate platform in the GC lymphomas, 
DLBCL and Burkitt lymphoma (Martin-Subero, et al 2009b). While such 
findings have been put forward as evidence for a stem cell origin of cancer, no 
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mechanistic link to explain this coincidence of findings has been established as 
yet. Martin-Subero and colleagues, in discussing their findings in GC 
lymphoma (Martin-Subero, et al 2009b) proposed a number of models of 
lymphomagenesis to account for this finding (Figure 6-1). 
 
Following on from the finding of preferential targeting of PRC2 target genes 
for DNA methylation, we attempted to establish what other factors may lead to 
certain genes being ―methylation prone‖ while others are ―methylation 
resistant‖. We used the latest methylation profiling technology to examine a 
subset of patients using a 14,000 gene platform. The results confirmed, on a 
genome wide scale, the broad findings of our initial study and allowed us to 
characterise some of the features of the almost 800 genes found to be 
aberrantly methylated in FL. Methylation preferentially affected not only genes 
marked by the repressive H3K27Me3 mark in ES cells but also genes marked 
by both H3K27Me3 and the activating H3K4Me3 mark. Indeed, the majority 
of H3K27Me3 marked genes in ESCs are also marked by H3K4Me3, a state 
referred to as ―bivalent chromatin‖. Such genes have the potential to be 
activated or repressed in ES cells through manipulation of their chromatin 
state, allowing differentiation into various mature cell lineages (Bernstein, et al 
2006). These key differentiation-related genes with bivalent chromatin have 
recently been suggested to undergo aging-related methylation as an early stage 
in carcinogenesis (Rakyan, et al 2010). Our analysis of Gene Ontology terms 
assigned to the studied genes confirmed that DNA methylation preferentially 
affected key development and differentiation genes.  
 
We now know that aberrant DNA methylation affects almost 800 genes in FL 
and that many of these genes have common characteristics that make them 
prone to methylation. Aberrant methylation typically occurs at high-density 
CpG promoters of genes with an established role in differentiation and 
development whose expression is controlled at the ESC stage by regulation of 
its bivalent chromatin structure.   
 
The focus of epigenetic studies is now shifting to identify the mechanistic links 
between the DNA methylation and histone methylation pathways. While much 
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is known about the distribution of H3K27Me3 in ESCs there is a gap in our 
knowledge of the profile of H3K27Me3 distribution in benign and malignant 
mature tissue. Genome-wide profiles such as that performed in ESCs (Lee, et 
al 2006b) are distinctly lacking in mature tissue.  
 
As a first step in examining the EZH2-H3K27Me3 pathway in B cell 
lymphoma, we performed immunohistochemical analysis of benign and 
malignant lymphoid tissue. Studies in tonsil showed distinctly different levels 
of H3K27Me3 expression at various stages of B cell differentiation. This is in 
keeping with previous studies that suggested a role for the EZH2-H3K27Me3 
pathway in GC lymphoma, including mouse studies that demonstrated 
involvement of the pathway in immunoglobulin gene rearrangement, a key 
process in normal B cell development (Su, et al 2003). Previous 
immunohistochemical studies had also shown distinct expression of various 
polycomb proteins in different B cell lymphoma subtypes (Raaphorst, et al 
2000).  Our study is the first to specifically examine H3K27Me3 expression in 
lymphoma and showed a wide heterogeneity in H3K27Me3 expression with 
28% showing strong expression with just over half of cases showing weak 
expression. 
 
Thus, in addition to identifying aberrant methylation of hundreds of genes in 
FL, my study also suggests disordered regulation of another key epigenetic 
mechanism, trimethylated H3K27. Intriguingly, these changes occur in the 
context of frequent mutation of the coding region of EZH2, the gene that 
catalyses the formation of this mark. We confirmed the finding of frequent 
EZH2 mutation in FL. To date, the sample cohort is too small to attempt to 
draw definitive conclusions between EZH2 expression, EZH2 mutation, 
H3K27Me3 expression and DNA methylation. However, the data provides the 
basis for expansion of the studies to larger sample sets. Furthermore, other 
potential causes of dysregulation of this pathway are being considered, such as 
the potential role of phosphorylated AKT and microRNAs. 
 
These future studies will depend, at least in part, on cell lines which mirror the 
epigenetic profile of their benign and malignant primary human tissue 
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counterparts. My studies suggest that the methylation profiles of cell lines and 
primary samples are similar for those CpG sites located within CpG islands. 
However, for CpG sites outside of CGIs, methylation profiles differed 
significantly between cell lines and primary samples, suggesting that caution 
should be exercised in drawing conclusions in epigenetic studies restricted to 
cell lines. 
 
In Chapter 1, I outlined the various stages of B cell development and some of 
the features of their corresponding malignant lymphoma counterparts. It is 
worth reflecting on how recently acquired knowledge of the two key epigenetic 
pathways, DNA methylation and H3K27 trimethylation, fits into this picture 
(Figure 6-2). We know that aberrant DNA methylation is highest in ALL and 
FL/DLBCL (Martin-Subero, et al 2009a, Rahmatpanah, et al 2006, Taylor, et 
al 2007), cancers which occur at stages of normal B cell development 
involving immunoglobulin gene rearrangement, in the bone marrow and 
germinal centre respectively. Some authors have speculated that the 
overexpression of repair-associated DNMTs at these stages may account for 
this increased methylation (Taylor, et al 2007). We also know that EZH2 
expression is highest at these two stages of normal B cell development 
(Hystad, et al 2007, van Kemenade, et al 2001). As EZH2 has been implicated 
in direct control of methylation, these findings have led to the suggestion that 
early cancer cells frozen at these development stages may undergo EZH2-
directed DNA methylation (Martin-Subero, et al 2009a). As well as a potential 
role in DNA methylation, EZH2 may also be involved in H3K27Me3-mediated 
control of B cell development as Ig gene rearrangements and B cell 
development have been shown to be impaired in Ezh2 knockout mice. It is of 
interest that frequent EZH2 mutations have been described in germinal centre 
lymphomas but have not been identified in a range of lymphoma samples 
corresponding to other stages of B cell differentiation. Notably, no study has 
examined for EZH2 mutations in ALL. It is clear that aberrations of the DNA 
methylation and EZH2-H3K27Me3 pathways occur at specific stages of the 
development of normal and malignant B cells.  
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Teasing out the various links between these two key pathways and their exact 
role in B cell lymphoma represents a major challenge for future research. It is 
encouraging that recent research has shown promise in further exploring some 
of the areas of interest outlined in this thesis. Given the links between DNA 
methylation and development related genes in ESCs, it is of interest that 
Gentles and colleagues noted that transformation of FL was associated with a 
gene expression signature related to pluripotency genes in ESCs (Gentles, et al 
2009). The first steps have also been taken in examining PRC2 targets in B 
cells with the identification of approximately 1800 gene promoters bound by 
EZH2 in germinal centre (GC) B cells (Velichutina, et al 2010). While many of 
these targets overlapped with those in ESCs, a group of EZH2/H3K27me3-
mediated repressed tumour suppressor genes specific to GC B cells was also 
identified.  
 
While much is still to be discovered about DNA and histone methylation, the 
promise of translating research in this area from bench to bedside is 
considerable. Unlike genetic changes, which are rarely modifiable, epigenetic 
changes may be reversible. Demethylating agents have demonstrated their 
promise in haematological malignancy and are indeed currently being trialled 
in FL. Notably, recent studies have used histone-modifying agents such as 
DZNep, which is reported to reverse the H3K27Me3 mark (Miranda, et al 
2009, Tan, et al 2007).  It is clear, however, that the effect of such drugs will 
need to be tested carefully as our studies have shown that hundreds of genes 
are hypermethylated in FL and the effect of demethylation of such a large 
number of genes cannot be predicted. Likewise, the complex interactions 
between DNA methylation and H3K27 methylation mean that reversal of the 
H3K27Me3 mark may have unforeseen consequences, particularly for B cells. 
 
Undoubtedly, the coming years will be an exciting time in epigenetics cancer 
research, as the role of DNA and histone methylation becomes clearer. In 
addition, the effect of these changes on patient prognosis and the potential for 
therapeutic modification of such changes is likely to be a major focus of study. 
Given the extent of aberrant DNA methylation and the frequent dysregulation 
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of the EZH2-H3K27Me3 pathway identified in germinal centre lymphomas, 
study of FL should be particularly rewarding. 
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Figure 6-1 DNA Methylation and lymphomagenesis 
 
Proposed models of lymphomagenesis incorporating recently acquired data on 
methylation in GC lymphoma. Martin-Subero and colleagues proposed the 
following models to account for the high levels of aberrant DNA methylation 
in germinal centre lymphomas of ESC PcG target genes (Martin-Subero, et al 
2009b). Part A demonstrates the commonly accepted model of 
lymphomagenesis where secondary genetic and epigenetic events follow an 
initial immortalising chromosomal aberration. Part B suggests an initial 
epigenetic event with aberrant methylation of PcG target genes in stem or 
progenitor cells followed by additional genetic and epigenetic changes. Part C 
suggests an initial genetic hit followed by repression of key development genes 
by PcG with subsequent aberrant methylation of these PcG target genes. 
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Figure 6-2 B Cell differentiation, lymphomagenesis and epigenetics 
 
Outline of comparison of B cell lymphoma subtypes with their corresponding 
differentiation stage. The figure is modified from that shown in the 
introductory chapter (Figure 1-1) to include our current knowledge regarding 
EZH2 and H3K27Me3 expression in benign B cells and DNA methylation and 
EZH2 mutation status in malignant B cell lymphoma subtypes. 
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Appendix 
 
Appendix A - Illumina GoldenGate Methylation Cancer Panel 1 
 
Additional material related to experiments using Illumina GoldenGate 
Methylation Cancer Panel 1 : 
 
- GoldenGate operating protocol 
- List of CpG loci excluded from analysis 
- List of hypermethylated CpG loci 
- List of hypomethylated CpG loci 
- List of genes showing significant inverse correlation between methylation 
and gene expression 
 
GoldenGate operating protocol 
 
Make BCS plate 
- Transfer 12µl of bisulphite-converted DNA to a 96-well 0.2ml skirted 
microplate (BCD plate). 
- Pulse centrifuge BCD plate to 250 xg. 
- Add 5µl MS1 reagent to each well of another 96-well 0.2ml skirted 
microplate (BCS plate). 
- Add 5µl of bisulphite-converted DNA to each well of the BCS plate 
- Heat seal the BCS plate with a microplate foil heat seal and pulse 
centrifuge to 250 xg. 
- Vortex BCS plate at 2300 rpm for 20 seconds then pulse centrifuge to 
250xg. 
- Incubate BCS plate at 95ºC for 30 minutes in a preheated heat block. 
- Pulse centrifuge the plate to 250 xg. 
 
Precipitate BCS plate 
- Add 5µl PS1 reagent to each well of the BCS plate. 
- Seal BCS plate and pulse centrifuge to 250 xg. 
- Vortex at 2300 rpm for 20 seconds or until the solution is uniformly 
blue. 
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- Centrifuge the sealed BCS plate to 3000 xg for 20 minutes to 
precipitate DNA (a blue pellet should be visible at the bottom of each 
well). 
- Remove plate seal and decant supernatant by inverting BCS plate and 
tapping plate firmly onto an absorbent pad. 
- Centrifuge the inverted BCS plate with pad to 8 xg for 1 minute. 
- Set plate upright and allow it to dry at room temperature for 15 minutes 
 
Resuspend BCS plate 
- Add 10µl RS1 reagent to each well of the BCS plate 
- Seal BCS plate and pulse centrifuge to 250 xg. 
- Vortex at 2300 rpm for 1 minute or until the blue pellet is completely 
dissolved to complete sample activation. 
 
Make Allele-specific extension (ASE) plate 
- Pulse centrifuge BCS plate to 250xg. 
- Add 10µl OMA reagent to each well of a new 96-well 0.2ml skirted 
microplate (ASE plate). 
- Add 30µl OB1 reagent to each well of the ASE plate. 
- Transfer 10µl of sample from each well of the BCS plate to the 
corresponding well of the ASE plate. 
- Heat seal the ASE plate and pulse centrifuge to 250 xg. 
- Vortex the ASE plate at 1600 rpm for 1 minute or until all beads are 
completely resuspended. 
- Place the sealed ASE plate on the 70ºC heat block and close heat block 
cover. 
- Immediately reset temperature to 30ºC. 
- Allow the ASE plate to cool to 30ºC. 
 
Add Master Mix for Extension & Ligation 
- Centrifuge the ASE plate to 250 xg. 
- Place the ASE plate on a raised-bar magnetic plate for approximately 2 
minutes or until the beads are completely captured. 
- Remove and discard all the liquid from the wells. 
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- Add 50µl AM1 reagent to each well of the ASE plate. 
- Seal ASE plate and vortex at 1600 rpm for 20 seconds or until all beads 
are resuspended. 
- Place the ASE plate on a raised-bar magnetic plate for approximately 2 
minutes or until the beads are completely captured. 
- Remove all AM1 reagent from each well, leaving the beads in the 
wells. 
- Repeat this process of adding and removing AM1 once. 
- Remove ASE plate from magnetic plate. 
- Add 50µl UB1 reagent to each well of the ASE plate and place the ASE 
plate on a raised-bar magnetic plate for approximately 2 minutes or 
until the beads are completely captured.  
- Remove all UB1 reagent from each well, leaving the beads in the wells. 
- Repeat this process of adding and removing UB1 once. 
- Add 37µl MEL to each well of the ASE plate, seal and vortex at 1725 
rpm for 1 minute or until the beads are resuspended. 
- Incubate ASE plate on a preheated 45ºC heat block for 15 minutes. 
 
Make PCR plate 
- Add 64µl Titanium Taq DNA Polymerase (Catalogue Number 639220, 
Clontech, Mountain View, CA, U.S.A) to the Master Mix (MMP 
reagent). 
- Add 50µl Uracil DNA glycosylase to the MMP tube and invert several 
times to mix the contents. 
- Add 30µl of mixture into each well of a new 96-well 0.2ml skirted 
microplate (PCR plate). 
- Seal plate and pulse centrifuge to 250 xg. 
 
Inoculate the PCR plate  
- Place the ASE plate on the raised bar magnetic plate for approximately 
2 minutes or until the beads are completely captured. 
- Remove and discard the supernatant from all wells of the ASE plate, 
leaving the beads in the well. 
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- Leaving the plate on the magnet, add 50µl UB1 to each well of the ASE 
plate. 
- Leave the ASE plate on the raised bar magnetic plate for approximately 
2 minutes or until the beads are completely captured. 
- Remove and discard the UB1 from the wells. 
- Add 35l IP1 to each well of the ASE plate. 
- Seal the plate with adhesive film. 
- Vortex at 1800 rpm for 1 minute or until all the beads are resuspended. 
- Place the ASE plate on the heat block at 95C for 1 minute to denature 
from beads. 
- Place the ASE plate on a magnetic plate for 2 minutes or until all the 
beads have settled. 
- Transfer 30l of the supernatant from each well of the ASE plate to the 
corresponding well of the PCR plate. 
- Seal the plate with PCR plate-sealing film. 
 
Cycle PCR to amplify template DNA 
- Place each sealed PCR plate into a thermal cycler and run the following 
program: 
- 1 cycle of 37°C for 10 minutes followed by 95°C for 3 minutes 
- 34 cycles of 95°C for 35 seconds, 56°C for 35 seconds, 72°C for 2 
minutes 
- 1 cycle of 72°C for 10 minutes followed by 4°C for 5 minutes 
 
Bind the biotinylated, fluorescent amplicons to paramagnetic beads. 
- Vortex MPB until the beads are completely resuspended. 
- Pulse centrifuge the PCR plate to 250 xg. 
- Add 20l of resuspended MPB into each well of the PCR plate. 
- Pipette the solution in the wells of the PCR plate up and down several 
times. 
- Transfer the contents of each well of the PCR plate to the 
corresponding well in the filter plate. 
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- Incubate the covered filter plate at 22C for 60 minutes in a light-
protected drawer. 
 
Make Hybridisation plate  
- Place a covered filter plate onto a filter plate adaptor and place the 
adaptor onto a new 96-well V-bottom plate. 
- Centrifuge the plate assembly to 1000xg for 5 minutes at 25C. 
- Add 30l of MH1 to each well of a separate 96-well V-bottom plate 
(INT plate). 
- Replace the waste plate with the INT plate. Discard the waste plate. 
- Add 30l 0.1M NaOH to each well of the filter plate. 
- Replace the lid on the filter plate. Immediately centrifuge to 1000xg for 
5 minutes at 25C. Discard the filter plate. 
- Gently move the INT plate from side to side without splashing. 
- Place a Humidity Control Template Card under a 384-well microplate 
(HYB plate) to act as a guide. Add 30l UB2 to the wells indicated by 
orange dots on the card. 
- Pipette the sample in the wells of the INT plate up and down several 
times to completely neutralise the pH. 
- Place a Sample Wells Template Card under the HYB plate. Transfer 
50l neutralised hybridisation solution from each well of the INT plate 
into the wells indicated by the blue dots. 
- Seal the HYB plate with adhesive film. Centrifuge to 3000xg for 4 
minutes at 25C to remove any bubbles. 
 
Hybridise sample to Sentrix® Array Matrix (SAM).  
- Place the SAM into an OmniTray filled with 70mls UB2 with fibre 
bundles pointing down and the barcode label on the SAM facing up. 
- Gently move the SAM up and down for 10 seconds to remove bubbles 
from the ends of the fibre bundles. 
- After 3 minutes, move the SAM into an OmniTray filled with 60mls 
0.1M NaOH. 
- After 30 seconds, move the SAM back into the UB2 tray. 
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- Place the HYB plate into the SAM Hyb Cartridge. 
- After 30 seconds in the UB2 tray, remove SAM and place in Hyb 
Cartridge so that the fiber bundles extend down into the sample. 
- Close the lid of the Hyb cartridge. 
- Incubate the HYB/SAM pair in the 60C oven for 30 minutes. Reset the 
oven to 45C. Incubate the HYB/SAM pair in the 45C for at least 14 
hours. 
 
Image SAM 
- Turn on BeadArray Reader and allow to intialise for 1 to 2 hours. 
- Make a 1:1 mixture of sec-butanol and 95% EtOH. 
- Add 940ml of the sec-butanol /EtOH mixture to 60ml of IS1 reagent. 
Invert several times to mix. 
- Pour 70ml UB2 into two OmniTrays. 
- Pour 70ml IS1 into the third OmniTray. 
- Lift the SAM out of the HYB plate. Check for anomalies such as dry 
fibre bundles or crystals on the base of the array. 
- Place the SAM into the first UB2 tray. Gently agitate 10 times and then 
set the timer for 1 minute. 
- Place the SAM into the second UB2 tray and set the timer for 1 minute. 
Gently agitate 10 times and then let the array sit. 
- Place the SAM into the IS1 tray for 5 minutes. Lift the SAM up and 
down a few times sto ensure complete buffer exchange. 
- Place the SAM upside-down on an empty OmniTray so that the fibres 
point upwards. Air-dry for at least 20 minutes. 
- Seal the HYB plate with adhesive film and store it at -20C. 
- Clean the non-bead ends of the SAM fibre bundles with canned air.  
- At the BeadArray Reader PC, copy the decode data from the CD 
accompanying the SAM into the decode folder identified in the 
BeadArray settings. 
- Place the SAM in the scanner tray and begin the scan. 
- Any other SAMs should be stored in a light-protected drawer until they 
are imaged. SAMs should be imaged within 24 hours. 
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CpG loci excluded from analysis  
(Gene_Location&base pairs from TSS_Direction (P=Promoter, E=Exon; F=Forward, R=Reverse) 
ABCG2_P178_R DAB2IP_P671_F GLI3_P453_R MCC_E23_R PPARD_P846_F SPARC_E50_R 
ACTG2_P346_F DDB2_P407_F GPX3_E178_F MFAP4_P10_R PPARG_E178_R SPDEF_E116_R 
ADCYAP1_E163_R DES_P1006_R GSTP1_seq_38_S153_R MLH3_P25_F PRSS1_P1249_R SPI1_E205_F 
AOC3_P890_R DNAJC15_E26_R GUCY2D_P48_R MMP7_E59_F PTGS1_P2_F TDGF1_E53_R 
APOC1_P406_R DSG1_P159_R HBII-52_E142_F MOS_P746_F PTPRO_P371_F TDGF1_P428_R 
APP_P179_R DSP_P440_R HBII-52_P563_F MPL_P657_F PYCARD_P393_F TERT_E20_F 
AREG_P217_R E2F3_P840_R HDAC5_E298_F MUC1_E18_R RAD54B_P227_F TESK2_P252_R 
ARHGDIB_P148_R EPHA1_E46_R HHIP_P307_R MYCN_E77_R RARA_E128_R TFPI2_E141_F 
ATP10A_P524_R EPHB6_E342_F HLA-DQA2_E93_F MYLK_E132_R RARRES1_P57_R THBS1_P500_F 
BCAM_E100_R EPHB6_P827_R HLA-DQA2_P282_R NFKB1_P336_R RASGRF1_P768_F THY1_P20_R 
BCL3_E71_F EPHX1_P1358_R HOXA9_P303_F NPY_P91_F RET_P717_F TMEFF2_P210_R 
C4B_E171_F EPO_P162_R HS3ST2_P546_F NR2F6_E375_R RIPK4_E166_F TNC_P198_F 
CALCA_P171_F EPS8_E231_F HTR1B_E232_R NRG1_E74_F RUNX1T1_P103_F TNC_P57_F 
CASP10_E139_F ETV6_E430_F IFNGR2_E164_F p16_seq_47_S85_F S100A12_P1221_R TNF_P158_F 
CASP3_P420_R EXT1_E197_F IFNGR2_P377_R PALM2-AKAP2_P183_R S100A2_E36_R TPEF_seq_44_S36_F 
CASP8_E474_F EYA4_P508_F IGF1_P933_F PARP1_P610_R SEMA3B_P110_R TRAF4_P372_F 
CAV1_P130_R F2R_P839_F IGF2_P36_R PAX6_P1121_F SEMA3C_P642_F TRIP6_P1274_R 
CCNE1_P683_F FABP3_P598_F IGF2AS_E4_F PDE1B_E141_F SERPINA5_E69_F TUBB3_E91_F 
CCR5_P630_R FASTK_P598_R IGFBP5_E144_F PDGFB_E25_R SERPINE1_E189_R TUSC3_P85_R 
CD34_E20_R FGF9_P1404_F IL12B_P392_R PEG3_E496_F SEMA3B_P110_R USP29_P205_R 
CEBPA_P1163_R FGFR1_E317_F IL1B_P829_F PENK_E26_F SEMA3C_P642_F WNT10B_P993_F 
CFTR_P115_F FGFR3_E297_R IRF5_P123_F PGR_P790_F SERPINA5_E69_F WNT5A_E43_F 
COL4A3_E205_R FLT4_E206_F LAMB1_E144_R PITX2_P183_R SERPINE1_E189_R ZNF215_P71_R 
COL6A1_P425_F GABRA5_E44_R LMTK2_P1034_F PLG_P370_F SH3BP2_P771_R ZNF264_P397_F 
CSF1R_P73_F GABRG3_P75_F MAF_E77_R PLSCR3_P751_R SLC22A3_P528_F  
CTNNB1_P757_F GFAP_P56_R MAP2K6_P297_R PLXDC1_E71_F SLC22A3_P634_F  
CYP1B1_P212_F GFI1_P45_R MC2R_P1025_F POMC_E254_F SLC5A8_P38_R  
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 List of hypermethylated CpG loci in FL  
ADAMTS12_E52_R CFTR_P372_R EPHA7_E6_F GATA6_P726_F IGFBP2_P353_R 
ADCYAP1_P398_F CHGA_E52_F EPHA7_P205_R GDF10_P95_R IGFBP3_E65_R 
ADCYAP1_P455_R COL18A1_P365_R EPO_E244_R GJB2_E43_F IGFBP3_P423_R 
AGTR1_P154_F COL18A1_P494_R ERBB4_P255_F GP1BB_P278_R IGSF4_P86_R 
AGTR1_P41_F COL1A1_P5_F ERBB4_P541_F GRB10_E85_R IHH_E186_F 
ALOX12_E85_R COL1A2_P48_R ERG_E28_F GRB10_P260_F IHH_P246_R 
ASCL1_P747_F CTSL_P264_R ETV1_P235_F GRB10_P496_R IMPACT_P234_R 
ASCL2_E76_R CTSL_P81_F ETV1_P515_F GUCY2D_E419_R INHA_P1144_R 
ASCL2_P360_F DAB2_P35_F EVI1_E47_R HHIP_E94_F INHA_P1189_F 
ASCL2_P609_R DAB2_P468_F EYA4_E277_F HIC-1_seq_48_S103_R INSR_E97_F 
ATP10A_P147_F DAPK1_E46_R EYA4_P794_F HIC2_P498_F IPF1_P234_F 
BCAM_P205_F DAPK1_P10_F FAT_P279_R HLF_E192_F IPF1_P750_F 
BDNF_E19_R DAPK1_P345_R FAT_P973_R HOXA11_E35_F IRAK3_P185_F 
BDNF_P259_R DBC1_E204_F FGF3_E198_R HOXA11_P698_F ISL1_E87_R 
CALCA_E174_R DBC1_P351_R FGF3_P171_R HOXA9_E252_R ISL1_P379_F 
CALCA_P75_F DCC_E53_R FGF5_P238_R HOXA9_P1141_R ISL1_P554_F 
CCKBR_P480_F DCC_P177_F FGFR2_P460_R HOXB13_E21_F KDR_E79_F 
CCNA1_E7_F DCC_P471_R FLT4_P180_R HOXB13_P17_R KDR_P445_R 
CDH1_P45_F DES_E228_R FRZB_E186_R HS3ST2_E145_R LOX_P313_R 
CDH1_P52_R DIO3_P674_F FZD9_E458_F HS3ST2_P171_F LOX_P71_F 
CDH11_E102_R DIO3_P90_F GABRB3_E42_F HTR1B_P222_F MAF_P826_R 
CDH11_P203_R DLK1_E227_R GABRB3_P92_F IGF1R_E186_R MLF1_E243_F 
CDH11_P354_R DSC2_E90_F GALR1_E52_F IGF2_E134_R MMP2_E21_R 
CDH13_E102_F EGFR_E295_R GAS7_E148_F IGF2AS_P203_F MOS_E60_R 
CDH13_P88_F EGFR_P260_R GAS7_P622_R IGFBP1_E48_R MT1A_P49_R 
CEBPA_P706_F EPHA5_E158_R GATA6_P21_R IGFBP2_P306_F MT1A_P600_F 
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MYOD1_E156_F PTGS2_P524_R TFAP2C_E260_F   
MYOD1_P50_F PYCARD_P150_F TFAP2C_P765_F   
NEFL_E23_R RAB32_E314_R TGFBI_P173_F   
NEFL_P209_R RAB32_P493_R THBS1_E207_R   
NGFB_E353_F RASGRF1_E16_F TIMP2_P267_F   
NGFB_P13_F RBP1_E158_F TIMP3_seq_7_S38_F   
NOTCH3_E403_F RBP1_P426_R TJP1_P326_R   
NOTCH3_P198_R RET_seq_53_S374_F TJP1_P390_F   
NPY_E31_R RET_seq_54_S260_F TMEFF2_E94_R   
NPY_P295_F ROR1_P6_F TMEFF2_P152_R   
NRG1_P558_R SCGB3A1_E55_R TNK1_P41_R   
NTRK2_P10_F SCGB3A1_P103_R TPEF_seq_44_S88_R   
NTSR1_P318_F SEMA3C_E49_R TUSC3_E29_R   
ONECUT2_E96_F SFRP1_E398_R TWIST1_E117_R   
ONECUT2_P315_R SFRP1_P157_F WNT2_P217_F   
OPCML_E219_R SHH_E328_F WT1_E32_F   
PALM2-AKAP2_P420_R SLC22A3_E122_R WT1_P853_F   
PAX6_E129_F SLC5A8_E60_R    
PAX6_P50_R SLIT2_E111_R    
PENK_P447_R SLIT2_P208_F    
PGF_P320_F SOX1_P1018_R    
PITX2_E24_R SOX1_P294_F    
PLXDC2_E337_F SOX17_P287_R    
PLXDC2_P914_R SOX17_P303_F    
PRKCDBP_E206_F TAL1_P594_F    
PTGS2_P308_F TBX1_P885_R    
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 List of hypomethylated CpG loci in FL  
 
AATK_E63_R GFI1_P208_R NOTCH4_E4_F WNT8B_E487_F  
ABCB4_P892_F HDAC7A_P344_F PADI4_P1011_R   
AGXT_P180_F HLA-DOB_E432_R PADI4_P1158_R   
AIM2_E208_F HLA-DOB_P357_R PDGFB_P719_F   
AIM2_P624_F HLA-DPB1_P540_F PI3_P1394_R   
APBA2_P305_R IFNG_P188_F PLA2G2A_P528_F   
ASB4_P391_F IGF1_E394_F PLG_E406_F   
CARD15_P302_R IL12B_P1453_F PMP22_P975_F   
CARD15_P665_F IL18BP_E285_F PRDM2_P1340_R   
CCL3_P543_R IL4_P262_R PROM1_P44_R   
CD82_P557_R KLK11_P103_R PRSS1_E45_R   
CHI3L2_E10_F KRT13_P676_F PTHR1_P258_F   
CLDN4_P1120_R LEFTY2_P719_F PTK6_E50_F   
CPA4_E20_F MAP3K8_P1036_F RAD50_P191_F   
CSF3_P309_R MAPK4_E273_R RAN_P581_R   
CTSD_P726_F MBD2_P233_F RHOH_P953_R   
CXCL9_E268_R MMP8_E89_R SLC14A1_E295_F   
DHCR24_P652_R MMP9_E88_R SPDEF_P6_R   
DLC1_P695_F MPO_E302_R STAT5A_P704_R   
EDNRB_P709_R NAT2_P11_F TFF1_P180_R   
EGF_P413_F NOS2A_E117_R TMPRSS4_P552_F   
EPHX1_E152_F NOS2A_P288_R TRIM29_P135_F   
ERCC1_P440_R NOS3_P38_F UGT1A1_P315_R   
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Correlation between gene expression and methylation 
 
Table shows list of all probes (n=226) showing significant (P<0.05; FDR 0.30) inverse correlation between probe methylation values and 
previously obtained corresponding gene expression values. 77 loci showed highly significant (P<0.001; FDR 0.03). Genes subsequently 
examined in demethylating experiments (Section 4.2.6) are highlighted in bold font. Location of GoldenGate probe in relation to CGI is shown. 
A full list of correlation values for all 819 loci with corresponding well-measured gene expression is available as Supplementary Table S5 at  
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2762475/?tool=pubmed. 
 
Gene.Symbol PROBE.ID Gene.Expression.ID Correlation P.value  CPG_ISLAND 
GSTM1 GSTM1_P266_F 1132600 -0.65 0 Within 
ITK ITK_E166_R 1136087 -0.53 1.17295E-13 Outside 
BLK BLK_P14_F 1121814 -0.50 3.23225E-12 Outside 
PTK2 PTK2_P735_R 1123105 -0.50 4.092E-12 Within 
MME MME_E29_F 1132123 -0.49 1.68436E-11 Within 
TES TES_P182_F 1119886 -0.48 3.33192E-11 Within 
TNFSF8 TNFSF8_P184_F 1106381 -0.48 3.73288E-11 Within 
BLK BLK_P668_R 1121814 -0.48 4.85982E-11 Outside 
HLA-DOB HLA-DOB_E432_R 1133138 -0.47 1.1607E-10 Outside 
E2F5 E2F5_P516_R 1140405 -0.45 8.57796E-10 Within 
MME MME_P388_F 1132123 -0.45 9.65816E-10 Within 
PKD2 PKD2_P287_R 1120356 -0.44 2.534E-09 Within 
MGMT MGMT_P281_F 1120984 -0.43 5.16983E-09 Within 
ACVR2B ACVR2B_P676_F 1106738 -0.43 6.3043E-09 Within 
CDH1 CDH1_P45_F 1130812 -0.42 7.19712E-09 Within 
ACVR2B ACVR2B_E27_R 1106738 -0.42 1.0312E-08 Within 
MGMT MGMT_P272_R 1120984 -0.42 1.35687E-08 Within 
IGSF4 IGSF4_P454_F 1123175 -0.41 2.53712E-08 Within 
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Gene.Symbol PROBE.ID Gene.Expression.ID Correlation P.value  CPG_ISLAND 
CHFR CHFR_P501_F 1128249 -0.40 3.84785E-08 Within 
WEE1 WEE1_P924_R 1124563 -0.40 3.88463E-08 Outside 
CDH1 CDH1_P52_R 1130812 -0.39 9.92921E-08 Within 
AIM2 AIM2_E208_F 1121974 -0.39 1.29885E-07 Outside 
RHOH RHOH_P953_R 1121015 -0.39 1.41582E-07 Outside 
AIM2 AIM2_P624_F 1121974 -0.39 1.61285E-07 Outside 
GSTM1 GSTM1_P363_F 1132600 -0.39 1.67935E-07 Within 
ABCB1 MDR1_seq_42_S300_R 1135266 -0.38 2.57675E-07 Within 
CHI3L2 CHI3L2_E10_F 1136895 -0.38 3.03248E-07 Outside 
MEST MEST_E150_F 1119591 -0.38 3.1557E-07 Within 
HLA-DOB HLA-DOB_P357_R 1133138 -0.37 4.45334E-07 Outside 
DAPK1 DAPK1_P10_F 1120089 -0.37 4.63957E-07 Within 
TES TES_E172_F 1119886 -0.37 5.93241E-07 Within 
IMPACT IMPACT_P186_F 1114785 -0.35 1.64111E-06 Within 
CHFR CHFR_P635_R 1128249 -0.35 1.73513E-06 Within 
CTLA4 CTLA4_E176_R 1106935 -0.35 1.92858E-06 Outside 
MEST MEST_P62_R 1119591 -0.35 2.30905E-06 Within 
DKFZP564O0823 DKFZP564O0823_E45_F 1098057 -0.35 2.69357E-06 Within 
FANCF FANCF_P13_F 1114795 -0.34 3.72895E-06 Within 
DAPK1 DAPK1_E46_R 1120089 -0.34 4.31654E-06 Within 
LMO2 LMO2_P794_R 1132520 -0.34 4.31819E-06 Outside 
SYK SYK_P584_F 1098280 -0.34 5.53529E-06 Outside 
MMP7 MMP7_P613_F 1120647 -0.33 6.15422E-06 Outside 
MEST MEST_P4_F 1119591 -0.33 6.51277E-06 Within 
RHOH RHOH_P121_F 1121015 -0.33 8.84165E-06 Within 
PRDM2 PRDM2_P1340_R 1131928 -0.33 1.00243E-05 Outside 
TNFSF8 TNFSF8_E258_R 1106381 -0.32 1.37614E-05 Outside 
MBD2 MBD2_P233_F 1131615 -0.32 1.83347E-05 Outside 
TIMP3 TIMP3_seq_7_S38_F 1130824 -0.31 2.28536E-05 Within 
PKD2 PKD2_P336_R 1120356 -0.31 3.06807E-05 Within 
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Gene.Symbol PROBE.ID Gene.Expression.ID Correlation P.value  CPG_ISLAND 
IFNG IFNG_E293_F 1123780 -0.30 4.00939E-05 Outside 
CDK10 CDK10_E74_F 1135593 -0.30 4.38714E-05 Within 
TGFBI TGFBI_P31_R 1119381 -0.30 4.4785E-05 Within 
HPSE HPSE_P93_F 1096173 -0.30 5.1013E-05 Within 
IGSF4 IGSF4_P86_R 1123175 -0.30 6.12746E-05 Within 
RAF1 RAF1_P330_F 1130888 -0.29 8.1023E-05 Within 
RAB32 RAB32_P493_R 1132499 -0.29 9.17384E-05 Within 
ETS2 ETS2_P835_F 1119308 -0.29 9.73933E-05 Within 
ETS2 ETS2_P684_F 1119308 -0.28 0.00012 Within 
CSF1 CSF1_P217_F 1123479 -0.28 0.00013 Within 
APP APP_E8_F 1137680 -0.27 0.00020 Within 
IL17RB IL17RB_E164_R 1106192 -0.27 0.00020 Within 
GSTP1 GSTP1_E322_R 1119119 -0.27 0.00021 Within 
VIM VIM_P343_R 1130990 -0.27 0.00023 Within 
SPI1 SPI1_P48_F 1121228 -0.27 0.00026 Outside 
GRB10 GRB10_E85_R 1123331 -0.27 0.00030 Within 
HCK HCK_P46_R 1134095 -0.26 0.00032 Within 
TJP1 TJP1_P326_R 1119589 -0.26 0.00032 Within 
TGFBI TGFBI_P173_F 1119381 -0.26 0.00036 Within 
INSR INSR_E97_F 1116126 -0.26 0.00045 Within 
TJP1 TJP1_P390_F 1119589 -0.25 0.00051 Within 
HSD17B12 HSD17B12_E145_R 1127764 -0.25 0.00056 Within 
IGFBP3 IGFBP3_E65_R 1135322 -0.25 0.00058 Within 
HPSE HPSE_P29_F 1096173 -0.25 0.00062 Within 
SGCE SGCE_P250_R 1120885 -0.25 0.00064 Within 
CSF1 CSF1_P339_F 1123479 -0.25 0.00065 Within 
BCR BCR_P422_F 1131509 -0.25 0.00066 Within 
IGFBP3 IGFBP3_P1035_F 1135322 -0.24 0.00088 Within 
ACTG2 ACTG2_E98_R 1119700 -0.24 0.00089 Outside 
FRZB FRZB_E186_R 1120359 -0.24 0.00107 Within 
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CCND2 CCND2_P898_R 1130706 -0.24 0.00108 Within 
ITK ITK_P114_F 1136087 -0.23 0.00136 Outside 
JAG1 JAG1_P66_F 1134788 -0.23 0.00144 Within 
MYCN MYCN_P464_R 1112030 -0.23 0.00150 Within 
KIT KIT_P367_R 1132892 -0.23 0.00154 Within 
DAB2 DAB2_P35_F 1135672 -0.23 0.00165 Within 
TGFA TGFA_P642_R 1121054 -0.23 0.00172 Within 
DHCR24 DHCR24_P652_R 1119131 -0.22 0.00216 Outside 
DAPK1 DAPK1_P345_R 1120089 -0.22 0.00219 Within 
LMO2 LMO2_E148_F 1132520 -0.22 0.00223 Outside 
AFF3 AFF3_P122_F 1099270 -0.22 0.00229 Outside 
YES1 YES1_P216_F 1114062 -0.22 0.00244 Within 
SCGB3A1 SCGB3A1_E55_R 1101934 -0.22 0.00246 Within 
MAF MAF_P826_R 1134926 -0.22 0.00250 Within 
KIT KIT_P405_F 1132892 -0.22 0.00254 Within 
DSC2 DSC2_E90_F 1098932 -0.22 0.00256 Within 
INSR INSR_P1063_R 1116126 -0.22 0.00262 Within 
DLL1 DLL1_P832_F 1115475 -0.22 0.00266 Within 
CHI3L2 CHI3L2_P226_F 1136895 -0.22 0.00279 Outside 
HDAC1 HDAC1_P414_R 1119258 -0.21 0.00293 Within 
CDKN1C CDKN1C_P6_R 1125136 -0.21 0.00296 Within 
PDGFRA PDGFRA_P1429_F 1120081 -0.21 0.00299 Within 
CSTB CSTB_E410_F 1119254 -0.21 0.00306 Within 
IAPP IAPP_E280_F 1125443 -0.21 0.00313 Outside 
ABCA1 ABCA1_E120_R 1120265 -0.21 0.00325 Within 
PTEN PTEN_P438_F 1097673 -0.21 0.00327 Within 
DNAJC15 DNAJC15_P65_F 1099795 -0.21 0.00358 Within 
YES1 YES1_P600_F 1114062 -0.21 0.00382 Within 
ASCL2 ASCL2_P609_R 1100963 -0.21 0.00397 Within 
ESR1 ESR1_E298_R 1121175 -0.21 0.00407 Within 
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CD86 CD86_P3_F 1135778 -0.21 0.00420 Outside 
CAV2 CAV2_E33_R 1120174 -0.20 0.00425 Within 
TUBB3 TUBB3_P364_F 1137023 -0.20 0.00451 Within 
ELK3 ELK3_P514_F 1129992 -0.20 0.00557 Within 
CEACAM1 CEACAM1_E57_R 1123377 -0.20 0.00557 Outside 
MMP2 MMP2_P197_F 1119212 -0.20 0.00588 Within 
CCND1 CCND1_P343_R 1123061 -0.19 0.00618 Within 
RBP1 RBP1_E158_F 1120221 -0.19 0.00635 Within 
ICAM1 ICAM1_P386_R 1131704 -0.19 0.00688 Within 
DKFZP564O0823 DKFZP564O0823_P386_F 1098057 -0.19 0.00690 Outside 
TGFBR3 TGFBR3_P429_F 1098758 -0.19 0.00700 Within 
ITPR3 ITPR3_P1112_F 1130855 -0.19 0.00726 Within 
BMPR2 BMPR2_P1271_F 1097496 -0.19 0.00739 Within 
DAB2 DAB2_P468_F 1135672 -0.19 0.00768 Within 
PTK2B PTK2B_P673_R 1120072 -0.19 0.00782 Within 
ASCL2 ASCL2_P360_F 1100963 -0.19 0.00791 Within 
TGFBR3 TGFBR3_E188_R 1098758 -0.19 0.00799 Within 
SLIT2 SLIT2_P208_F 1101726 -0.19 0.00806 Within 
WRN WRN_E57_F 1121443 -0.19 0.00830 Within 
FLT4 FLT4_P180_R 1101526 -0.19 0.00860 Within 
BCR BCR_P346_F 1131509 -0.19 0.00878 Within 
IGFBP3 IGFBP3_P423_R 1135322 -0.19 0.00879 Within 
IGFBP5 IGFBP5_P9_R 1124173 -0.18 0.00902 Within 
SYK SYK_E372_F 1098280 -0.18 0.00906 Within 
GRB10 GRB10_P260_F 1123331 -0.18 0.01016 Within 
CDKN1C CDKN1C_P626_F 1125136 -0.18 0.01018 Within 
TCF4 TCF4_P317_F 1120384 -0.18 0.01030 Within 
IMPACT IMPACT_P234_R 1114785 -0.18 0.01044 Within 
PTPRG PTPRG_P476_F 1112353 -0.18 0.01102 Within 
HDAC7A HDAC7A_P344_F 1138887 -0.18 0.01110 Outside 
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ICA1 ICA1_P61_F 1135548 -0.18 0.01118 Within 
GRB10 GRB10_P496_R 1123331 -0.18 0.01121 Within 
TRIP6 TRIP6_P1090_F 1123207 -0.18 0.01130 Within 
MMP19 MMP19_P306_F 1132671 -0.18 0.01138 Outside 
GPX1 GPX1_E46_R 1130555 -0.18 0.01147 Within 
EPS8 EPS8_P437_F 1119835 -0.18 0.01163 Within 
AXL AXL_E61_F 1131733 -0.18 0.01182 Outside 
HGF HGF_P1293_R 1135244 -0.18 0.01199 Outside 
ASCL2 ASCL2_E76_R 1100963 -0.18 0.01213 Within 
NKX3-1 NKX3-1_P871_R 1123472 -0.18 0.01225 Outside 
FAT FAT_P279_R 1119417 -0.18 0.01235 Within 
FASTK FASTK_P257_F 1137319 -0.17 0.01265 Within 
CCKBR CCKBR_P361_R 1117322 -0.17 0.01267 Within 
ABCA1 ABCA1_P45_F 1120265 -0.17 0.01267 Within 
CTNNA1 CTNNA1_P382_R 1135740 -0.17 0.01306 Within 
THBS1 THBS1_E207_R 1105785 -0.17 0.01385 Within 
MAPK14 MAPK14_P327_R 1119807 -0.17 0.01393 Within 
IGFBP7 IGFBP7_P297_F 1130835 -0.17 0.01404 Within 
EGR4 EGR4_P479_F 1102966 -0.17 0.01446 Within 
RAB32 RAB32_E314_R 1132499 -0.17 0.01493 Within 
MLH1 MLH1_P381_F 1131634 -0.17 0.01493 Within 
ZNF264 ZNF264_E48_R 1101666 -0.17 0.01514 Within 
CPA4 CPA4_E20_F 1121543 -0.17 0.01542 Outside 
NTRK3 NTRK3_E131_F 1100660 -0.17 0.01553 Within 
AKT1 AKT1_P310_R 1133694 -0.16 0.01742 Within 
PTPRO PTPRO_E56_F 1134172 -0.16 0.01764 Within 
HLA-DOA HLA-DOA_P594_F 1098986 -0.16 0.01819 Outside 
KIAA1804 KIAA1804_P689_R 1100420 -0.16 0.01963 Within 
SMAD2 SMAD2_P708_R 1098709 -0.16 0.01969 Within 
CDKN1B CDKN1B_P1161_F 1123198 -0.16 0.02018 Outside 
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HDAC9 HDAC9_P137_R 1121436 -0.16 0.02091 Outside 
SFTPB SFTPB_P689_R 1137444 -0.16 0.02134 Outside 
TK1 TK1_E47_F 1119729 -0.16 0.02139 Within 
CTNNA1 CTNNA1_P185_R 1135740 -0.16 0.02152 Within 
TNFRSF1B TNFRSF1B_P167_F 1120267 -0.16 0.02166 Within 
BCAM BCAM_P205_F 1118763 -0.16 0.02203 Within 
BCL2L2 BCL2L2_P280_F 1123286 -0.16 0.02237 Outside 
SFRP1 SFRP1_E398_R 1131353 -0.16 0.02255 Within 
AFF3 AFF3_P808_F 1099270 -0.16 0.02287 Outside 
PLXDC2 PLXDC2_P914_R 1099336 -0.16 0.02289 Within 
TIAM1 TIAM1_P117_F 1124985 -0.16 0.02334 Within 
GATA6 GATA6_P21_R 1110601 -0.16 0.02362 Within 
IGFBP2 IGFBP2_P306_F 1119885 -0.15 0.02390 Within 
GAS7 GAS7_E148_F 1131445 -0.15 0.02476 Within 
EPHA1 EPHA1_P119_R 1133252 -0.15 0.02525 Within 
BCL6 BCL6_P248_R 1120090 -0.15 0.02541 Within 
PTPRG PTPRG_E40_R 1112353 -0.15 0.02572 Within 
GAS7 GAS7_P622_R 1131445 -0.15 0.02643 Within 
FAT FAT_P973_R 1119417 -0.15 0.02774 Within 
CPNE1 CPNE1_P138_F 1133593 -0.15 0.02796 Within 
ST6GAL1 ST6GAL1_P528_F 1119582 -0.15 0.02800 Within 
S100A4 S100A4_E315_F 1131987 -0.15 0.02817 Outside 
UNG UNG_P170_F 1131519 -0.15 0.02822 Within 
FRZB FRZB_P406_F 1120359 -0.15 0.02912 Within 
EGR4 EGR4_E70_F 1102966 -0.15 0.02945 Within 
ITPR3 ITPR3_E86_R 1130855 -0.15 0.02947 Within 
ERCC6 ERCC6_P698_R 1122490 -0.15 0.02990 Within 
SFRP1 SFRP1_P157_F 1131353 -0.15 0.03021 Within 
MTA1 MTA1_P478_F 1136418 -0.15 0.03053 Within 
STAT5A STAT5A_E42_F 1120026 -0.15 0.03076 Outside 
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Gene.Symbol PROBE.ID Gene.Expression.ID Correlation P.value  CPG_ISLAND 
ERG ERG_E28_F 1137049 -0.15 0.03113 Within 
ACVR1B ACVR1B_E497_R 1125027 -0.15 0.03164 Within 
HDAC9 HDAC9_E38_F 1121436 -0.14 0.03239 Outside 
PYCARD PYCARD_P150_F 1140463 -0.14 0.03395 Within 
FGFR1 FGFR1_P204_F 1098832 -0.14 0.03419 Within 
GLI3 GLI3_E148_R 1121155 -0.14 0.03427 Outside 
SGCE SGCE_E149_F 1120885 -0.14 0.03432 Within 
NKX3-1 NKX3-1_P146_F 1123472 -0.14 0.03514 Within 
RARB RARB_P60_F 1121088 -0.14 0.03605 Within 
GUCY2D GUCY2D_E419_R 1122763 -0.14 0.03647 Within 
EPHB1 EPHB1_E202_R 1101974 -0.14 0.03747 Within 
ESR1 ER_seq_a1_S60_F 1121175 -0.14 0.03789 Within 
TUSC3 TUSC3_E29_R 1137007 -0.14 0.03898 Within 
PDGFA PDGFA_P78_F 1133056 -0.14 0.04073 Within 
SLIT2 SLIT2_E111_R 1101726 -0.14 0.04086 Within 
TIAM1 TIAM1_P188_R 1124985 -0.13 0.04252 Within 
ETS1 ETS1_P559_R 1097232 -0.13 0.04318 Within 
ITGB4 ITGB4_P517_F 1132862 -0.13 0.04332 Within 
EPHB4 EPHB4_E476_R 1119972 -0.13 0.04381 Within 
CDKN1A CDKN1A_P242_F 1131490 -0.13 0.04510 Within 
DCN DCN_P1320_R 1131271 -0.13 0.04536 Outside 
ELL ELL_P693_F 1132452 -0.13 0.04546 Within 
THBS2 THBS2_P605_R 1120059 -0.13 0.04691 Outside 
RBP1 RBP1_P150_F 1120221 -0.13 0.04866 Within 
CTGF CTGF_P693_R 1123193 -0.13 0.04908 Outside 
IFNG IFNG_P459_R 1123780 -0.13 0.04937 Outside 
ITPR2 ITPR2_P804_F 1114152 -0.13 0.04940 Within 
EPHB4 EPHB4_P313_R 1119972 -0.13 0.04969 Within 
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Appendix B - MSP 
 
Additional details of MSP procedure 
 
Gene  Primer Sequence 
  
IGFBP7 – U - F:  AAGGGTAAAGTTGGGGTAGTAGTTG  
IGFBP7 – U - R:  ACTCTCAACCCTCTAACTAACAACA 
IGFBP7 – M - F:  GAAGGGTAAAGTCGGGGTAGTAGTC   
IGFBP7 – M - R:  TCTCGACCCTCTAACTAACGACG   
  
MGMT – U – F: TTTGTGTTTTGATGTTTGTAGGTTTTTGT 
MGMT – U – R:  AACTCCACACTCTTCCAAAAACAAAACA 
MGMT – M - F:  TTTCGACGTTCGTAGGTTTTCGC 
MGMT – M - R:  GCACTCTTCCGAAAACGAAACG 
 
U = Reaction specific for unmethylated state 
M = Reaction specific for methylated state 
F = Forward 
R = Reverse 
    
Reaction mix: 
 
5µl of bisulphite-modified DNA (5ng/µl pre-treatment DNA) 
0.1µl of forward primer (100µM) 
0.1µl of reverse primer (100µM) 
10µl Thermostart MasterMix (Abgene, Epsom, UK) 
4.8µl H2O 
   
MSP reaction conditions: 
    
Step 1: Denaturation at 95ºC for 2 minutes  
Step 2: Annealing (60ºC for IGFBP7, 55ºC for MGMT) for 30 seconds 
Step 3: Extension at 72ºC for 30 seconds  
Step 4: Repeat Steps 1-3 7 times  
Step 5: Denaturation at 95ºC for 30 seconds  
Step 6: Annealing (60ºC for IGFBP7, 55ºC for MGMT) for 30 seconds 
Step 7: 72ºC for 30 seconds  
Step 8: Repeat steps 5-7 31 times 
Step 9: 72ºC for 5 minutes 
Step 10: Storage at 4ºC indefinitely  
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Appendix C – Pyrosequencing 
 
Additional information related to Pyrosequencing experiments: 
 
- PCR conditions 
- Primer sequences, sequence to analyse, corresponding GoldenGate probes 
and annealing temperatures of individual genes studied 
- Individual values obtained using Pyrosequencing 
- Correlation between Pyrosequencing and GoldenGate values 
 
Reaction mixture for PCR reaction. 
 
 
Reagent Concentration Volume per 25µl 
reaction (µl) 
PCR Buffer II 1x 2.5 
MgCl2 3mM 3.0 
dNTPs 200µM of each 2.0 (0.5 of each) 
Forward primer (10µM) 5 pmol (0.2µM) 0.5 
Reverse primer (10µM) 5 pmol (0.2µM) 0.5 
Amplitaq Gold DNA Polymerase  0.8 Units 0.2 
ddH2O  14.3 
DNA template 10-12ng 2.0 
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Details of Pyrosequencing experiments  
 
Primer sequences, sequence being analysed (YG indicates CpG site), 
GoldenGate probe interrogating corresponding CpG and annealing temperature 
for initial PCR reaction. 
 
CDH1  
Forward primer GGGGTTAGAGTTGTTGATTGGTT 
Reverse primer  TAACTTCCCCAAACTCACAAATACT 
Sequencing primer TAGGTGAATTTTTAGTTAAT 
  
Sequence analysed TAGYGGTAYGGGGGGYGGTGTTTTYGGGG 
Corresponding GoldenGate probes CDH1_P45_F; CDH1_P52_R 
  
Annealing Temperature 58ºC 
DAPK1   
Forward primer AGTGTTAGGTATAAGTTGGGATTTTAGT 
Reverse primer  ACCCCCCACCTATAACACATTA 
Sequencing primer TGGGATTTTAGTATATATTT 
  
Sequence analysed YGGGAYGGAAGAATYGTG  
Corresponding GoldenGate probes DAPK1_P345_R 
  
Annealing Temperature 55ºC 
FAT  
Forward primer AAAGTTTTTTTTTTTTGGTAGGGAGTTT 
Reverse primer  AACCCAAAAAACCCCAATC 
Sequencing primer TTTTTTTAATTTTTTGTATA 
  
Sequence analysed GYGTTTGTGGTTGGTYGTAATTAATTTYGGT
ATTATAAGT TTYGTTTTGTTTTTYGGAG  
Corresponding GoldenGate probes FAT_P279_R 
  
Annealing Temperature 58ºC 
SLIT2  
Forward primer AGGGGTTATAATATTTATTGAGATTT 
Reverse primer  CCTCTTCTATCTCCCAAAAATAAACTTA 
Sequencing primer AGTTATTGGTATAGGATTTG 
  
Sequence analysed TAGAAGYGTGYGTGGGATTAGAGGATYGTT 
TTTTTTATAATAATYG 
Corresponding GoldenGate probes SLIT2_P208_F 
  
Annealing Temperature 52ºC 
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Sample methylation values obtained by Pyrosequencing 
 
Tables show methylation values at each of the CpG sites studied in 4 individual 
genes in 25 samples. Values for replicate samples are included. Standard 
deviation (SD) of values across adjacent CpG loci is shown (SD >0.1 
highlighted in bold font). 
CDH1 CpG location (bases 5’ to TSS)  
 57 52 45 36 SD 
Sample ID      
878 0.679 0.706 0.665 0.733 0.030 
888 0.649 0.566 0.599 0.696 0.057 
1073 0.521 0.537 0.512 0.489 0.020 
1076 0.556 0.563 0.552 0.587 0.016 
1077 0.109 0.244 0.189 0.127 0.062 
1081 0.466 0.437 0.422 0.83 0.195 
1087 - 1 0.171 0.177 0.186 0.164 0.009 
1087 - 2 0.203 0.228 0.213 0.217 0.010 
1098 0.396 0.606 0.569 0.691 0.124 
1107 0.352 0.361 0.289 0.289 0.039 
1419 0.371 0.394 0.4 0.424 0.022 
1610 0.208 0.222 0.265 0.191 0.032 
1622 0.679 0.683 0.691 0.765 0.041 
1626 0.797 0.82 0.83 0.874 0.032 
1638 0.512 0.47 0.473 0.45 0.026 
1644 0.281 0.319 0.294 0.288 0.017 
1661 0.281 0.312 0.236 0.304 0.034 
1732 0.882 0.892 0.875 0.961 0.040 
1880 0.799 0.845 0.671 0.634 0.101 
1885 0.486 0.486 0.504 0.238 0.127 
1896 0 0.12 0 0 0.060 
Meth - 1 1 1 0.882 0.929 0.058 
Meth - 2 0.93 1 0.927 0.991 0.039 
BLN6 0.071 0.063 0 0 0.039 
BLN10 0 0 0 0 0 
BLN16 0 0 0 0 0 
BLN17 0 0 0 0 0 
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DAPK1 CpG Site location (bases 5’ to TSS)  
 350 345 336 SD 
Sample ID     
878 0.54 0.627 0.094 0.286 
888 0.765 0.802 0.732 0.035 
1073-1 0.595 0.653 0.643 0.031 
1073-2 0.648 0.691 0.645 0.026 
1076 0.533 0.577 0.567 0.023 
1077 0 0.103 0 0.059 
1081 0.66 0.699 0.611 0.044 
1087 0.139 0.194 0.103 0.046 
1098 0.672 0.691 0.608 0.043 
1107-1 0.253 0.334 0.226 0.056 
1107-2 0.27 0.327 0.216 0.056 
1419 0.048 0 0 0.028 
1610 0.166 0.291 0.143 0.080 
1622 0.617 0.644 0.515 0.068 
1626-1 0.113 0.744 0.412 0.316 
1626-2 0.118 0.765 0.426 0.324 
1638 0.226 0.354 0.21 0.079 
1644 0.195 0.24 0.144 0.048 
1661-1 0.184 0.249 0.246 0.037 
1661-2 0.169 0.262 0.212 0.047 
1732 0.48 0.583 0.297 0.145 
1880 0.716 0.741 0.71 0.016 
1885 0.145 0.115 0.104 0.021 
1896 0 0 0 0 
Meth - 1 0.88 0.919 0.962 0.041 
Meth - 2 0.901 0.942 0.948 0.026 
BLN10 0 0 0 0 
BLN16 0 0 0 0 
BLN17 -1 0 0 0 0 
BLN17 -2 0 0 0 0 
BLN6 0 0 0 0 
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FAT CpG Site location (bases 5’ to TSS)  
 293 279 267 252 240 SD 
Sample ID   
878 0.693 0.79 0.525 0.668 0.834 0.120 
888 0.576 0.633 0.664 0.595 0.666 0.040 
1073 0.475 0.502 0.523 0.515 0.568 0.034 
1076 0.457 0.546 0.259 0.481 0.574 0.124 
1077 - 1 0.181 0.239 0.113 0.272 0.254 0.065 
1077 - 2 0.239 0.265 0.173 0.335 0.329 0.067 
1081 0.571 0.687 0.671 0.581 0.75 0.075 
1087 0.154 0.215 0.124 0.135 0.193 0.039 
1098 0.581 0.594 0.668 0.542 0.647 0.051 
1107 0.324 0.351 0.306 0.3 0.361 0.027 
1419 0.185 0.233 0 0.284 0.401 0.147 
1610 0.296 0.344 0.333 0.316 0.345 0.021 
1622 0.557 0.6 0.601 0.604 0.645 0.031 
1626 0.535 0.729 0.748 0.744 0.808 0.104 
1638 0.447 0.533 0.516 0.503 0.528 0.035 
1644 0.213 0.211 0.198 0.178 0.208 0.014 
1661 0.208 0.251 0.242 0.207 0.277 0.030 
1732 0.787 0.845 0.895 0.87 0.942 0.058 
1880 0.565 0.581 0.606 0.611 0.596 0.019 
1885 0.131 0.319 0.209 0.302 0.223 0.076 
1896 0.246 0.291 0.117 0.306 0.326 0.084 
Meth - 1 0.922 0.957 1 1 1 0.035 
Meth - 2 1 0.905 1 1 1 0.042 
BLN10 0 0.068 0.049 0 0 0.033 
BLN16 0 0 0 0 0 0 
BLN17 0 0.052 0.05 0 0 0.028 
BLN6 0 0 0 0 0 0 
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SLIT2 CpG Location (Basepairs 5' to TSS)  
 212 208 192 174 SD 
Sample ID   
878 0.485 0.76 0.756 0.8 0.145 
888 0.684 0.666 0.765 0.754 0.050 
1073 0.571 0.591 0.655 0.601 0.036 
1076 0.575 0.656 0.617 0.625 0.033 
1077 0.237 0.183 0.277 0.137 0.061 
1081 0.41 0.569 0.712 0.465 0.133 
1087 - 1 0.19 0.247 0.066 0.351 0.119 
1087 - 2 0.161 0.235 0.079 0.315 0.101 
1098 0.392 0.654 0.653 0.733 0.149 
1107 0.448 0.516 0.541 0.504 0.039 
1419 0.453 0.441 0.438 0.508 0.033 
1610 0.329 0.36 0.344 0.369 0.018 
1622 0.535 0.678 0.714 0.798 0.110 
1626 0.76 0.813 0.841 0.861 0.044 
1638 0.353 0.386 0.393 0.572 0.099 
1644 0.2 0.258 0.283 0.275 0.037 
1661 0.325 0.365 0.337 0.318 0.021 
1732 0.591 0.829 0.846 0.933 0.146 
1880 0.681 0.796 0.811 0.803 0.061 
1885 0.375 0.41 0.41 0.467 0.038 
1896 0.237 0.303 0.233 0 0.133 
Meth - 1 1 1 1 0.987 0.006 
Meth - 2 1 0.936 0.991 0.974 0.028 
BLN10 0 0 0 0 0 
BLN16 0 0 0 0 0 
BLN17 0 0 0 0 0 
BLN6 - 1 0 0.091 0.099 0.111 0.051 
BLN6 - 2 0 0 0 0 0 
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Correlation of methylation values obtained by Pyrosequencing and 
GoldenGate methods 
 
Tables show methylation values obtained by Pyrosequencing and GoldenGate 
methods at each of the CpG sites studied in 4 individual genes in 25 samples. 
Mean values for replicate samples are shown. Pearson correlation coefficients 
are shown. 
 
 
CDH1 Pyrosequencing GoldenGate Pyrosequencing GoldenGate 
 52 bp 5‘ to TSS 45 bp 5‘ to TSS 
Sample ID   
878 0.71 0.95 0.67 0.75 
888 0.57 0.87 0.60 0.62 
1073 0.54 0.89 0.51 0.32 
1076 0.56 0.86 0.55 0.60 
1077 0.24 0.27 0.19 0.27 
1081 0.44 0.80 0.42 0.58 
1087 (Mean) 0.20 0.41 0.20 0.31 
1098 0.61 0.80 0.57 0.66 
1107 0.36 0.57 0.29 0.32 
1419 0.39 0.66 0.40 0.48 
1610 0.22 0.34 0.27 0.33 
1622 0.68 0.88 0.69 0.70 
1626 0.82 0.93 0.83 0.78 
1638 0.47 0.71 0.47 0.61 
1644 0.32 0.47 0.29 0.35 
1661 0.31 0.55 0.24 0.34 
1732 0.89 0.95 0.88 0.83 
1880 0.85 0.90 0.67 0.46 
1885 0.49 0.63 0.50 0.30 
1896 0.12 0.15 0.00 0.13 
Meth (Mean) 1.00 0.90 0.90 0.66 
BLN6 0.06 0.05 0 0.04 
BLN10 0 0.06 0 0.10 
BLN16 0 0.02 0 0.07 
BLN17 0 0.04 0 0.10 
     
Pearson r 0.93  0.92  
r
2
 0.86  0.84  
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DAPK1 Pyrosequencing GoldenGate 
 345 bp 5‘ to TSS 
Sample ID  
878 0.63 0.78 
888 0.80 0.92 
1073 (Mean) 0.67 0.90 
1076 0.58 0.86 
1077 0.10 0.04 
1081 0.70 0.94 
1087 0.19 0.46 
1098 0.69 0.90 
1107 (Mean) 0.33 0.69 
1419 0 0.04 
1610 0.29 0.58 
1622 0.64 0.90 
1626 (Mean) 0.75 0.73 
1638 0.35 0.56 
1644 0.24 0.61 
1661 (Mean) 0.26 0.43 
1732 0.58 0.88 
1880 0.74 0.91 
1885 0.12 0.26 
1896 0 0.02 
Meth (Mean) 0.93 0.88 
BLN10 0 0.05 
BLN16 0 0.04 
BLN17 (Mean) 0 0.04 
BLN6 0 0.01 
   
Pearson r 0.94  
r
2
 0.88  
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FAT Pyrosequencing GoldenGate 
 279 bp 5‘ to TSS 
Sample ID  
878 0.79 0.93 
888 0.63 0.86 
1073 0.50 0.81 
1076 0.55 0.82 
1077 (Mean) 0.25 0.52 
1081 0.69 0.87 
1087 0.22 0.49 
1098 0.59 0.84 
1107 0.35 0.68 
1419 0.23 0.62 
1610 0.34 0.70 
1622 0.60 0.85 
1626 0.73 0.82 
1638 0.53 0.82 
1644 0.21 0.53 
1661 0.25 0.65 
1732 0.85 0.91 
1880 0.58 0.81 
1885 0.32 0.46 
1896 0.29 0.66 
Meth (Mean) 0.93 0.83 
BLN10 0.07 0.10 
BLN16 0.00 0.07 
BLN17 0.05 0.10 
BLN6 0.00 0.12 
   
Pearson r 0.89  
r
2
 0.79  
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SLIT2 Pyrosequencing GoldenGate 
 208 bp 5‘ to TSS 
Sample ID   
878 0.76 0.93 
888 0.67 0.84 
1073 0.59 0.64 
1076 0.66 0.74 
1077 0.18 0.51 
1081 0.57 0.79 
1087 (Mean) 0.24 0.36 
1098 0.65 0.86 
1107 0.52 0.69 
1419 0.44 0.69 
1610 0.36 0.63 
1622 0.68 0.84 
1626 0.81 0.91 
1638 0.39 0.75 
1644 0.26 0.52 
1661 0.37 0.59 
1732 0.83 0.93 
1880 0.80 0.89 
1885 0.41 0.59 
1896 0.30 0.31 
Meth (Mean) 0.97 0.95 
BLN10 0.00 0.09 
BLN16 0.00 0.06 
BLN17 0.00 0.08 
BLN6 (Mean) 0.05 0.08 
   
Pearson r 0.94  
r
2
 0.89  
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Appendix D – Illumina Infinium Human Methylation 27 array 
Additional Material related to experiments using Illumina Infinium array : 
 
- Infinium operating protocol 
- Hypermethylated genes 
- Methylation values of genes with multiple CpG loci 
- Gene Ontology analysis 
 
Infinium operating protocol 
 
Make Bisulphite-converted DNA (BCD) Plate 
- Add 10µl of each bisulphite-converted DNA sample to an individual well of a 
0.2ml skirted microplate. 
 
Make MSA2 
- Dispense 20µl MA1 into the MSA2 plate wells. 
- Transfer 4l of bisulphite-converted DNA sample from the BCD plate to the 
corresponding wells in the MSA2 plate. 
- Dispense 4µl 0.1N NaOH into each well of the MSA2 plate containing MA1 
/ DNA sample. 
- Seal the MSA2 plate with a 96-well cap mat. 
- Vortex the plate at 1600 rpm for 1 minute then centrifuge to 280 xg for 1 
minute. 
- Incubate for 10 minutes at room temperature. 
- Dispense 68µl MA2 into each well of the MSA2 plate containing sample. 
- Dispense 75 µl MSM into each well of the MSA2 plate containing sample. 
- Seal MSA2 plate with cap mat. 
- Invert the sealed plate at least 10 times to mix contents. 
- Pulse centrifuge to 280 xg for 1 minute. 
- Incubate MSA2 plate in Illumina Hybridisation Oven for at least 20 but no 
more than 24 hours at 37ºC to amplify DNA. 
 
Fragment MSA2 
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This process enzmatically fragments the amplified DNA samples using end-
point fragmentation. 
- Remove the MSA2 plate from the Hybridisation Oven. 
- Centrifuge the plate to 50 xg for 1 minute. 
- Remove cap mat from plate and add 50µl FMS to each well containing 
sample. 
- Seal the MSA2 plate with the 96-well cap mat. 
- Vortex the plate at 1600rpm for 1 minute. 
- Centrifuge the plate to 50 xg for 1 minute at 22ºC. 
- Place sealed plate on heat block at 37ºC for 1 hour. 
 
Precipitate MSA2 
- Add 100µl PM1 to each MSA2 plate well containing sample. 
- Seal the plate with the cap mat and vortex plate at 1600 rpm for 1 minute. 
- Incubate at 37ºC for 5 minutes. 
- Centrifuge to 50 xg at 22ºC for 1 minute. 
- Add 300µl 100% 2-propanol to each well containing sample. 
- Seal the MSA2 plate with a new, dry cap mat. 
- Invert plate at least 10 times to  mix contents thoroughly. 
- Incubate at 4ºC for 30 minutes. 
- Centrifuge to 3000 xg at 4ºC for 20 minutes so that a blue pellet is visible in 
each well. 
- Remove cap mat. 
- Decant supernatant  by quickly inverting the MSA2 plate and smacking it 
down onto an absorbent pad. 
- Tap firmly several times for 1 minute or until all wells are devoid of liquid. 
- Leave uncovered plate at room temperature for 1 hour to air dry the pellet. 
 
Resuspend MSA2 
- Add 42µl RA1 to each well of the MSA2 plate. 
- Heat seal the MSA2 plate and place in the Illumina Hybridisation Oven and 
incubate for 1 hour at 48ºC. 
- Vortex the plate at 1800 rpm for 1 minute and pulse centrifuge to 280 xg. 
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Hybridise Multi BeadChip 
- Assemble Hybridisation chambers according to instructions 
- Dispense 200µl PB2 into the humidifying buffer reservoirs in the Hyb 
Chambers. 
- Place the resuspended MSA2 plate on the heat block to denature the samples 
at 95ºC for 20 minutes. 
- Pulse centrifuge the MSA2 plate to 280 xg. 
- Remove BeadChip from storage, unpack and place into a HybChamber 
insert. 
- Dispense 12µl of each DNA sample onto the appropriate BeadChip section. 
- Ensure DNA sample covers all of each bead stripe. 
- Load HybChamber inserts containg BeadChips into the HybChamber and use 
clamps to shut. 
- Place the HybChamber into an Illumina Hybridisation Oven at 48ºC. 
- Incubate for between 16 and 24 hours. 
 
Wash BeadChip 
- Remove HybChamber inserts from the HybChambers and remove BeadChips 
from the HybChamber inserts one at a time. 
- Remove coverseal from each BeadChip and slide each BeadChip onto a wash 
rack which has been submerged in a wash dish containing 200mls WB1. 
- Move the wash rack up and down gently for 1 minute. 
- Remove wash rack from wash dish and place into a wash dish containing 
PB1. 
- Move the wash rack up and down gently for 1 minute. 
- Assemble flow-through chamber as per instructions. 
 
Stain BeadChip 
- When the Chamber Rack reaches 44°C, quickly place each Flow-Through  
Chamber assembly into the Chamber Rack. 
- Shake the XC4 bottle vigorously to ensure complete resuspension. If  
necessary, vortex until completely dissolved. 
- Into the reservoir of each Flow-Through Chamber, dispense: 
- 150 μl RA1. Incubate for 30 seconds. Repeat 5 times. 
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- 450 μl XC1. Incubate for 10 minutes.  
- 450 μl XC2. Incubate for 10 minutes.  
- 200 μl TEM. Incubate for 15 minutes.  
- 450 μl 95% formamide/1 mM EDTA. Incubate for 1 minute. Repeat  once. 
Incubate 5 minutes.  
- 450 μl XC3. Incubate for 1 minute. Repeat once.  
- Begin ramping the Chamber Rack temperature to the temperature  indicated 
on the LTM tube, or to 37°C if none is shown.  
- Wait until the Chamber Rack reaches the correct temperature. 
- Into the reservoir of each Flow-Through Chamber, dispense:  
- a. 250 μl LTM and incubate for 10 minutes. 
-  b. 450 μl XC3 and incubate for 1 minute. Repeat once, and then wait  5 
minutes.  
- c. 250 μl ATM and incubate for 10 minutes.  
- d. 450 μl XC3 and incubate for 1 minute. Repeat once, and then wait  5 
minutes.  
- e. 250 μl LTM and incubate for 10 minutes.  
- f. 450 μl XC3 and incubate for 1 minute. Repeat once, and then wait  5 
minutes.  
- g. 250 μl ATM and incubate for 10 minutes.  
- h. 450 μl XC3 and incubate for 1 minute. Repeat once, and then wait  5 
minutes.  
- i. 250 μl LTM and incubate for 10 minutes.  
- j. 450 μl XC3 and incubate for 1 minute. Repeat once, and then wait  5 
minutes. 
- Immediately remove the Flow-Through Chambers from the Chamber  Rack 
and place horizontally on a lab bench at room temperature. 
 
Wash and Coat BeadChip 
o Pour 310 ml PB1 per 8 BeadChips into a wash dish. Cover the dish.  
o Place the staining rack inside the wash dish.  
o Use the dismantling tool to remove the two metal clamps from  the Flow-
Through Chamber.  
o Remove the glass back plate, the spacer, and then the  BeadChip. 
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o Immediately place each BeadChip into the staining rack that is in the wash 
dish. 
o Slowly move the staining rack up and down 10 times, breaking the surface of 
the reagent.  
o Soak for 5 minutes.  
o Pour 310 ml XC4 into a wash dish. Do not let it sit for more than 10 minutes.  
o Move the BeadChip staining rack into the XC4 dish.  
o Slowly move the staining rack up and down 10 times, breaking the surface of 
the reagent. 
o Soak for 5 minutes. 
o Lift the staining rack out of the solution and place it on a tube rack with the 
staining rack and BeadChips horizontal, barcodes facing up.  
o Remove the BeadChips from the staining rack with locking tweezers and 
place each BeadChip on a tube rack to dry. Remove the staining rack handle 
after removing the first four BeadChips. 
o Dry the BeadChips in the vacuum desiccator for 50–55 minutes at 508 mm 
Hg (0.68 bar).  
o Clean the underside of each BeadChip with a ProStat EtOH wipe.  
o Clean and store the glass back plates and Hyb Chamber components.  
 
Image BeadChip 
o Turn power on and wait for the ready indicator to stop flashing.   
o Open the BeadScan software.   
o Log in and click Scan. 
o Imaging  BeadChip  
o When the BeadArray Reader is initialized, follow these steps to perform 
the  scanning process.   
o From the Docking Fixture listbox, select BeadChip.   
o Check the Data Repository path and the Decode Map path in the  Settings 
area.   
o Copy the decode map (*.dmap) files for each BeadChip from the  
BeadChip CD to the Decode Map path directory.   
o For each BeadChip:   
a. Place the BeadChip into the BeadArray Reader tray.   
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b. If either the Sentrix Type or Scan Settings are not correct, open the Select 
Scan Settings dialog box.   
c. Select the Infinium Methylation scan setting and click Select.   
o Make sure that the BeadChips are properly seated in the BeadArray  
Reader tray.   
o Click Scan.  
 
Scanning Process  
BeadScan begins the BeadArray Reader Tilt and Align processes.  Once the 
Tilt and Align processes are complete, the Scan process begins.  
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List of hypermethylated genes in FL identified by Infinium array 
 
AADAT ADRA1D ATOH1 C1orf51 CCDC37 CHST3 CST3 DMRT2 EMX2 FBLIM1 FLJ46831 
ABCA3 ADRA2A ATP10A C1orf76 CCDC60 CHX10 CST6 DMRT3 EN1 FBLN2 FLJ90650 
ABCC3 ADRA2B ATP8A2 C20orf100 CCK CIDEA CTDSPL DOCK5 EN2 FBN2 FLRT2 
ABCC6 ADRA2C ATP9A C20orf133 CCRK CITED4 CTNND2 DOK5 ENTPD3 FBXO39 FLT4 
ABHD9 ADRB1 AYTL1 C20orf39 CD164L2 CKB CTSF DPYS EOMES FERD3L FN3K 
ABO ADRB3 B3GAT1 C20orf58 CD8A CLDN3 CTSL DPYSL4 EPB41L3 FGF12 FNDC4 
ACADL AFAP BAPX1 C2orf21 CD8B1 CLEC14A CTTNBP2 DRD2 EPHA10 FGF19 FOXA1 
ACOT12 AFAR3 BARHL2 C6orf118 CDC14B CNIH3 CX36 DRD4 EPHA5 FGF3 FOXA2 
ACTA1 AJAP1 BCAN C6orf155 CDCP1 CNN3 CXCL1 DRD5 EPHA8 FGF4 FOXD3 
ACTC AKAP12 BCL11B C9orf125 CDH1 CNTN1 CXCL12 DSC2 EPHX2 FGFR2 FOXE3 
ACTL6B ALDH1A2 BDNF CA4 CDH11 CNTNAP2 CXCL5 DSC3 EPO FIGN FOXF1 
ACTN2 ALDH1A3 BHMT CACNA1A CDH13 CNTNAP3 CYP24A1 DSCR6 ERBB2 FLJ10661 FOXF2 
ADAM12 ALDH1L1 BMP2 CACNA1H CDH22 COL14A1 CYP26B1 DSG2 ERBB4 FLJ11155 FOXG1B 
ADAMTS1 ALK BMPR1B CACNA2D1 CDH8 COL15A1 CYP4X1 DUSP23 ERG FLJ14166 FOXL1 
ADAMTS14 ALX4 BNC1 CACNB2 CDKN2A COL23A1 CYYR1 EBF3 ERRFI1 FLJ21511 FOXL2 
ADAMTS15 AMPH BOLL CACNG6 CELSR1 COL5A1 DAB2IP EDG2 EVX1 FLJ23577 FOXQ1 
ADAMTS17 ANKMY1 BRSK2 CADPS CENTG2 COL6A2 DAPK1 EDG3 EYA4 FLJ25477 FRMD5 
ADAMTS18 ANKRD38 BRUNOL6 CALCA CFTR COLEC12 DBC1 EDIL3 FAM19A4 FLJ30277 FSTL3 
ADAMTS2 AQP5 BTBD11 CALCB CGI-38 CPLX2 DCC EDN3 FAM20A FLJ30834 FZD10 
ADCY2 ARHGAP29 BTBD3 CART CGNL1 CPXM2 DEPDC2 EDNRB FAM3B FLJ32447 GABBR2 
ADCY5 ARHGAP8 BTG4 CART1 CHAD CRABP1 DES EFCAB1 FAM43B FLJ39237 GABRA4 
ADCY8 ART5 C10orf107 CAST1 CHD5 CRMP1 DGKI EFS FAM46B FLJ39599 GABRB1 
ADCYAP1 ASAM C10orf35 CBLN4 CHGA CRY1 DLK1 EGFR FAM62C FLJ42486 GAD2 
ADCYAP1R1 ASCL1 C10orf82 CBX4 CHODL CRYGN DLX5 ELAVL3 FAM84A FLJ45717 GALNT11 
ADRA1A ASCL2 C1orf188 CCDC3 CHRNA3 CSMD1 DMN EMILIN3 FAT FLJ45983 GALR1 
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GALR2 GPR6 HCN1 HS3ST3A1 KCNA1 KLK10 LOC89944 ME1 NEF3 NTSR1 PCDHB15 
GAS7 GPR78 HCN4 HSPA2 KCNA5 KREMEN1 LOXL1 MEGF10 NEFH OCLN PCDHB2 
GATA3 GPR83 HEBP1 HTR1B KCNB1 KRT19 LPA MGC16291 NEFL OLIG2 PCDHB5 
GATA4 GPRC5C HHIP HTR5A KCNC1 KRT7 LPHN2 MGC16372 NELL1 ONECUT2 PCSK6 
GATA5 GRB10 HLF HTR7 KCNE3 LAMA1 LPL MGC33530 NES OPRK1 PCSK9 
GBX2 GREM1 HMGA2 HTRA1 KCNG1 LAMA2 LPPR4 MGC33600 NETO1 OSMR PDE10A 
GCM2 GRIA2 HNT HYDIN KCNIP1 LAMA3 LR8 MGC34646 NEUROG1 OTOP1 PDE1C 
GDA GRIA4 HOXA13 ID4 KCNJ6 LARP6 LRFN5 MGC39545 NGFB OTOP3 PDE3A 
GDNF GRID2 HOXA9 IGF1R KCNK17 LATS2 LRIG3 MGC39633 NID2 OTX2 PDE4B 
GENX-3414 GRIK1 HOXB13 IGF2 KCNK3 LBX1 LRP12 MLF1 NKX2-2 P2RY6 PDE4C 
GFPT2 GRIK2 HOXB8 IGF2AS KCNK5 LECT1 LRRC3 MMP2 NKX2-8 PABPC3 PDE4DIP 
GFRA1 GRIK3 HOXC11 IGFBP2 KCNK9 LGI2 LRRN5 MN1 NKX6-1 PAK7 PDGFC 
GHSR GRIN3A HOXC13 IGFBP3 KCNQ1 LHCGR LRRTM1 MSI1 NKX6-2 PALM PDPN 
GIPC2 GRM6 HOXD1 IGFBP7 KCNQ1DN LHX2 LSAMP MSX1 NOL4 PAPPA PDZRN3 
GLRA1 GRM7 HOXD10 IGSF21 KCNS2 LHX5 LTF MSX2 NOS1 PARD3 PENK 
GLRB GSC HOXD11 IGSF4 KCTD8 LIN7A LYNX1 MT1A NOTCH3 PARD6G PGF 
GNA14 GSCL HOXD12 IHH KIAA0980 LMX1A LYPD5 MT3 NPAS2 PARVA PGLYRP1 
GNAI1 GSH1 HOXD4 INHA KIAA1446 LMX1B MAFB MTNR1A NPAS4 PAX3 PHACTR3 
GNG4 GSTM3 HOXD8 IRX2 KIAA1944 LOC112937 MAGI2 MYF5 NPR3 PAX6 PHOX2A 
GNMT GUCY2D HOXD9 IRX3 KIF17 LOC124842 MALL MYLK NPTX2 PAX7 PHYHIPL 
GPC2 GULP1 HPSE2 IRX4 KIF1A LOC349136 MAMDC2 MYO10 NPY5R PAX9 PITX2 
GPC6 HAND1 HR IRX5 KITLG LOC387758 MAP1B MYO3A NR2E1 PCDH17 PKDREJ 
GPR103 HAND2 HRASLS IRXL1 KLF11 LOC389199 MARVELD3 MYOD1 NRG1 PCDH8 PKP1 
GPR26 HBQ1 HS3ST1 ISL1 KLF4 LOC389458 MATN2 NAGS NRP1 PCDHAC1 PLA2G7 
GPR27 HCA112 HS3ST2 IZUMO1 KLHL1 LOC63928 MCHR2 NEBL NTRK3 PCDHAC2 PLAC2 
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PLD5 PRSS23 RAB37 SCGN SLC18A3 SNAP91 STEAP2 TIMP3 UTF1 ZNF228 
PLEKHG6 PSD2 RAI14 SCN4B SLC22A3 SNCAIP STEAP4 TITF1 VAX1 ZNF232 
PLOD2 PSD3 RARB SCRT1 SLC25A21 SOCS2 STK25 TLE6 VAX2 ZNF285 
PLXDC2 PTF1A RARRES2 SCTR SLC27A6 SORCS1 STK32C TLX3 VGCNL1 ZNF312 
PNMA2 PTGDR RASEF SCUBE3 SLC2A14 SORCS3 SULF2 TMEFF2 VGLL2 ZNF454 
POU3F1 PTGER3 RASGRF2 SEC14L4 SLC30A2 SOX1 SUMO3 TMEM45B VIPR2 ZNF471 
POU3F3 PTGFR RASL12 SEMA3B SLC32A1 SOX11 SYN2 TMEM51 VMP ZNF541 
POU4F3 PTGIS RBP1 SEMA3C SLC34A2 SOX14 SYT10 TNK1 VSX1 ZNF560 
PPFIA2 PTGS2 RBP7 SEMA3E SLC35F3 SOX17 SYT12 TPBG WBSCR14 ZNF659 
PPP1R13L PTHR2 RCN3 SEMA5A SLC5A7 SOX2 SYT6 TRAM1L1 WBSCR17 ZNF677 
PPP1R1A PTPN14 RELN SFRP1 SLC5A8 SOX21 SYT9 TRH WDFY3 ZNF702 
PPP1R3C PTPNS1 RET SFRP2 SLC6A1 SOX7 TACR1 TRHDE WDR72 ZNF83 
PRDM12 PTPRE RFXDC1 SFRP4 SLC6A15 SPAG6 TBX2 TRIM58 WIF1 ZSCAN1 
PRDM14 PTPRK RHCG SH3BP4 SLC6A2 SPDY1 TBX20 TRMU WIT-1  
PRDM16 PTPRM RHEB SH3GL2 SLC6A3 SPG20 TBX3 TRPA1 WNK2  
PRG2 PTPRN RIMS4 SH3GL3 SLC6A5 SPON1 TBX4 TRPC4 WNT3A  
PRG-3 PTPRN2 RIPK4 SIX2 SLC7A10 SPRY2 TCERG1L TRPC6 WNT7A  
PRKG1 PTPRO RLN3R1 SIX6 SLC9A3 SRD5A2 TCF15 TRPV4 WNT9B  
PRLHR PTPRT ROR2 SKIP SLCO2A1 SST TDRD5 TSCOT WT1  
PRLR PTPRZ1 RPRM SLC12A5 SLIT2 SSTR1 TEKT3 TSPAN2 WWTR1  
PRMT8 PVR RYR2 SLC12A7 SLIT3 SSTR4 TF UACA ZFP2  
PRP2 PXDN SALL1 SLC13A5 SLITRK1 ST6GAL2 TFAP2C UCP1 ZFP42  
PRRX1 PYGO1 SALL3 SLC15A1 SLITRK3 ST6GALNAC3 TGFBI UGT3A2 ZIC1  
PRRX2 RAB18 SASH1 SLC16A12 SLITRK5 ST8SIA2 THAP10 UNC5C ZNF135  
PRSS12 RAB32 SCARF2 SLC18A2 SMOC2 STAC2 THBD UNQ9433 ZNF177  
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Methylation values of genes with multiple CpG loci 
 
Table shows average methylation values (ß) for all CpG islands with 6 or more CpG probes. Values are shown for the FL group, the benign 
lymph node (BLN) group as well as the difference in ß value (∆ß) between the two groups. The standard deviation (SD) of values obtained with 
multiple probes is also shown. 
SYMBOL CPG_ISLAND_LOCATIONS 
Distance (bp) covered 
by probes 
Number 
of probes 
Average 
FL ß 
Average 
∆ß 
Average 
BLN ß SD FL SD ∆ß SD BLN 
ALDH1A3 15:99236455-99238833 2232 7 0.67 0.44 0.22 0.10 0.19 0.17 
ALX4 11:44282161-44283221 829 6 0.57 0.49 0.08 0.09 0.12 0.04 
ATP10A 15:23658498-23660531 2015 6 0.57 0.30 0.28 0.16 0.32 0.29 
BCDIN3 7:99863663-99866414 1383 6 0.06 -0.02 0.08 0.04 0.03 0.06 
BCL2 18:59137551-59139457 1843 7 0.07 -0.02 0.09 0.05 0.04 0.09 
BIK 22:41835870-41837797 1644 6 0.16 -0.01 0.17 0.24 0.09 0.19 
BNC1 15:81742719-81745331 2497 7 0.68 0.52 0.15 0.10 0.12 0.11 
BRAF 7:140270307-140271594 1142 6 0.05 -0.02 0.07 0.04 0.02 0.05 
C1orf83 1:54290592-54292083 937 6 0.08 -0.03 0.11 0.06 0.02 0.07 
CALCA 11:14949913-14950639 667 7 0.54 0.35 0.19 0.13 0.14 0.06 
CAV1 7:115951805-115954180 1825 6 0.12 0.03 0.09 0.06 0.07 0.04 
CCND1 11:69164197-69168027 3367 7 0.18 -0.01 0.19 0.30 0.03 0.31 
CCND1 11:69170075-69170635 500 6 0.81 -0.05 0.87 0.14 0.07 0.09 
CCND2 12:4252826-4255273 1905 10 0.11 0.03 0.09 0.12 0.11 0.06 
CD44 11:35116811-35117939 829 6 0.05 -0.02 0.07 0.02 0.01 0.04 
CDC7 1:91738697-91739771 373 6 0.04 -0.01 0.05 0.02 0.01 0.02 
CDH1 16:67328348-67330000 1486 8 0.76 0.55 0.22 0.09 0.26 0.27 
CDH13 16:81217810-81219323 1397 6 0.60 0.46 0.14 0.11 0.16 0.09 
CDK2 12:54646626-54647300 565 6 0.05 -0.01 0.07 0.03 0.01 0.04 
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SYMBOL CPG_ISLAND_LOCATIONS 
Distance (bp) covered 
by probes 
Number 
of probes 
Average 
FL ß 
Average 
∆ß 
Average 
BLN ß SD FL SD ∆ß SD BLN 
CDKN1C 11:2861494-2864350 2723 8 0.60 0.43 0.17 0.15 0.22 0.21 
CDKN2B 9:21995095-21996291 940 6 0.59 0.43 0.17 0.09 0.06 0.10 
CHFR 12:131973620-131975130 1406 7 0.33 0.13 0.21 0.25 0.10 0.21 
CRABP1 15:76419520-76421296 1070 7 0.57 0.50 0.08 0.16 0.20 0.04 
DAB2IP 9:123500662-123502056 1174 8 0.14 0.08 0.06 0.22 0.18 0.04 
DAPK1 9:89301899-89304060 2055 7 0.58 0.45 0.13 0.16 0.19 0.12 
DCC 18:48120150-48121583 1153 6 0.59 0.41 0.18 0.05 0.09 0.06 
DCC 18:48122009-48122893 687 6 0.61 0.49 0.12 0.15 0.16 0.06 
DIRAS3 1:68285082-68285689 524 6 0.53 0.03 0.50 0.26 0.14 0.17 
DIRAS3 1:68288302-68289231 839 8 0.75 0.13 0.62 0.11 0.06 0.09 
DLX5 7:96490825-96492388 1531 8 0.64 0.46 0.18 0.10 0.11 0.09 
DNM2 19:10689460-10690393 357 7 0.12 0.01 0.11 0.10 0.03 0.08 
DUS2L 16:66613904-66615043 617 7 0.08 0.05 0.03 0.15 0.14 0.02 
DUSP1 5:172129758-172132362 2172 7 0.03 -0.01 0.04 0.01 0.01 0.02 
EDNRB 13:77390197-77391989 1652 6 0.56 0.35 0.21 0.11 0.24 0.24 
EFNB1 X:67965268-67967122 1603 7 0.32 -0.13 0.44 0.13 0.12 0.11 
ERBB2 17:35109518-35110599 937 6 0.64 0.46 0.18 0.24 0.28 0.18 
ESR1 6:152170010-152172178 1879 7 0.30 0.12 0.18 0.21 0.09 0.24 
EYA4 6:133603260-133605886 2104 8 0.57 0.47 0.09 0.13 0.13 0.07 
FANCF 11:22603124-22604113 889 6 0.05 0.00 0.05 0.02 0.02 0.01 
FEN1 11:61316278-61317629 534 8 0.05 -0.03 0.08 0.02 0.03 0.04 
FHIT 3:61211519-61212421 723 8 0.14 0.06 0.08 0.03 0.05 0.06 
GALR1 18:73090255-73093032 2606 7 0.70 0.57 0.12 0.06 0.09 0.05 
GATA4 8:11598711-11600557 1681 6 0.46 0.38 0.08 0.15 0.15 0.03 
GATA4 8:11602473-11604934 1838 6 0.76 0.61 0.15 0.06 0.07 0.07 
GATA5 20:60474622-60475245 491 6 0.79 -0.13 0.92 0.17 0.13 0.05 
GNAS 20:56847904-56850722 2694 7 0.71 0.08 0.63 0.14 0.10 0.11 
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SYMBOL CPG_ISLAND_LOCATIONS 
Distance (bp) covered 
by probes 
Number 
of probes 
Average 
FL ß 
Average 
∆ß 
Average 
BLN ß SD FL SD ∆ß SD BLN 
GNAS 20:56862299-56864797 1925 6 0.77 0.03 0.74 0.11 0.05 0.10 
GNAS 20:56896598-56901302 4284 6 0.23 -0.06 0.29 0.24 0.09 0.31 
GNMT 6:43035706-43036927 934 7 0.75 0.45 0.30 0.11 0.24 0.32 
GPSN2 19:14500498-14502147 843 10 0.10 0.01 0.09 0.05 0.05 0.06 
GRB10 7:50827590-50829211 1419 7 0.74 0.66 0.07 0.07 0.09 0.05 
GSTP1 11:67106980-67108634 1542 6 0.16 -0.11 0.28 0.17 0.13 0.27 
H19 11:1973888-1974871 925 8 0.82 -0.06 0.88 0.10 0.07 0.08 
HDAC11 3:13495978-13497310 670 6 0.06 0.01 0.05 0.05 0.03 0.03 
HOXB4 17:44009922-44011032 848 8 0.30 0.21 0.09 0.12 0.14 0.06 
HSPC268 7:138675096-138676960 1239 8 0.04 -0.02 0.06 0.02 0.03 0.04 
IGF2AS 11:2121548-2122565 985 6 0.43 0.32 0.11 0.25 0.23 0.08 
ITPR2 12:26876264-26878375 1850 7 0.03 -0.01 0.04 0.01 0.01 0.02 
KRAS 12:25294308-25295937 1251 6 0.03 -0.02 0.05 0.01 0.02 0.03 
LOX 5:121440312-121442369 1743 7 0.55 0.48 0.07 0.09 0.11 0.03 
MEG3 14:100360178-100364204 3294 7 0.70 0.05 0.65 0.19 0.13 0.13 
MEST 7:129912883-129914215 1035 6 0.42 0.20 0.22 0.24 0.11 0.22 
MGC33302 4:129104666-129106616 719 8 0.11 -0.01 0.12 0.10 0.01 0.09 
MGMT 10:131154808-131155770 856 6 0.31 0.12 0.19 0.23 0.17 0.31 
MGMT 10:131244704-131245359 520 6 0.76 0.05 0.72 0.07 0.04 0.10 
MGMT 10:131302456-131302963 461 6 0.73 -0.04 0.77 0.15 0.08 0.11 
MRPL12 17:77279932-77281470 885 8 0.03 -0.01 0.04 0.01 0.01 0.02 
MSX1 4:4908144-4911629 1745 7 0.52 0.46 0.06 0.11 0.08 0.04 
MSX1 4:4915141-4915899 513 6 0.78 0.32 0.46 0.15 0.12 0.18 
NDN 15:21482512-21483863 1307 6 0.70 0.10 0.60 0.17 0.12 0.18 
NEUROG1 5:134898284-134900130 1610 6 0.71 0.60 0.10 0.12 0.13 0.05 
NNAT 20:35581886-35583655 1382 7 0.69 0.00 0.69 0.08 0.02 0.09 
OBFC2B 12:54903894-54904729 477 6 0.09 -0.04 0.13 0.11 0.03 0.14 
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SYMBOL CPG_ISLAND_LOCATIONS 
Distance (bp) covered 
by probes 
Number 
of probes 
Average 
FL ß 
Average 
∆ß 
Average 
BLN ß SD FL SD ∆ß SD BLN 
PEG10 7:94122326-94124641 2040 7 0.45 0.04 0.41 0.20 0.14 0.28 
PEG10 7:94131111-94132325 1028 6 0.86 0.01 0.85 0.09 0.05 0.12 
PHLDA2 11:2906274-2908366 1777 6 0.40 0.34 0.06 0.25 0.24 0.04 
PIGO 9:35085675-35086818 739 6 0.08 -0.02 0.11 0.06 0.02 0.04 
PLAGL1 6:144370510-144371695 992 8 0.60 -0.10 0.71 0.18 0.04 0.18 
PPME1 11:73559258-73560445 853 9 0.07 -0.03 0.09 0.04 0.03 0.07 
PPP1R9A 7:94374717-94375964 1106 6 0.57 0.46 0.11 0.11 0.16 0.08 
PSMB6 17:4645846-4646896 498 6 0.08 -0.02 0.10 0.06 0.02 0.07 
PTEN 10:89611198-89614163 2683 8 0.07 0.02 0.05 0.10 0.09 0.05 
PTGS2 1:184915751-184916808 927 6 0.61 0.50 0.11 0.11 0.10 0.06 
PTPRO 12:15366460-15367398 849 8 0.60 0.51 0.09 0.17 0.18 0.04 
PYCARD 16:31120978-31121976 936 6 0.09 -0.02 0.11 0.06 0.02 0.08 
RAB32 6:146905888-146907189 1240 6 0.62 0.43 0.20 0.12 0.27 0.28 
RASSF1 3:50349160-50350983 1370 6 0.06 -0.01 0.06 0.02 0.01 0.03 
RB1 13:47790461-47792049 1417 6 0.75 0.09 0.67 0.13 0.06 0.16 
RBP1 3:140740275-140741996 1140 7 0.56 0.47 0.10 0.20 0.17 0.07 
RUNX3 1:25101076-25101799 610 6 0.85 -0.03 0.89 0.14 0.12 0.07 
SACM1L 3:45705432-45706421 765 9 0.08 0.00 0.08 0.09 0.03 0.09 
SEMA3B 3:50285369-50286362 851 6 0.33 0.14 0.19 0.33 0.18 0.27 
SFRP4 7:37922026-37923244 1106 6 0.57 0.48 0.09 0.19 0.20 0.03 
SLC5A8 12:100127137-100128325 973 7 0.61 0.41 0.21 0.10 0.16 0.18 
SMPDL3A 6:123151903-123153198 309 6 0.12 0.07 0.06 0.04 0.03 0.04 
SOCS1 16:11255994-11258397 1659 7 0.06 -0.05 0.11 0.04 0.10 0.12 
SOCS2 12:92487620-92490276 2541 7 0.08 0.01 0.07 0.05 0.06 0.04 
SOCS2 12:92490435-92491891 1394 6 0.49 0.39 0.10 0.18 0.23 0.09 
SRF 6:43246300-43248449 727 6 0.09 -0.01 0.10 0.07 0.01 0.08 
SYK 9:92603527-92604494 827 7 0.06 -0.01 0.07 0.03 0.01 0.04 
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SYMBOL CPG_ISLAND_LOCATIONS 
Distance (bp) covered 
by probes 
Number 
of probes 
Average 
FL ß 
Average 
∆ß 
Average 
BLN ß SD FL SD ∆ß SD BLN 
TFPI2 7:93357211-93358411 1044 7 0.17 0.07 0.11 0.07 0.06 0.11 
THRB 3:24510366-24512597 1661 6 0.19 0.11 0.09 0.08 0.04 0.07 
TNFRSF10C 8:23016236-23017035 703 6 0.39 0.28 0.10 0.15 0.21 0.08 
TP73 1:3556965-3559547 1620 6 0.19 0.13 0.06 0.23 0.21 0.03 
TWIST1 7:19122442-19124663 2048 7 0.52 0.45 0.07 0.09 0.09 0.03 
UGDH 4:39204770-39206279 814 8 0.07 -0.01 0.08 0.06 0.02 0.06 
ZIM2 19:62041489-62042391 794 6 0.74 0.11 0.63 0.14 0.10 0.15 
ZNF264 19:62394167-62395368 822 6 0.19 0.01 0.17 0.32 0.05 0.28 
ZNF512 2:27659123-27659757 495 9 0.09 -0.04 0.13 0.06 0.05 0.09 
ZNF688 16:30490076-30491410 878 12 0.05 -0.01 0.06 0.03 0.01 0.03 
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Gene Ontology analysis 
 
Tables show list of assigned GO and InterPro terms overrepresented (normal font) or underrepresented (bold font) within the hypermethylated 
gene set relative to all genes examined on the Infinium array.  
 
Biological processes categories: 
 GO 
Level 
GO term Frequency in hypermethylated 
gene set (%) 
Frequency in Infinium 
array set (%) 
Adjusted P 
value 
3 Multicellular organismal development 38.1 18.5 2.05 x10
-25
 
3 Anatomical structure development 34.5 17.2 2.79 x10
-21
 
4 System development 30.4 14.4 3.01 x10
-19
 
5 Nervous system development 18.45 7.1 1.18 x10
-14
 
4 Cell-cell signalling 15.1 5.5 8.77 x10
-14
 
5 Organ development 22.3 10.9 2.46 x10
-11
 
4 anatomical structure morphogenesis 18.7 9.4 1.8 x10
-9
 
5 cell surface receptor linked signal transduction 21.3 11.2 7.64 x10
-9
 
6 G-protein coupled receptor protein signaling pathway  13.3 5.4 4.2 x10
-8
 
5 Neuron differentiation 11.3 3.5 7.21 x10
-8
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6 neurogenesis 9.49 3.23 2.45 x10
-8
 
7 generation of neurons 10.8 3.6 1.95 x10
-7
 
4 Embryonic development 8 2.9 2.41 x10
-7
 
4 Protein metabolic process 16.4 26.9 2.41 x 10
-7
 
4 Cellular macromolecule metabolic process 15.7 25.8 4.5 x 10
-7
 
3 Cellular metabolic process 49.4 61 5.32 x 10
-7
 
3 Neurological process 11.8 5.6 5.32 x10
-7
 
6 Intracellular transport 1.14 6.7 6.1 x10
-7
 
3  Primary metabolic process 48.4 59.8 6.98 x10
-7
 
6 Central nervous system development  7.6 2.5 9.29 x10
-7
 
3 Cell adhesion 10.6 5 1.67 x 10
-6
 
5 Cellular protein metabolic process 16.2 26.5 1.82 x 10
-6
 
3 Biosynthetic process 4.9 11.2 1.83 x 10
-6
 
4 Pattern specification process 5.5 1.7 2.48 x 10
-6
 
3 Cell communication 38.4 28.4 2.82 x 10
-6
 
5 Transmission of nerve impulse 8.3 3.2 4.23 x 10
-6
 
5 Embryonic morphogenesis 4.9 1.4 4.5 x 10
-6
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5 Regionalisation 4.8 1.3 8.45 x 10
-6
 
6 Synaptic transmission 8 3 1.31 x 10
-5
 
3 Protein localisation 2.1 6.5 1.88 x 10
-5
 
6 Organ morphogenesis 9.3 3.9 2.58 x 10
-5
 
4 Regulation of developmental process 6 2.3 2.73 x 10
-5
 
5 Ion transport 11.8 6 2.77 x 10
-5
 
3 Macromolecule biosynthetic process 43 52.5 4.41 x 10
-5
 
4 Cellular biosynthetic process 4.5 10.2 2.81 x 10
-5
 
6 RNA processing 0.6 4.4 3.56 x 10
-5
 
6 Translation 0.8 4.8 3.56 x 10
-5
 
3 Macromolecule metabolic process 43 52.5 4.41 x 10
-5
 
4 Establishment of protein localisation 2 6.3 5.8 x 10
-5
 
4 Cellular localisation 2.8 7.5 5.8 x 10
-5
 
5 Cell fate commitment 3.7 1 6.57 x 10
-5
 
5 DNA metabolic process 2.3 6.9 7.89 x 10
-5
 
5 Establishment of cellular localisation 2.8 7.7 9.88 x 10
-5
 
4 Cell-cell adhesion 4.7 1.7 1.7 x 10
-4
 
5 Homophilic cell adhesion 3.3 0.9 1.11 x 10
-4
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5 Protein transport 1.9 6.2 1.13 x 10
-4
 
6 Sensory organ development 3.6 0.9 1.18 x 10
-4
 
9 Neuron development 14.9 4.8 1.24 x 10
-4
 
5 Cellular macromolecule catabolic process 0.2 2.8 1.51 x 10
-4
 
6 mRNA metabolic process 0.2 3.2 1.57 x 10
-4
 
7 Intracellular protein transport 0.5 4.6 2 x 10
-4
 
7 mRNA processing 0 3.2 3.18 x 10
-4
 
8 Ubiquitin cycle 0.7 5.5 3.35 x 10
-4
 
7 Cyclic-nucleotide-mediated signalling 5.17 1.54 5.02 x 10
-4
 
5 Negative regulation of developmental process 3.2 0.9 5.29 x 10
-4
 
8 G-protein signaling, coupled to cyclic nucleotide 
second messenger 
5.7 1.7 5.95 x 10
-4
 
4 Tube development 3 0.9 6.42 x 10
-4
 
7 RNA splicing 0 2.94 6.58 x 10
-4
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Molecular function categories: 
GO 
Level 
GO term Frequency in hypermethylated 
gene set (%) 
Frequency in Infinium 
array set (%) 
Adjusted P value 
5 Sequence-specific DNA binding 15.2 5.68 1.18 x 10
-11
 
5 Transcription factor activity 21.47 10.73 1.42 x 10
-9
 
4 RNA binding 1.2 6.73 8.79 x 10
-8
 
4 Transmembrane receptor activity 13.38 5.89 8.79 x 10
-8
 
6 rhodopsin-like receptor activity 
 
11.29 3.69 2.12 x 10
-6
 
5 G-protein coupled receptor activity 
 
9.54 3.8 3.62 x 10
-6
 
4 neurotransmitter receptor activity 
 
3.43 0.79 5.21 x 10
-5
 
4 alpha-type channel activity 
 
4.97 1.78 3.21 x 10
-4
 
4 Ligase activity, forming carbon-nitrogen 
bonds 
 
0 2.04 9.5 x 10
-4
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Interpro classification 
 
Interpro ID Associated term Frequency in hypermethylated 
gene set (%) 
Frequency in Infinium array set (%) P value 
IPR001356 Homeobox 8.73 1.78 2.03 x 10
-17
 
IPR013847 POU 5.35 0.78 1.21 x 10
-13
 
IPR000047 HTH_lambrepressr 6.06 1.19 3.53 x 10
-12
 
IPR000276 TM_GPCR_Rhodpsn 5.21 1.85 2.08 x 10
-4
 
IPR002126 Cadherin 2.54 0.54 7.52 x 10
-4
 
 
Interpro classification terms significantly (adjusted p value; FDR 0.001) overrepresented in hypermethylated gene set compared to 
Infinium array set 
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Appendix E – Direct sequencing 
 
Additional material related to direct sequencing analysis 
 
PCR reaction mix: 
 
Reagent Volume per 25µl 
reaction (µl) 
PCR Buffer II 2.5 
MgCl2 (3mM) 1.5 
dNTPs (200µM) 2.0 (0.5 of each) 
Forward primer (20µM) 0.5 
Reverse primer (20µM) 0.5 
taq Polymerase  0.5 
ddH2O 15 
DNA template (100ng/µl) 1 
 
 
PCR was performed on a thermocycler with initial denaturation at 94°C for 5 
minutes followed by 31 cycles of denaturation at 94°C for 30 seconds, 
annealing at 60°C for 30 seconds and extension at 72°C for 30 seconds before 
final extension at 72°C for 7 minutes. 
 
 Primer Sequence 
EZH2 Forward GTGTGCCCAATTACTGCCTT 
EZH2 Reverse AGCATGCAAATCCACAAAC 
 
 
 
 
 
Appendix 
 280 
Appendix F - Copy of Leukemia article 
 
Article based on findings described in Chapter 3 (O'Riain, et al 2009) 
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